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ABSTRACT 
 
Sacsin, which is mutated in the neurodegenerative disease Autosomal Recessive Spastic 
Ataxia of Charlevoix-Saguenay (ARSACS), is a 520 kDa modular protein with regions 
of homology to molecular chaperones and domains linking to the ubiquitin proteasome 
system. This suggests a role in proteostasis.   
Previously, sacsin has been shown to partially localise with mitochondria, and loss of 
sacsin results in elongated and dysfunctional mitochondria. Moreover, alterations in 
neurofilaments have recently been reported in a mouse model of ARSACS. Despite 
these findings, pathophysiological mechanisms of ARSACS are poorly understood. 
The aim of this thesis was to elucidate the cellular role of sacsin by determining how 
loss of its function leads to the observed mitochondrial and intermediate filament 
defects. This hoped to shed light on the mechanism of disease in ARSACS.  
The results indicate that the mitochondrial elongation seen in ARSACS is likely due to 
reduced mitochondrial localisation of the essential fission factor DRP1. This may be 
mediated by loss of function of a complex involving sacsin and dynactin-6, a subunit of 
the dynein-dynactin motor complex, which has previously been shown to be required 
for DRP1 mitochondrial recruitment. DRP1-mediated mitochondrial fission is necessary 
for mitochondrial quality control; hence a disruption to mitochondrial quality control is 
likely to occur in sacsin deficient cells, which may explain the mitochondrial 
dysfunction in ARSACS.  
Furthermore, sacsin null cells display a dramatic collapse and perinuclear bundling of 
the vimentin intermediate filament network. This is coupled with the displacement of 
cellular organelles, particularly mitochondria, early endosomes and the Golgi, which 
accumulate at the periphery of the vimentin bundle. These are characteristic features of 
aggresome formation, indicating an aggregation of misfolded protein, which occurs due 
to disrupted proteostasis. Further supporting this, the proteostasis components ubiquitin, 
HSP70, LAMP2 and p62 are recruited to the perinuclear vimentin bundles.  
In summary, the findings of this thesis indicate a role for sacsin in mitochondrial and 
protein quality control, the dysfunction of which is likely to be particularly detrimental 
in neurons. Mitochondrial dysfunction along with protein misfolding and aggregation 
are implicated in many neurodegenerative diseases, and ARSACS is no exception.
ACKNOWLEDGEMENTS 
	   III 
ACKNOWLEDGEMENTS 
 
First and foremost, I would like to express my appreciation and gratitude to my 
supervisor Professor Paul Chapple for his guidance, support, and valuable time. It has 
been a privilege to work on such an interesting and fruitful project.  
The work of this thesis would not have been possible without the generous funding 
from the Ataxia Charlevoix-Saguenay Foundation and the Medical Research Council, to 
whom I am most grateful. In particular, I would like to thank the founders of the Ataxia 
Charlevoix-Saguenay Foundation, Jean Groleau and Sonia Gobeil, for an inspirational 
visit to Montreal. 
I would like to thank my second supervisor Dr Louise Metherell and my panel of 
advisors Dr Gregory Michael and Professor Andrew Tinker for their valuable time and 
useful suggestions.  
I would also like to thank members of the Chapple group, Dr Teisha Bradshaw, Dr 
Suran Nethisinghe, Dr Sam O’Toole and Lisa Romano for their encouragement, 
friendship and support. I am grateful to have been part of such a great team! 
I would like to thank Professor Carol Shoulders for providing me with the opportunity 
to start a career in research and for continuing to be a great mentor throughout my PhD.  
My thanks also go to Professor Mike Cheetham, Professor Alison Hardcastle and 
members of the UCL Institute of Ophthalmology for their useful advice throughout my 
project.  
Thanks to my colleagues in the Centre for Endocrinology, both past and present, for 
creating such an enjoyable place to work and for sharing their expertise. In particular, I 
am thankful to Tozen Ozkan who made doing my PhD all the more pleasurable with her 
wonderful friendship and kindness.  
Thank you to my boyfriend, Luke Williams for his support, encouragement and 
patience throughout my PhD. He kept me smiling through the tough bits!  
Finally, thank you to my friends and family for their continued support and 
encouragement throughout my education, especially my parents Jeanette and Andrew 
Duncan, to whom I dedicate this thesis. I hope that I have made them proud. 
 
CONTENTS 
	   IV 
CONTENTS 
 
STATEMENT OF ORIGINALITY        I 
ABSTRACT            II 
ACKNOWLEDGEMENTS          III 
CONTENTS            IV 
LIST OF FIGURES           XI 
LIST OF TABLES           XIV 
LIST OF ABBREVIATIONS         XV 
 
CHAPTER 1 – INTRODUCTION         1 
 
1.1. Cerebellar Ataxias          2 
1.2. Autosomal Recessive Cerebellar Ataxias       3 
1.2.1. Friedreich’s Ataxia         5 
1.2.2 Ataxia Telangiectasia         6 
1.2.3 Marinesco-Sjogren’s Syndrome       6 
1.3. Autosomal Recessive Spastic Ataxia of Charlevoix Saguney (ARSACS)   7 
1.3.1. Clinical features         7 
1.3.2. Causative gene and mutations        8 
1.3.3. Sacsin (DNAJC29)         15 
1.3.4. Sacsin expression and localisation       17 
1.3.5. Sacsin knockout mouse model        17 
1.4. Protein Homeostasis (proteostasis)        18 
 1.4.1. Protein folding          18 
 1.4.2. Mechanisms of proteostasis        19 
1.4.3. Molecular chaperones         21 
  1.4.3.1. Heat shock proteins        21 
  1.4.3.2. HSP70/HSPA and HSP40/DNAJ chaperone system   22 
  1.4.3.3. HSP90/HSPC         25 
 1.4.4. Protein degradation         27 
  1.4.4.1. Chaperone-mediated autophagy (CMA)     30 
  1.4.4.2. Mitophagy         30 
1.5. Disrupted Proteostasis in Neurodegeneration      31 
CONTENTS 
	   V 
1.5.1. HSP70 and HSP40 as modulators of neurodegeneration    32 
1.6. Sacsin Domains           33 
 1.6.1. Sacsin repeating region (SRR)        33 
 1.6.2. J-domain          34 
 1.6.3. HEPN domain          35 
 1.6.4. UBL-domain, XPCB-domain, and UIM domain     36 
1.7. Mitochondrial Dynamics         37 
1.7.1. Mitochondrial fusion         38 
 1.7.2. Mitochondrial fission         40 
  1.7.2.1. FIS1          42 
  1.7.2.2. MFF          42 
  1.7.2.3. MID49 and MID51        43 
 1.7.3. Post-translational modifications of DRP1      43 
1.7.3.1. Phosphorylation of DRP1       44 
  1.7.3.2. S-Nitrosylation of DRP1       45 
  1.7.3.3. Sumoylation of DRP1       45 
  1.7.3.4. Ubiquitination of DRP1       46 
 1.7.4. Dynamin and DRP1         47 
1.8. Mitochondrial Transport         48 
1.8.1. Dynein-dynactin complex        49 
1.8.1.1. Dynactin-6/p27 subunit       51 
1.9. Mitochondrial Dysfunction and Neurodegeneration      52 
1.9.1. Alzheimer’s disease         53 
1.9.2. Parkinson’s disease         55 
1.9.3. Huntington’s disease         55 
1.9.4. Hereditary Optic Atrophy        56 
1.9.5. Charcot-Marie-Tooth Neuropathy (CMT)      57 
1.9.6. Mitochondrial dysfunction in ARSACS      57 
1.10. Intermediate Filaments         59 
1.10.1. Neurofilaments         61 
1.10.2. Intermediate filaments and mitochondria      61 
1.11. Intermediate Filament Abnormalities and Neurodegeneration    62 
 1.11.1. Intermediate filament abnormalities in ARSACS     63 
1.12. Aims and Objectives          64 
CONTENTS 
	   VI 
CHAPTER 2 – MATERIALS AND METHODS       66 
 
2.1. Cell Culture           67 
2.1.1. Cell lines and maintenance        67 
2.1.2. Subculturing          67 
2.1.3. Freezing down cells         68 
2.1.4. Cell counting          68 
2.2. Transient Transfections         69 
2.2.1. Lipofectamine and Plus Reagent       69 
2.2.2. Lipofectamine 3000         70 
2.3. RNA Extraction           72 
2.4. cDNA Synthesis           73 
2.5. Polymerase Chain Reaction (PCR)        74 
2.6. Agarose Gel Electrophoresis         76 
2.7. Gel Extraction           76 
2.8. Cloning            77 
2.8.1. Generation of dynactin-6 vectors       77 
2.8.2. Restriction digest         79 
2.8.3. Ligation           79 
2.8.4. Preparation of LB agar plates        80 
2.8.5. Transformation          81 
2.8.6. Plasmid purification         82 
2.9. Immunoblotting           82 
2.9.1. Cell lysate preparation         82 
2.9.2. Bradford protein assay         83 
2.9.3. SDS-PAGE          84 
2.9.4. Immunoblotting         83 
2.9.5. Coomassie blue staining        84 
2.10. Immunoprecipitation          85 
2.10.1. Crosslinking          85 
2.10.2. Cell lysis          85 
2.10.3. Tag-coupled bead immunoprecipitation      85 
2.11. Subcellular Fractionation         86 
2.11.1. Mitochondrial isolation        86 
CONTENTS 
	   VII 
2.11.2. Cytoskeletal fraction           86 
2.11.3. Intermediate-filament-enriched fraction      87 
2.12. Immunocytochemistry          87 
 2.12.1. MitoTracker          88 
2.13. Confocal Microscopy          91 
2.14. Statistics           91 
 
CHAPTER 3 – DISRUPTED MITOCHONDRIAL FISSION IN ARSACS   92 
 
3.1. Introduction and Aims          93 
3.2. Results            95 
3.2.1. Identification of an interaction between DRP1 and DCTN6    95      
3.2.1.1. Verification of DCTN6-FLAG and DCTN6-GFP construct 
   expression         95 
3.2.1.2. Co-immunoprecipitation between DRP1 and DCTN6   96 
 3.2.2. A role for sacsin in the mitochondrial translocation of DRP1    98 
  3.2.2.1. Sacsin expression can be reduced in SH-SY5Y cells by  
 siRNA         98 
  3.2.2.2. Reduced levels of mitochondrial associated DRP1 in sacsin    
    deficient cells         101 
  3.2.2.3. Reduction in higher order DRP1 complexes in sacsin  
 deficient cells         104 
 3.2.3. A role for DCTN6 in the regulation of mitochondrial fission    106 
  3.2.3.1. DCTN6 overexpression leads to mitochondrial  
 fragmentation         106 
  3.2.3.2. DCTN6 siRNA knockdown leads to mitochondrial  
 elongation         108 
 3.2.4. DCTN6 knockdown leads to reduced mitochondrial localisation of  
          DRP1           112 
 3.2.5. DCTN6 knockdown leads to reduced mitochondrial membrane  
          potential          114 
3.3. Conclusions           116 
3.3.1. Further work          119 
 
CONTENTS 
	   VIII 
CHAPTER 4 – INTRACELLULAR DISORGANISATION IN ARSACS   122 
 
4.1. Introduction and Aims          123 
4.2. Results            125 
4.2.1. Colocalisation of a proportion of sacsin protein with vimentin 
  intermediate filaments        125 
4.2.2. Cellular fractionation of SH-SY5Y cells and human dermal  
          fibroblasts          129 
4.2.3. Disorganisation of the vimentin IF network in ARSACS patient  
          HDFs           130 
4.2.3.1. Collapsed and bundled vimentin IFs in ARSACS    133 
4.2.3.2. Vimentin protein levels were unchanged in ARSACS  
 patient HDFs         140  
4.2.4. Organisation of the microtubule and microfilament network in  
         ARSACS patient HDFs         140 
 4.2.4.1. Acetylated α-tubulin disorganisation in ARSACS patient  
 HDFs          145 
4.2.5. Disrupted localisation of other cellular organelles in ARSACS patient   
          HDFs            146 
4.2.5.1. Golgi apparatus        146 
4.2.5.2. Primary cilia         148 
4.2.5.3. Early endosomes        150 
4.2.6. Disorganisation of the vimentin network in sacsin knockdown cells   153 
4.2.6.1. Collapsed and bundled vimentin IF network     153 
4.2.6.2. Reduced fluorescence recovery of vimentin-GFP in sacsin 
             knockdown cells        155 
4.3. Conclusions           157 
 4.3.1. Further work          160 
 
CHAPTER 5 – DISRUPTED PROTEOSTASIS IN ARSACS      161 
 
5.1. Introduction and Aims          162 
 5.1.1. Characteristics of aggresome formation      163 
 5.1.2. Autophagy          165 
CONTENTS 
	   IX 
5.2. Results            167 
5.2.1. Perinuclear accumulation of HSP70 in ARSACS patient HDFs   167 
5.2.2. HSP70 protein levels were unchanged in ARSACS patient HDFs   169 
5.2.3. HSP90 colocalisation with vimentin in WT control and ARSACS  
          patient HDFs          170 
 5.2.4. HSP90 protein levels were unchanged in ARSACS patient HDFs   172 
5.2.5. Perinuclear accumulation of ubiquitin in ARSACS patient HDFs   173 
5.2.6. Perinuclear accumulation of p62/SQSTM1 in ARSACS patient  
          HDFs           176 
5.2.7. Re-localisation of lysosomes in ARSACS patient HDFs    179 
5.2.8. LAMP2 upregulation in sacsin knockdown cells     181 
5.2.9. Investigating mitophagy in ARSACS patient HDFs     183 
5.3. Conclusions           186 
 5.3.1. Further work          188 
 
CHAPTER 6 – DISCUSSION         191 
 
6.1. Disrupted Mitochondrial Fission in ARSACS     193 
6.2. Cellular Localisation of Sacsin        196 
6.2.1. Sacsin as a cytoskeletal linker       197 
6.3. Intermediate Filament Disruption in ARSACS     199 
6.4. Disrupted Proteostasis in ARSACS       201 
 6.4.1. Autophagy dysfunction in ARSACS      204 
 6.4.2. Potential mechanisms of autophagy dysfunction in ARSACS   207 
  6.4.2.1. ATP6AP2        208 
  6.4.2.2. Snapin        209 
  6.4.2.3. COP9 signalsome       210 
  6.4.2.4. DRP1         210 
  6.4.2.5. DCTN6        211 
 6.4.3. Further work to investigate autophagy dysfunction in  
         ARSACS         212 
6.5. Potential Therapeutic Strategies for ARSACS     213 
6.6. Final Conclusions         214 
REFERENCES           215 
APPENDICES           264 
LIST OF FIGURES 
	   XI 
LIST OF FIGURES 
 
Figure 1.1. Schematic of SACS gene and protein domain structure    16 
Figure 1.2.  Schematic of the cellular protein quality control mechanisms   20 
Figure 1.3.  Schematic representation of the HSP70 protein domains    23 
Figure 1.4.  Schematic of the ubiquitination pathway      28 
Figure 1.5.  Schematic of macroautophagy       29 
Figure 1.6.  Schematic representation of mitochondrial fission and fusion   38 
Figure 1.7. Schematic of mitochondrial fission through oligomerisation of  
DRP1 on the outer mitochondrial membrane      41 
Figure 1.8.  Schematic representation of the dynactin complex     49 
Figure 1.9.  Schematic representation of the defects in mitochondrial dynamics  
that lead to abnormal mitochondrial distribution in neurons    53 
 
Figure 2.1.  Schematic of haemocytometer grid       69 
Figure 2.2.  Constructs used in this thesis        78	  
	  
Figure 3.1.  Verification of DCTN6-FLAG and DCTN6-GFP expression   96	  
Figure 3.2.  Co-IP of DCTN6-FLAG and DRP1-GFP      97	  
Figure 3.3.  Cellular levels of sacsin can be significantly reduced by targeting  
SACS with siRNAs         99 
Figure 3.4.  Reduced mitochondrial localisation of DRP1 in sacsin knockdown  
cells           102  
Figure 3.5.  Reduced DRP1 in the mitochondrial fraction of sacsin knockdown  
cells           104   
Figure 3.6.  Reduced higher molecular weight DRP1 complexes in sacsin  
knockdown cells         105	  
Figure 3.7.  The mitochondrial network appears more fragmented in  
DCTN6-GFP overexpressing cells       107 
Figure 3.8.  DCTN6 expression can be reduced by RNA interference using  
siRNA           108  
Figure 3.9.  DCTN6 knockdown leads to elongated and interconnected  
mitochondria          109  
LIST OF FIGURES 
	   XII 
Figure 3.10.  FRAP analysis of DCTN6 knockdown cells indicates a more 
interconnected mitochondrial network      111 	  
Figure 3.11.  Reduced mitochondrial localisation of DRP1 in DCTN6  
knockdown cells         113	  
Figure 3.12.  DCTN6 knockdown leads to reduced mitochondrial membrane  
potential          115  
Figure 3.13.  Putative interactions identified between sacsin, DCTN6 and DRP1  
may provide a mechanistic link for sacsin in mitochondrial fission   116 	  
 
Figure 4.1.  Sacsin localises in close proximity to vimentin intermediate  
filaments          126 
Figure 4.2.  Sacsin localises in close proximity to both vimentin intermediate 
filaments and mitochondria        128 
Figure 4.3. Sacsin is enriched in an insoluble cytoskeletal fraction    129 
Figure 4.4.  Sacsin is present in an insoluble IF-enriched fraction    130 
Figure 4.5.  Schematic showing location of ARSACS patient mutations in sacsin 131 
Figure 4.6.  Sacsin protein levels in WT control and ARSACS HDFs    132 
Figure 4.7.  Collapsed and bundled vimentin IFs in ARSACS patient HDFs   134 
Figure 4.8.  Quantification of the collapsed and bundled vimentin IF phenotype 
in ARSACS patient HDFs        137 
Figure 4.9. Sacsin localisation is consistent with vimentin localisation in  
ARSACS patient HDFs with SACS mutations K1715* and R4331Q  139 
Figure 4.10.  Total cellular levels of vimentin were unchanged in ARSACS  
patient HDFs          140 
Figure 4.11.  Organisation of the F-actin network in ARSACS patient HDFs   141	  
Figure 4.12. 	   Organisation of the microtubule network in ARSACS patient HDFs  144	  
Figure 4.13. 	   Acetylated α-tubulin disorganisation in ARSACS patient HDFs   145	  
Figure 4.14. 	   Fragmentation of the Golgi apparatus in ARSACS patient HDFs   147	  
Figure 4.15. 	   Cilia incidence and length are reduced in ARSACS HDFs    149	  
Figure 4.16.	   Early endosome relocalisation around the area of perinuclear 
mitochondrial disruption in ARSACS patient HDFs     151	  
Figure 4.17. 	   Sacsin knockdown leads to collapsed and bundled vimentin IFs   154	  
Figure 4.18. 	   FRAP analysis of sacsin knockdown cells showed reduced  
fluorescence recovery compared to controls      156 
LIST OF FIGURES 
	   XIII 
Figure 5.1.  Schematic model of aggresome formation      164 	  
Figure 5.2.  Perinuclear accumulation of HSP70 in ARSACS patient HDFs   168	  
Figure 5.3.  Total cellular levels of HSP70 were unchanged in ARSACS patient 
HDFs             169	  
Figure 5.4. HSP90 co-localises with vimentin in WT and ARSACS patient  
HDFs           171 
Figure 5.5.  Total cellular levels of HSP90 were unchanged in ARSACS patient 
HDFs           172 	  
Figure 5.6.  Perinuclear accumulation of ubiquitin in ARSACS patient HDFs   174	  
Figure 5.7.  Perinuclear accumulation of p62 in ARSACS patient HDFs    177	  
Figure 5.8.  Perinuclear accumulation of LAMP-2 in ARSACS patient HDFs   180	  
Figure 5.9.  Upregulation of LAMP2 mRNA and protein expression in sacsin 
knockdown cells         182	  
Figure 5.10.  TOM20 and MitoTracker co-localise on mitochondria    184 	  
 
Figure 6.1.  Schematic representation of the hypothesis that sacsin and DCTN6 
function together in the mitochondrial translocation of DRP1   194 
Figure 6.2.  Structure-aided alignment of the C-termius of sacsin with  
cytoskeletal associated proteins containing a CAP-Gly domain   198 	  
Figure 6.3.  Schematic representation of autophagy when turnover is blocked 
vs. normal autophagic flux        205	  
Figure 6.4.  Putative interactions between the N-terminal region of sacsin  
encompassing the UbL domain and proteins implicated in protein 








LIST OF TABLES 
	   XIV 
LIST OF TABLES 
 
Table 1.1.  Autosomal Recessive Cerebellar Ataxias      4 
Table 1.2.  SACS mutations in ARSACS patients      9 
Table 1.3.  HSPA (HSP70) members        22 
Table 1.4.  DNAJ mutations and resulting human diseases     25 
Table 1.5.  Dynactin subunits         50 
Table 1.6. Intermediate filament proteins in mammals      60 
 
Table 2.1. Transfection using lipofectamine and plus reagent     70	  
Table 2.2. Transfection using lipofectamine 3000      71	  
Table 2.3. siRNA sequences         71	  
Table 2.4. Reverse-transcription reaction components      73	  
Table 2.5.  Standard PCR Mastermix        74	  
Table 2.6. PCR cycling conditions        75	  
Table 2.7.  Primer sequences         75	  
Table 2.8. Restriction digest reaction mix       79	  
Table 2.9. Ligation reaction mixes        80	  
Table 2.10. Primary antibodies used in immunoblotting and  
Immunocytochemistry        89 
Table 2.11. Secondary fluorescent antibodies used in immunoblotting and 
Immunocytochemistry        90 
 
Table 4.1.  ARSACS HDF lines used in this thesis      131 
 







LIST OF ABBREVIATIONS 
	   XV 
LIST OF ABBREVIATIONS 
 
ACTN4  α-actinin-4 
AD   Alzheimer's disease 
ADOA  Autosomal dominant optic atrophy 
ADP   Adenosine diphosphate 
ALP  Autophagy-lysosome pathway 
ALS  Amyotrophic lateral sclerosis 
ARCA  Autosomal recessive cerebellar ataxia 
ARSACS Autosomal recessive spastic ataxia of Charlevoix-Saguenay 
AT   Ataxia telangiectasia 
ATG   Autophagy-related 
ATP   Adenosine triphosphate 
ATPase Adenosine triphosphatase 
ATP6ap2  ATP6 associated protein 2 
ATXN3 Ataxin 3 
ADOA  Autosomal dominant optic atrophy 
Aβ   β-amyloid  
BSA  Bovine serum albumin 
CAD  Coronay artery disease 
CaMK1α Calcium/calmodulin-dependent kinase 1α 
CaN  Calcineurin 
CAPs  Cytoskeletal associated proteins 
CAP-Gly Glycine-rich cytoskeleton-associated protein 
Ca2+   Calcium ion 
CCCP   Carbonyl cyanide m-chlorophenylhydrazone 
CDK5   Cyclin-dependent kinase 5 
cDNA   Complementary DNA 
CFTR  Cystic Fibrosis Transmembrane Conductance Regulator 
CHIP   C-terminus of HSP70 interacting protein 
CMA   Chaperone mediated autophagy 
CMT  Charcot-Marie-Tooth 
CNS   Central nervous system 
Co-IP  Co-immunoprecipitation 
LIST OF ABBREVIATIONS 
	   XVI 
COPS5  COP9 subunit 5 
CO2  Carbon dioxide 
C-terminus  Carboxy-terminus 
DAPI   4',6-diamidino-2-phenylindole dihydrochloride 
DCTN6  Dynactin-6 
dH20  Deionised water 
DIC   Dynein intermediate chain 
DMEM  Dulbecco's Minimum Eagle Medium 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTP   Deoxynucleotide 
DPBS   Dulbecco’s phosphate buffered saline 
DRG  Dorsal root ganglion 
DRP1   Dynamin related protein 1 
DSP   Dithiobis[succinimidylpropionate] 
DUB   Deubiquitinating enzyme 
E.coli   Escherichia coli 
ECACC  European Collection of Cell Culture 
EDTA   Ethylenediaminetetraacetic acid 
EEA1   Early endosome antigen 1 
EGTA  Ethylene glycol tetraacetic acid 
ER   Endoplasmic reticulum 
ERAD  ER-associated degradation 
EV  Empty vector 
FBS   Foetal bovine serum 
Fis1   Mitochondrial fission protein 1 
FP  Fluorescent polarisation 
FRAP  Fluorescence recovery after photobleaching  
FRDA  Friedreich ataxia 
g  Standard acceleration due to gravity 
GAN  Giant axonal neuropathy 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
gDNA  Genomic DNA 
GED  GTPase effector domain 
LIST OF ABBREVIATIONS 
	   XVII 
GFAP  Glial fibrillary acidic protein 
GFP   Green fluorescent protein 
GTP   Guanosine triphosphate 
HD   Huntington's disease 
HDAC6 Histone deacetylase 6 
HDF  Human dermal fibroblasts 
HEK293 Human embryonic kidney 293 cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEPN   Higher eukaryote and prokaryote nucleotide binding 
HIP   HSP70 interacting protein 
HOP   HSP70 and HSP90 organising protein 
HPA   Health Protection Agency 
HPD   Histidine-proline-glutamate 
HSF1  Heat shock factor 1 
HSP   Heat shock protein 
HSR  Heat shock response 
HuH-7  Human hepatoma cell line 7 
IB  Immunoblotting 
IC  Immunocytochemistry 
IF  Intermediate filaments 
IFT  Intraflagellar transport 
IGF  Insulin growth factor 
IMM  Inner mitochondrial membrane 
IP  Immunoprecipitation 
iPSC  Induced pluripotent stem cells 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
kDa   kiloDalton 
LAMP2  Lysosome-associated membrane protein-2 
LB   Luria broth 
LSD  Lysosome storage disease 
MAPL  Mitochondria-anchored protein ligase 
MEFs  Mouse embryonic fibroblasts 
MFF  Mitochondrial fission factor 
MFN1  Mitofusin 1 
LIST OF ABBREVIATIONS 
	   XVIII 
MFN2  Mitofusin 2 
MiD49/51 Mitochondrial dynamics proteins of 49 and 51 kDa 
MJD  Machado-Joseph disease 
MOPS  3-(N-morpholino)propanesulfonic acid 
MPP   Mitochondrial processing peptidase 
MRI   Magnetic resonance imaging 
mRNA  messenger RNA 
MSS   Marinesco-Sjögren syndrome 
mtDNA  mitochondrial DNA 
MTOC  Microtubule organising centre 
mTOR  Mammalian target of rapamycin 
NEFs  Nucleotide exchange factors 
NFs  Neurofilaments 
NFH  Neurofilament heavy chain 
NFL  Neurofilament light chain  
NFM  Neurofilament medium chain 
NFT  Neurofibrillary tangles 
NGS   Normal goat serum 
NHDF  Normal human dermal fibroblasts 
nm  Nanometers 
nM  Nanomoles 
NO  Nitric oxide 
npNFH Non-phosphorylated neurofilament heavy chain 
N-terminus  amino-terminus 
O2  Oxygen 
OMIM  Online mendelian inheritance in man 
OMM  Outer mitochondrial membrane 
OPA1   Optic atrophy 1 
OCT  Optical coherence tomography 
PARL  Presenilins-associated rhomboid-like protein 
PBST  Phosphate buffered saline with Tween20 
PCR   Polymerase chain reaction 
PD   Parkinson's disease 
Pen/Strep  Penicillin/streptomycin 
LIST OF ABBREVIATIONS 
	   XIX 
PICK1  Protein interacting with C kinase 1 
PINK-1  PTEN-induced kinase 1 
PKA   Protein kinase A 
PolyQ   Polyglutamine 
PS1  Preslin 1 
Rad23A  Radiation-sensitive mutant 23 
RNFL  Retinal nerve-fibre layer 
RIPA  Radio-Immunoprecipitation assay 
RNA   Ribonucleic acid 
RNAi   RNA interference 
RNAase  Ribonuclease 
ROS  Reactive oxygen species 
rpm   Revolutions per minute 
RT  Reverse transcription 
RT-qPCR Reverse transcription-quantitative polymerase chain reaction 
SACS  Sacsin 
SCA   Spinocerebellar ataxias 
SCRM  Scrambled 
SD  Standard deviation 
SDS   Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM  Standard error of mean 
SENP  Sentrin-specific protease 
Ser  Serine 
sHSP  Small heat shock protein 
siRNA  Small interfering RNA 
SOC  Super optimal broth with catabolite repression 
SRR   Sacsin repeating region 
SR-SIM Super resolution structured illumination microscopy 
SUMO  Small ubiquitin-like modifier 
TAE  Tris-acetate-EDTA buffer 
Taq  Thermus aquaticus 
TBST  Tris buffered saline with Tween20 
TMRM  Tetra methylrhodamine methyl ester 
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TOM20  Translocase of outer mitochondrial membrane 20 
TPR   Tetratricopeptide repeat 
Ub   Ubiquitin 
UbA   Ubiquitin-associated 
UbL   Ubiquitin-like 
UIM   Ubiquitin-interaction motif 
UPR  Unfolded protein response 
UPS   Ubiquitin-proteasome system 
UV  Ultraviolet 
V-ATPase Vacuolar-type adenosine triphosphatase 
VDCCs Voltage-dependent calcium channels 
WT  Wild type 
X-Gal   5-bromo-4-chloro-3-indolyl- beta-D-galactopyranoside 
XPCB   Xeroderma pigmentosum complementation group C binding 
Y2H   Yeast two-hybrid 
ΔΨm   Mitochondrial membrane potential 
2-ME              2-Mercaptoethan 
3D                  Three dimensional 
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1.1. Cerebellar Ataxias 
Within the brain, the cerebellum plays an important role in motor control. It does not 
initiate movement, but coordinates and regulates motor activity. The cerebellum is 
divided into three distinct layers: the fibre-rich molecular layer, the Purkinje cell layer, 
and the inner granular layer, which has high concentrations of granule cells. Lesions of 
the cerebellum or spinal cord result in disorders known as ataxias. Ataxias are 
characterised by loss of gross muscle control, leading to posture and gait disturbances, 
uncoordinated movement and unsteadiness. Other features may include dysarthria 
(motor speech disorder), dysphagia (difficulty swallowing), vertigo, and diplopia 
(double vision (Perlman, 2004)). 
Ataxias can be inherited or sporadic, and are also caused by external forces or agents 
such as injury, drugs or alcohol (Manto and Marmolino, 2009). Purkinje cell 
degeneration is frequently observed (Crossman and Neary, 2004), along with atrophy of 
the cerebellum, which can be seen on magnetic resonance imaging (MRI) of patients 
(Fogel and Perlman, 2007; Palau and Espinas, 2006; Viau and Boulanger, 2004). 
Hereditary ataxias are usually divided into four main categories based on their mode of 
inheritance: autosomal dominant, autosomal recessive, X-linked and mitochondrial 
(Fogel and Perlman, 2007). The autosomal dominant ataxias, also known as 
spinocerebellar ataxias (SCAs), typically have adult onset (Schols et al., 2004) and more 
than 35 have been described (Jayadev and Bird 2013, Soong and Paulson, 2007). The 
most common subtypes are SCA 1, 2, 3, 6, and 7, all of which are nucleotide repeat 
expansion disorders. The autosomal recessive ataxias manifest mostly in children and 
young adults (Anheim et al., 2012b) and are typically associated with loss-of-function 
protein mutations. More than 20 have been described to date (Embirucu et al., 2009; 
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1.2. Autosomal Recessive Cerebellar Ataxias  
Autosomal recessive cerebellar ataxias (ARCAs) represent a heterogeneous and 
complex group of inherited neurodegenerative diseases. They are generally associated 
with peripheral sensorimotor neuropathy and also tend to have involvement outside the 
nervous system (Di Donato et al., 2001; van de Warrenburg et al., 2002). The major 
ARCAs can be divided into three groups: (1) Friedreich’s ataxia and phenotypically 
related disorders, (2) Friedreich’s ataxia phenotype with cerebellar atrophy, and (3) 
early-onset ataxia with cerebellar atrophy (Table 1.1 (Fogel and Perlman, 2007)). In the 
latter group, Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) 
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Table 1.1. Autosomal Recessive Cerebellar Ataxias  
 Defective gene/protein Proposed protein function 
Friedreich’s ataxia-like 
Friedreich’s ataxia Frataxin (FXN) Mitochondrial iron metabolism 
Ataxia with vitamin E 
deficiency 
α-tocopherol transfer protein (TTPA) Vitamin E homeostasis 
Abetalipoproteinaemia Microsomal triglyceride transfer 
protein (MTP) 
Lipoprotein metabolism 
Refsum’s disease Phytanoyl-CoA hydroxylase (PHYH) 
Peroxin 7 (PEX7) 
Fatty-acid oxidation 
Peroxisomal protein importation 
Friedreich’s ataxia-like with cerebellar atrophy 
Late-onset Tay-Sachs 
disease 
Β-hexosaminidase A (HEXA) Glycosphingolipid metabolism 
Cerebrotendinous 
xanthomatosis 
Sterol 27-hydroxylase (CYP27) Bile-acid synthesis 
DNA polymerase γ 
disorders  
DNA polymerase γ (POLG) 
 
Mitochondrial DNA repair and 
replication 
Spinocerebellar ataxia 
with axonal neuropathy 
Tyrosyl-DNA phosphodiesterase 1 
(TDP1) 
DNA repair 
Early-onset ataxia with cerebellar atrophy 
Ataxia telangiectasia Ataxia telangiectasia-mutated (ATM) DNA damage response 
Ataxia telangiectasia-like 
disorder 
Meiotic recombination 11 (MRE11) DNA damage response 
Ataxia with oculomotor 
apraxia, type 1 
Aprataxin (APTX) DNA repair, possibly RNA 
processing 
Ataxia with oculomotor 
apraxia, type 2 
Senataxin (SETX) Possibly DNA repair, DNA 
transcription, or RNA 
processing 
Autosomal recessive 
spastic ataxia of 
Charlevoix-Saguenay 
Sacsin (SACS) Possibly protein folding 
Infantile-onset 
spinocerebellar ataxia 
Twinkle, twinky (C10orf2) DNA replication 




BiP-associated protein (SIL1) Possibly protein folding 
Table adapted from (Fogel and Perlman, 2007) 
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ARCAs are heterogeneous within and between disorders with respect to the age of 
onset, the severity of disease progression, and the frequency of extra-cerebellar and 
systemic signs (Anheim et al., 2012b). Even mutations in the same gene can lead to 
distinct phenotypes. For example, Friedreich’s ataxia may manifest as early-onset 
(Anheim et al., 2012a), late-onset (Schols et al., 1997), or very late-onset (Berciano et 
al., 2005) disease (before 10 years, after 25 years, and after 40 years of age, 
respectively). 
 
1.2.1. Friedreich’s ataxia 
Friedreich’s ataxia (OMIM: 229300) is the most common ARCA in North America and 
Europe, with a prevalence of approximately 1 in 30,000-50,000 in most populations and 
a carrier frequency of approximately 1 in 85 in white Caucasians (Cossee et al., 1997; 
Pandolfo, 1999; Schols et al., 1997). Age of onset is typically before 25 years and 
characteristic features include progressive gait and limb ataxia, dysarthria, loss of 
vibration and proprioceptive sense, areflexia (absence of reflexes), abnormal eye 
movements, cardiomyopathy, diabetes mellitus, scoliosis (abnormal curvature of the 
spine to the sides), and pes cavus (high-arched foot) (Alper and Narayanan, 2003; 
Delatycki et al., 2000; Harding, 1981).  
The disease is caused by a triplet Guanine-Adenine-Adenine (GAA) expansion within 
the first intron of the frataxin gene (FXN) on chromosome 9q13 in 98% of patients 
(Campuzano et al., 1996). There is an inverse correlation between both the age of onset 
and severity of the disease with the size of the GAA repeat expansions, which range 
from 70-90 repeats to over 1000 (normal size of the GAA tract in unaffected individuals 
is less than 40). Point mutations can also cause the disorder in 2-4% of patients 
(Pandolfo, 1999; Pandolfo, 2001; Schols et al., 1997). 
The frataxin protein is associated with the inner mitochondrial membrane and cristae, 
and contains a N-terminal mitochondrial targeting sequence, which is encoded by the 
first 20 amino acids (Campuzano et al., 1997). Loss of frataxin impairs mitochondrial 
iron handling and respiratory chain function and contributes to increased oxidative 
stress and cellular damage (Bradley et al., 2000; Cavadini et al., 2002; Lodi et al., 
1999). Neuron-specific and striated-muscle-specific knockout mice have ataxia, 
proprioceptive loss, cardiac hypertrophy and a deficiency in respiratory-chain 
complexes (Puccio et al., 2001).  
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1.2.2. Ataxia telangiectasia 
Ataxia telangiectasia (AT, OMIM: 208900), also known as Louis–Bar syndrome, is the 
second most common ARCA, with a prevalence of 1 in 40,000-100,000 people 
worldwide (Swift et al., 1986) and age of onset is early childhood, typically before 5 
years. It is a multi-systemic disorder characterised by neurodegeneration with 
progressive cerebellar ataxia and oculomotor dysfunction (Chun and Gatti, 2004; Hoche 
et al., 2012; Sedgwick, 1991), elevated serum alpha-fetoprotein levels, chromosome 
instability, immunodeficiency and a predisposition to cancer. Telangiectases, small 
clusters of enlarged blood vessels in the eyes and on the surface of the skin, are also 
characteristic of this condition. Brain imaging and post-mortem analysis reveals atrophy 
and degeneration of the cerebellar cortex, with loss of Purkinje and granule cells 
(Verhagen et al., 2012). 
The disease is caused by mutations in ATM on chromosome 11q22-23, which encodes a 
constitutively expressed Serine/Threonine protein kinase involved in the control of cell 
division and DNA repair (Mavrou et al., 2008; Savitsky et al., 1995). Over 400 ATM 
mutations have been identified, with about 85% of mutations resulting in premature 
protein truncation. Most patients have compound heterozygous mutations (Hall, 2005). 
ATM phosphorylates several proteins that play key roles in DNA damage response 
pathways. In the brain, the ATM kinase may also be involved in vesicle traffic to the 
Golgi (Cara et al., 2016; Li et al., 2009). Loss of function of ATM leads to oxidative 
stress and cell apoptosis, particularly of Purkinje cells in the cerebellum (Chen et al., 
2003b; Takao et al., 2000). 
 
1.2.3. Marinesco-Sjogren’s syndrome 
Marinesco-Sjogren syndrome (MSS, OMIM: 248800) was identified as the fourth most 
common form of ARCA (Anheim et al., 2010). Characteristic features include 
cerebellar atrophy due to loss of Purkinje and granule cells (Mahloudji et al., 1972; 
Todorov, 1965), congenital cataracts, progressive muscle weakness due to myopathy, 
and delayed psychomotor development (Lagier-Tourenne et al., 2003; Sjogren, 1950). 
Additional features include short stature, hypergonadotrophic hypogonadism, and 
skeletal deformities. The disease is caused by homozygous or compound heterozygous 
mutations in SIL1 on chromosome 5q31, which lead to premature termination of 
translation or abnormal splicing of the transcript, resulting in loss of SIL1 function 
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(Anttonen et al., 2005; Senderek et al., 2005). SIL1 is ubiquitously expressed and 
encodes a nucleotide exchange factor for the heat-shock protein 70 (HSP70) family 
molecular chaperone BiP (also known as GRP78 and HSPA5), which functions in the 
endoplasmic reticulum (ER) lumen (Chung et al., 2002; Tyson and Stirling, 2000). SIL1 
regulates the ATPase cycle of GRP78 and hence, may be involved in protein 
translocation into the ER, protein folding and degradation, and responses to cell stress 
(Hendershot, 2004). 
 
1.3. Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) 
ARSACS (OMIM: 270550) is a rare complex hereditary neurological disease originally 
described in a founder population in the Charlevoix and Saguenay-Lac Saint Jean 
regions of North-Eastern Québec in Canada, in 1978, where the carrier frequency is 
estimated to be 1 in 22 (Bouchard et al., 1978; Bouchard et al., 1998; De Braekeleer et 
al., 1993). ARSACS patients have now been identified worldwide, with cases in 
Europe, North Africa, Turkey, Japan and Brazil (Bouhlal et al., 2011; Pyle et al., 2012). 
Along with Freidreich’s ataxia, AT and MSS, ARSACS is one of the more common 
types of ARCA worldwide (Bouhlal et al., 2011; Synofzik et al., 2013; Vermeer et al., 
2008). Disease onset is typically in early childhood, but may also be later in life, 
particularly in patients outside of Québec (Pyle et al., 2012). The disease has frequently 
been confused with cerebral palsy and secondary spastic diplegia.  
 
1.3.1. Clinical Features 
Bouchard et al. first reported the clinical features of ARSACS in 1978, with most 
patients showing a typical triad of slowly progressive, early-onset cerebellar ataxia, 
lower limb spasticity and peripheral neuropathy (Synofzik et al., 2013). Lower limb 
spasticity is evident between the ages of 12-24 months when patients begin to walk, 
although this may develop later, but rarely after the age of 12 (Bouhlal et al., 2011). 
However, the classical triad is not present in all ARSACS patients. Patients more 
recently identified outside of Canada display considerable phenotypic heterogeneity, so 
that now neither spasticity nor ataxia can be regarded as obligate features of the 
condition (Synofzik et al., 2013). For example, several ARSACS siblings were 
misdiagnosed with Charcot-Marie-Tooth (CMT) disease due to the absence of 
cerebellar ataxia and lower limb spasticity (Pyle et al., 2012; Synofzik et al., 2013). 
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ARSACS patients with an absence of peripheral neuropathy have also been identified 
(Synofzik et al., 2013). Age of onset may be later in patients outside of Canada, for 
example, out of a series of 17 Belgian patients, 29% had onset of symptoms at or after 
age 20, with one as late as 40 years of age (Baets et al., 2010).	   
Retinal changes are an additional characteristic phenotype, not seen in other ataxias. 
These retinal changes were originally described as hypermyelination of retinal nerve 
fibres (Bouchard et al., 1998; Richter et al., 2004), however more recently this has been 
suggested to be a thickening of the retinal nerve-fibre layer (RNFL) rather than 
hypermyelination (Nethisinghe et al., 2011; Pilliod et al., 2015). In support of this, a 29-
year old British male patient had a RNFL thickness above the 95th percentile, as 
determined by optical coherence tomography (OCT) (Nethisinghe et al., 2011). It has 
been suggested that more ARSACS patients have their RNFL thickness assessed using 
OCT, as this retinal phenotype could be useful in diagnosis. Despite the presence of 
thickened RNFL, optic nerve and retinal function are not generally affected, with 
normal acuity, fields and colour vision (Bouchard, 1991). 
Other disease characteristics include dysarthria, which is reported in all ARSACS 
patients worldwide, with slurring of speech in childhood, which becomes explosive in 
adulthood (Bouhlal et al., 2011), nystagmus (involuntary eye movement), amyotrophy 
(muscle wasting), and finger and foot deformities, which are due to distal muscle 
weakness and atrophy (Haga et al., 2012; Li, 2013; Tzoulis et al., 2013). 
Pathological features of ARSACS include atrophy of the upper cerebellar vermis 
(Bouhlal et al., 2011; Martin et al., 2007; Pilliod et al., 2015), and absence of Purkinje 
cells post mortem (Bouchard, 1991; Bouchard, 2000). Spinal cord and linear T2 
hypointensities are also commonly found in the basis pontis (Bouchard et al., 1998; 
Martin et al., 2007; Sanchez et al., 2015). Québec patients are wheelchair-bound on 
average by age 41, and their life expectancy is shortened to a mean age of 51 
(Bouchard, 1991; Dupre et al., 2006). There is no available therapy for ARSACS and 
treatment is provided to control symptoms.  
 
1.3.2. Causative Gene and Mutations 
SACS (OMIM: 604490) was identified as the causative gene for ARSACS in 2000 and 
has been mapped to chromosome 13q12.12 (Engert et al., 2000). The gene was initially 
thought to be encoded by a single gigantic exon spanning 12,794bp with a 11,487bp 
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open reading frame (Engert et al., 2000), but since then 8 further coding exons and a 
tenth non-coding exon have been identified upstream of this, forming a 13,737bp open 
reading frame (Figure 1.1A, (Ouyang et al., 2006; Parfitt et al., 2009; Vermeer et al., 
2008). To date, over 120 pathogenic mutations in SACS have been identified worldwide 
(Table 1.2), which consist of missense, nonsense, frameshift and splice-site mutations, 
the most of which are located in the giant exon 10 (Kamada et al., 2008; Ouyang et al., 
2006; Takado et al., 2007; Thiffault et al., 2013; Vermeer et al., 2008). The majority of 
cases of ARSACS in Québec are caused by two founder mutations: a single nucleotide 
deletion (c.8844delT) and a nonsense mutation (c.7504C>T (Engert et al., 2000; Engert 
et al., 1999; Richter et al., 1999)).  
 
Table 1.2. SACS mutations in ARSACS patients  
Mutation Amino Acid Change 
Protein 
Domain Origin Reference 
216delT C72fs*76  Belgium (Baets et al., 2010) 
237insAfs* S80Ifs*98  Canada (Thiffault et al., 2013) 
414 C >G Y138* R1: sr1 Japan (Shimazaki et al., 2012) 
482delA N161-fs*175 R1: sr1 Japan (Kamada et al., 2008) 




fs*214 R1: sr1 Italy 
(Terracciano et al., 
2009) 
602 C >A T201K R1: sr1 Belgium (Baets et al., 2010) 
814 C > T R272C R1: sr1 Canada (Guernsey et al., 2010) 
815 G > A R272H R1: sr1 Italy (Dibilio et al., 2013) 
826 C > T R276C R1: sr1 Italy (Prodi et al., 2012) 
922 C > T L308F R1: sr1 Japan (Takado et al., 2007) 




fs*407 R1 Japan (Ouyang et al., 2006) 
1190insAfs* S397Kfs*405 R1 Canada (Thiffault et al., 2013) 
1228_1229delT
T S409fs*2 R1: sr2 Italy (Prodi et al., 2012) 
1373 C > T T458I R1: sr2 Germany (Synofzik et al., 2007) 
1420 C > T R474C R1: sr2 Italy (Romano et al., 2013) 
1475 G> A W492* R1: sr2 Netherlands (Vermeer et al., 2008) 
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1597 C > T P536L R1: sr2 France (Anheim et al., 2010) 
1647_1658del L549_552del R1: sr2 Germany (Synofzik et al., 2007) 
1667 T > C L556P R1: sr2 Morocco (Baets et al., 2010) 
2063delT V687-fs*713 R1: srX Japan (Ouyang et al., 2006) 
2076delG T692T fs*713 R1: srX UK (Pyle et al., 2012) 
2094-2A > G  R1: srX Netherlands (Vermeer et al., 2008) 
2115_2116insC R707Kfs*6 R1: srX India (Faruq et al., 2014) 




8del R1: srX Italy (Prodi et al., 2012) 
2387del L796Yfs*13 R1: srX Germany (Synofzik et al., 2007) 
2405 T > C L802P R1: srX Japan (Kamada et al., 2008) 
2439_2440delA
T V815Gfs*4 R1: srX Tunisia (Hammer et al., 2013) 
2881 C > T 
c11634ins A 
R961*K3878
fs*13 R1: srX Italy (Prodi et al., 2012) 
2971 T > C C991R R1: srX Belgium (Baets et al., 2010) 
2983 G > T V995F R1: srX Germany (Synofzik et al., 2007) 
3161 T > C F1054S R1: srX Japan (Shimazaki et al., 2005) 
3328insA I1110-fs*1111 R1: srX Tunisia 





fs*1150 R1: srX Belgium (Baets et al., 2010) 
3491 T > A M1164K  Belgium (Ouyang et al., 2006) 
3585 delT I1195-fs*1206  Tunisia 
(El Euch-Fayache et al., 
2003) 
3769 G > T G1257* R1: sr3 Japan (Shimazaki et al., 2012) 




343 R1: sr3 UK (Pyle et al., 2012) 
4033 T > C Q1345* R1: sr3 Japan (Okawa et al., 2006) 
4033insC Q1345-fs*1349 R1: sr3 Italy (Criscuolo et al., 2004) 
4060 C > T Q1354* R1: sr3 Italy (Prodi et al., 2012) 
4108 C > T Q1370* R1: sr3 Italy (Grieco et al., 2004) 
4145_4146insA H1382Qfs*2  Italy (Prodi et al., 2012) 
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4195 T > C C1398R  Turkey (Richter et al., 2004) 
4205 A > T D1402V  Canada (Thiffault et al., 2013) 
4593dupA S1531fs*9 R2: sr1 Italy (Prodi et al., 2012) 
4724 G > C R1575P R2: sr1 Serbia (Baets et al., 2010) 
4744 G > A D1582N R2: sr1 Canada (Thiffault et al., 2013) 
4760 T > G H1587R R2: sr1 Belgium (Baets et al., 2010) 
4775_4776insA I1592fs*1 R2: sr1 Italy (Prodi et al., 2012) 
4954 C > T Q16652* R2: sr1 Germany (Synofzik et al., 2007) 




Q1628* R2: sr1 Algeria (H'mida-Ben Brahim et al., 2011) 
5125 C >T E1709* R2: sr1 Netherlands (Vermeer et al., 2008) 
5143 A>T K1715* R2: sr1 Netherlands (Vermeer et al., 2008) 




fs*1736 R2: sr1 Japan 
(Yamamoto et al., 
2005) 
5263-4delAA K1755Vfs*1775 R2 Japan (Shimazaki et al., 2012) 
5544dupA V1849Sfs*48 R2: sr2 Germany (Synofzik et al., 2007) 
5629 C > T R1877* R2: sr2 Italy (Anesi et al., 2011) 
5719 C >T R1907* R2: sr2 Italy (Prodi et al., 2012) 
5836 T > C W1946R R2: sr2 Tunisia (El Euch-Fayache et al., 2003) 
5948 C > T S1983F R2 UK (Stevens et al., 2013) 
5988-9delT fs*1999 R2 Japan (Shimazaki et al., 2007) 
6006delA R2002fs*2013 R2 Netherlands (Vermeer et al., 2008) 
6093_6095delT
TC S2032del R2 Serbia (Baets et al., 2010) 
6172delT S2058Lfs*2076 R2 Japan 
(Yamamoto et al., 
2005) 
6355C > T R2119* R2 Japan (Hara et al., 2007) 
6352delT F2131fs*2144 R2 UK (Stevens et al., 2013) 
6409 C > T Q2137* R2 Algeria (H'mida-Ben Brahim et al., 2011) 
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6890 T>G L2297W R2: sr3 Norway (Tzoulis et al., 2013) 
6835insA E2280Rfs*2291 R2: sr3 Italy (Grieco et al., 2004) 
7121 T > C L2374S R2: sr3 Italy (Terracciano et al., 2009) 
7250_7254del T2417-fs*2429 R2: sr3 Italy (Grieco et al., 2004) 
7255_7259 E2418fs*10 R2: sr3 Italy (Prodi et al., 2012) 
7277 G > C R2426P R2: sr3 Germany (Synofzik et al., 2007) 
7279 C > T R2426* R2: sr3 Belgium (Baets et al., 2010) 




fs*2463  Algeria 
(H'mida-Ben Brahim et 
al., 2011) 
7504 C > T R2502*  Canada (Engert et al., 2000) 
7613 C > T A2558V R3: sr1 France (Anheim et al., 2010) 
8107 C > T R2703C R3: sr1 Spain (Criscuolo et al., 2005) 
8339 T > G F2780C R3 UK  
8393 C > A P2798Q R3 Morocco (Baets et al., 2010) 
8401-8403del E2801del R3 Netherlands (Vermeer et al., 2008) 
8584 A > T K2862* R3: sr2 Germany (Synofzik et al., 2007) 
8793delA K2931-
fs*2952 R3: sr2 Japan (Hara et al., 2005) 
8844delT K2948-fs*2952 R3: sr2 Canada (Engert et al., 2000) 
8920_8923dup Y2975Ffs*29 R3 Germany (Synofzik et al., 2007) 
9305_9306 insT L3102Ffs* R3: srX Germany (Synofzik et al., 2007) 
9497_9498delT
T F3166* R3: srX Canada (Thiffault et al., 2013) 
9508C>T R3170* R3: srX Canada (Thiffault et al., 2013) 
9742 T > C W3248R R3: srX Japan (Ogawa et al., 2004) 
9911_9912del L3304fs R3: srX Netherlands (Vermeer et al., 2008) 
10034 T > C V3345A R3: srX Italy (Prodi et al., 2012) 
10290 C > G Y3430* R3: srX Algeria (H'mida-Ben Brahim et al., 2011) 
10298delC T3433-fs*3458 R3: srX Turkey (Richter et al., 2004) 
10442 T > C L3481P R3: srX Netherlands (Vermeer et al., 2008) 
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10517 T > C F3506S R3: srX Belgium (Breckpot et al., 2008) 
10906 C > T R3636Q R3: srX Belgium (Baets et al., 2010) 
10906 C > T R3636* R3: srX Netherlands (Vermeer et al., 2008) 
10954 C > A R3652T R3: srX Belgium (Baets et al., 2010) 
10958 T > C F3653S R3: srX Belgium (Baets et al., 2010) 
11012_11013del
AA Q3671Rfs*23 XPCB Italy (Masciullo et al., 2012) 




fs*3746 XPCB Belgium (Baets et al., 2010) 




fs*3762 XPCB Hungary (Baets et al., 2010) 
11361-2insT R3788Sfs*3820 R3: sr3 Japan (Shimazaki et al., 2012) 
11375 C > T R3792* R3: sr3 Tunisia (Bouhlal et al., 2011) 
11542_11544del I3848del R3: sr3 Germany (Synofzik et al., 2007) 
11598delC G3866fs*3 R3: sr3 Italy (Masciullo et al., 2012) 
11624 G > A R3875H R3: sr3 Germany (Synofzik et al., 2007) 
11675 C > G S3892* R3: sr3 UK  
11707 C > T R3903*  Canada (Guernsey et al., 2010) 
11803 C > T Q3935*  China (Liu et al., 2016)  
11829-32AGTT L3943-fs*3958  Turkey (Richter et al., 2004) 
11984_11986du
pTGT L3995dup  Germany (Synofzik et al., 2007) 
12020 C>T S4007F  Japan (Miyatake et al., 2012) 
12160 C >T Q4054*  Netherlands (Vermeer et al., 2008) 
12220 G > C A4074P  Tunisia (El Euch-Fayache et al., 2003) 
12232 C > T R4078  Italy (Prodi et al., 2012) 
12416 T > C L4139S  UK  
12428_12429ins
A Y4143*  Italy (Prodi et al., 2012) 




fs*4305  Tunisia (Bouhlal et al., 2009) 
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fs*4307  Algeria 
(H'mida-Ben Brahim et 
al., 2011) 
12973 C > T R4325* J-domain Japan (Yamamoto et al., 2005) 
12982 delA K4327fs*7 J-domain Italy (Prodi et al., 2012) 
12991 C > T R4331W J-domain Italy (Prodi et al., 2012) 
12992 G > A R4331Q J-domain Netherlands (Vermeer et al., 2008) 
13027 G > A E4343K J-domain Belgium (Baets et al., 2010) 
13048 G >T E4350 J-domain UK (Pyle et al., 2013) 
13056 delT F4352Lfs*11 J-domain Germany (Synofzik et al., 2007) 
13132 C > T R4378* J-domain Italy (Anesi et al., 2011) 
13237 T > C Q4413*  UK (Terracciano et al., 2010) 
13352 T > C L4451P  Norway (Tzoulis et al., 2013) 
13389 G > T D4464Y HEPN Tunisia (Bouhlal et al., 2011) 
13523 A > C K4508T HEPN Belgium (Baets et al., 2010) 
13538 G > A S4513N HEPN Germany (Synofzik et al., 2007) 
13645 A > G N4549D HEPN Turkey (Richter et al., 2004) 
Del 0.7Mb 
13q12.12   UK (Pyle et al., 2013) 
Del 1.33Mb 
13q12.12   China (Liu et al., 2016) 
Amino acid changes refer to full length sacsin (4579 amino acids, ENSP00000371729). 
Amino acid change to an * indicates a truncated protein, fs indicates a frameshift and 
del indicates a deletion. For the protein domains, R1: repeat region 1, R2: repeat region 
2, R3: repeat region 3, sr1: subrepeat 1, sr2: subrepeat 2, sr3: subrepeat 3, srX: 
subrepeat X (Figure 1.1B). 
 
 
There is no current evidence for a genotype-phenotype correlation in ARSACS. Patients 
with mutations in coding exon 7 are clinically identical to those with mutations in 
coding exon 9 (Takado et al., 2007). Also, in two unrelated Tunisian families with the 
same mutation (12220G>C) only one had skeletal deformities and the age of onset was 
different between the two families (Bouhlal et al., 2011). Possible explanations for these 
differences may be that an additional mutation is present in another gene in one of the 
families, or environmental factors are influencing phenotype.   
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1.3.3. Sacsin (DNAJC29) 
SACS encodes the protein sacsin, a modular protein of 4579 amino acids (520 kDa), one 
of the largest known proteins in the human genome. From N- to C-terminus, sacsin is 
composed of a ubiquitin-like (UbL) domain that binds to the proteasome (Parfitt et al., 
2009), three large sacsin repeat region (SRR) supra-domains, which contain regions of 
homology to HSP90 (Anderson et al., 2010; Romano et al., 2013), a xeroderma 
pigmentosum complementation group C (XPC)-binding domain that binds to the 
UBE3A ubiquitin protein ligase (Kamionka and Feigon, 2004), a DNAJ domain that 
binds and stimulates HSP70 (Parfitt et al., 2009), and a higher eukaryotes and 
prokaryotes nucleotide (HEPN)-binding domain that mediates sacsin dimerisation 
(Figure 1.1B, (Girard et al., 2012; Grynberg et al., 2003)). The nature of these domains 
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1.3.4. Sacsin Expression and Localisation 
The gene encoding sacsin is found in all vertebrate genomes sequenced so far (Engert et 
al., 2000; Parfitt et al., 2009; Romano et al., 2013). Human sacsin shares ~99% to ~93% 
amino acid identity with that of other mammals (orangutan, mouse, rat, horse, dog), 
~84% similarity with birds (chicken, zebra finch), 83% similarity with reptiles (anole 
lizard), and ~70% to ~68% similarity with fish (zebrafish, tetraodon, fugu, stickleback 
and medaka). Moreover, all vertebrate sacsin orthologues have the same structural 
architecture (Romano et al., 2013).  
Human sacsin is expressed in many tissues, with high levels of messager RNA (mRNA) 
and protein in large neurons, particularly cerebellar Purkinje cells (Parfitt et al., 2009). 
Expression patterns are similar in other mammals and fish (Engert et al., 2000; Parfitt et 
al., 2009; Romano et al., 2013).  
The subcellular localisation of sacsin is cytoplasmic with a significant mitochondrial 
component in SH-SY5Y neuroblastoma cells (Parfitt et al., 2009). Colocalisation of 
sacsin with mitochondrial markers was also shown in the soma, dendrites and axons of 
cultured hippocampal neurons, as well as in COS-7 and HeLa cells (Girard et al., 2012).  
Analyses of the sacsin protein sequence did not reveal the presence of a mitochondrial 
leader sequence (Parfitt et al., 2009), suggesting that sacsin’s mitochondrial localisation 
is at or near the cytoplasmic face of the mitochondria. 
 
1.3.5. Sacsin knockout mouse model 
Sacs knockout (Sacs-/-) mice have been generated to study the pathophysiological basis 
of ARSACS. Behavioural analysis conducted over a one-year period demonstrated that 
Sacs-/- mice develop a grossly abnormal gait with progressive motor, cerebellar, and 
peripheral nerve dysfunctions (Lariviere et al., 2015). Specifically, assessment of 
general motor coordination using the rotorod test showed that Sacs-/- mice had 
significantly poorer performance compared to controls, with the most significant 
differences occurring at 90 days (Lariviere et al., 2015). This is accompanied by an 
early onset, progressive loss of cerebellar Purkinje cells followed by spinal motor 
neuron loss and peripheral neuropathy (Lariviere et al., 2015). Thus, the sacsin 
knockout mouse model recapitulates many of the clinical and pathological features 
found in ARSACS patients.  
CHAPTER 1: INTRODUCTION 
	   18 
In addition, neurons from Sacs-/- mice display both mitochondrial and neurofilament 
defects (Girard et al., 2012; Lariviere et al., 2015). These are discussed further in 
sections 1.9.6 and 1.11.1, respectively. 
 
1.4. Protein Homeostasis (Proteostasis) 
A key molecular pathogenic mechanism in many neurodegenerative diseases, including 
ataxias, is a disruption to protein quality control mechanisms. This can be a 
consequence of protein misfolding and lead to the accumulation of protein aggregates 
that are particularly detrimental to neurons.  
 
1.4.1. Protein folding 
The folding of a protein into its native three-dimensional (3D) structure determines the 
function of the protein. Proteins are constantly under threat of unfolding due to cellular 
stresses, such as heat shock, nutrient or oxygen deprivation, or local tissue 
inflammation. Under conditions of stress, proteins denature due to disruption of the 
bonding interactions responsible for secondary and tertiary structure of proteins, 
meaning they become unfolded. Protein misfolding can also occur as a result of 
missense mutations, high levels of protein expression, abberant post-translational 
modifications, or a shortage of necessary co-factors or components of multimeric 
complexes (Del Monte and Agnetti, 2014; Goldberg, 2003). Unfolded or partially 
folded proteins may expose hydrophobic amino acids, which are normally buried in the 
core of correctly folded proteins, and these may have undesirable interactions with other 
molecules (Vabulas et al., 2010). This in turn can lead to aggregation of proteins. 
Protein aggregates are defined by their insolubility in aqueous or detergent solvents, 
aberrant subcellular or extracellular localisation and non-native secondary structure 
(Fink 1998). The risk of misfolding and aggregation in vivo is enhanced due to the 
cellular environment being crowded at the molecular level, with a typical mammalian 
cell having a total protein concentration of ~300 mg per ml (Ellis, 2001; Zhou et al., 
2008b).  
The cellular protein quality control machinery has evolved to cope with misfolded and 
unfolded proteins by refolding or degrading misfolded proteins. These processes that 
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maintain normal cellular function contribute to what is termed proteostasis. The 
mechanisms are described in detail below. 
 
1.4.2. Mechanisms of Proteostasis 
In the cytoplasm, there are four main lines of defence against unfolded or misfolded 
proteins (Figure 1.2): (1) protein folding and refolding by molecular chaperones (Bukau 
and Horwich, 1998; Hartl and Hayer-Hartl, 2002), (2) proteasome dependent 
degradation (Alberti et al., 2002; Chapple et al., 2004; Connell et al., 2001), (3) 
autophagy-lysosome mediated degradation (Cuervo, 2004), (4) chaperone-mediated 
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Figure 1.2. Schematic of the cellular protein quality control mechanisms. The 
chaperone, ubiquitin-proteasome, and autophagy-lysosome systems function 
simultaneously to maintain intracellular protein homeostasis. (1) Molecular chaperones 
represent the first line of defence in ensuring the correct folding and refolding of 
proteins. When a native folding state cannot be achieved, chaperones direct the 
misfolded protein for degradation by (2) the ubiquitin-proteasome or (3) autophagy-
lysosome pathways. Proteins that are destined for proteasome-mediated degradation are 
tagged with a polyubiquitination chain at lysine residue K48, whereas proteins destined 
for autophagy are tagged with a polyubiquitination chain at lysine residue K63. The 
autophagy process involves the sequestration of misfolded proteins into a double-
membrane structure called an autophagosome. The autophagosome then fuses with a 
lysosome to form autolysosomes, within which the proteins and/or organelles are 
degraded by acidic lysosomal hydrolases. (4) Chaperone-mediated autophagy (CMA) is 
a selective autophagy pathway. HSC70 chaperones target misfolded proteins to the 
lysosome where they bind to the receptor lysosome-associated membrane protein 2A 
(LAMP2A), to be translocated into the lysosome for degradation.  
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1.4.3. Molecular Chaperones 
Molecular chaperones, along with their associated co-chaperones, represent the first line 
of defence against aberrant protein accumulation in vivo. Unlike other proteins, 
molecular chaperones are more resistant to becoming denatured under conditions of 
stress, as they are more hydrophobic and have enhanced secondary protein structure. 
They prevent protein aggregation by recognising and binding to the exposed 
hydrophobic amino acids of unfolded proteins (Hartl and Hayer-Hartl, 2002). They also 
enhance the efficiency of de novo protein folding, and promote refolding of proteins 
that have become misfolded due to cellular stress (Bukau and Horwich, 1998; Hartl and 
Hayer-Hartl, 2002). In addition, they assist protein translocation across membranes, 
protein-protein interactions (Kampinga et al., 2009; Meimaridou et al., 2011; 
Muchowski and Wacker, 2005), proteasome dependent degradation (Alberti et al., 
2002; Chapple et al., 2004; Connell et al., 2001), and inclusion formation and lysosome-
mediated autophagy (Cuervo, 2004).   
 
1.4.3.1. Heat Shock Proteins 
Many molecular chaperones are induced by cellular stresses, such as an increase in 
temperature (heat shock), infection, inflammation, starvation and hypoxia. These 
proteins are classified as heat shock proteins (HSPs, also known as stress proteins). 
They make up a group of structurally unrelated protein families, including HSPA 
(HSP70), HSPB (small HSPs), HSPC (HSP90), HSPD/E (HSP60/HSP10), HSPH 
(HSP110), and DNAJ (HSP40). They play key roles in proteostasis by promoting 
protein folding through binding to substrates to keep them in a state competent for 
either refolding or degradation. They are crucial for recovery from stress-induced 
protein damage and are synthesised at greatly increased levels under stress conditions. 
Most HSPs have a constitutively expressed member that plays a housekeeping role, and 
a stress-induced member is expressed under cellular stress conditions (Turturici et al., 
2011). Heat shock transcription factor 1 (HSF1) is responsible for transcriptional 
activation of HSPs (Bukau et al., 2006; Hartl and Hayer-Hartl, 2002) by binding to heat 
shock elements (HSEs) in the promoter of HSPs (Morimoto and Santoro, 1998). HSP90 
plays a key role in the regulation of HSF1, and hence in the transcriptional activation or 
deactivation of HSPs (Ali et al., 1998; Nadeau et al., 1993; Nair et al., 1996).  
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1.4.3.2. HSP70/HSPA and HSP40/DNAJ chaperone system  
HSP70 proteins are central components of the molecular chaperone network and their 
function is facilitated by HSP40 proteins and other co-chaperones. The HSP70/HSP40 
chaperone system is known as DnaK/DnaJ in bacteria (Bardwell and Craig, 1984; Craig 
et al., 1979; McKenzie et al., 1975; Saito and Uchida, 1977). The human genome 
encodes 13 different HSP70 proteins, the majority of which localise to the cytosol or 
nucleus (Table 1.3).  
 
Table 1.3. HSPA (HSP70) members 
HSPA Gene and 
Protein name 
Alternative names Molecular 
mass (kDa)  
Subcellular 
localisation 
1 HSPA1A  HSP70-1; HSP72; HSPA1 70.0 
Cytosol, 
nucelus 
2 HSPA1B  HSP70-2 70.0 
Cytosol, 
nucelus 
3 HSPA1L  hum70t; hum70t; Hsp-hom 70.4 
Cytosol, 
nucelus 






5 HSPA5  BIP; GRP78; MIF2 71.0 ER 
6 HSPA6  





7 HSPA7  Heat shock 70kD protein 7 ND 
Cytosol, 
nucelus 
8 HSPA8  





9 HSPA9  
GRP75; HSPA9B; MOT; 
MOT2; PBP74; mot-2 
73.7 Mitochondria 
10 HSPA12A  FLJ13874; KIAA0417 141.0 ND 





12 HSPA13  Stch 51.9 ER 






Taken from (Hageman et al., 2011; Kampinga et al., 2009). ND: not determined. 
 
Typically, HSP70 proteins are composed of two major functional domains, an N-
terminal ATPase domain of 45 kDa and a C-terminal substrate-binding domain of 25 
kDa, which are separated by a linker domain (Figure 1.3). Cooperation between these 
CHAPTER 1: INTRODUCTION 
	   23 
domains is required for HSP70-mediated protein folding (Turturici et al., 2011). 
Additionally, a C-terminal EEVD sequence motif plays an important role in co-
chaperone binding (Figure 1.3 (Turturici et al., 2011)).	  The HSP70s are functionally 
diverse, yet have high sequence identity within and across species (Hageman, 2008). 
The constitutively active member of the HSP70 protein family in eukaryotes is HSPA8, 
also known as HSC70, which is ubiquitously expressed and considered an essential 





Figure 1.3. Schematic representation of the HSP70 protein domains. 
 
 
The binding and release of substrates to HSP70 is regulated by its adenosine 
triphosphatase (ATPase) activity. In an ATP-bound state, the substrate binding pocket 
of HSP70 is in an open conformation, resulting in a low affinity and fast exchange rate 
for its substrates (Hartl and Hayer-Hartl, 2002). Upon the hydrolysis of ATP to ADP, 
which is accelerated by DNAJ/HSP40 proteins (Bukau and Horwich, 1998), a 
conformational change to HSP70 occurs. Specifically, the α-helical lid of the substrate 
binding domain of HSP70 closes, leading to tight binding of the substrate (Hartl et al., 
2011; Shiber and Ravid, 2014). Thus, this ADP-bound state results in a high affinity 
and low exchange rate for its substrates (Hartl and Hayer-Hartl, 2002). Nucleotide 
exchange factors (NEFs), such as BAG1 or HSPBP1, then bind to HSP70, catalysing 
the disassociation of ADP. Re-association of ATP then induces the opening of the α-
helical lid, thereby enabling substrate release (Hartl et al., 2011; Shiber and Ravid, 
2014). 
 
Over 50 DNAJ/HSP40-encoding genes have been identified in the human genome, with 
their encoded proteins ranging in molecular weight from 18-520 kDa (Hageman et al., 
2011; Kampinga and Craig, 2010). The 520 kDa DNAJ protein is sacsin (DNAJC29). 
DNAJ proteins have a highly conserved J-domain over ~70 amino acids. There are four 
α-helices in the J-domain, and a His, Pro and Asp tripeptide (HPD) motif between the 
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two main helices (helix II and helix III) is crucial for J-domain function (Kelley, 1998; 
Tsai and Douglas, 1996; Walsh et al., 2004). Mutations in the HPD tripeptide affect the 
ability of the J-domain protein to bind to a HSP70 partner and stimulate its ATPase 
activity. 
There are three distinct subgroups of DNAJ proteins, based on the presence of certain 
structural motifs: Type I/DNAJA, which have an N-terminal J-domain followed by a 
glycine/phenylalanine (G/F) -rich region and a cysteine-rich region stabilised by two 
zinc ions; Type II/DNAJB, which have the N-terminal J-domain and the G/F-rich region 
only; and Type III/DNAJC, which have the J-domain only, located anywhere within the 
protein (Cheetham and Caplan, 1998; Hageman et al., 2011). The presence of a J-
domain within the protein defines it as a DNAJ family member.  
Outside of the conserved J-domain, DNAJ proteins have high sequence and structural 
divergence, which determines their specific functions (Kampinga and Craig, 2010). All 
DNAJ proteins that have been studied so far accelerate the ATPase activity of HSP70 
proteins. Overstimulation of ATPase activity by DNAJ results in failed capture of 
clients, hence the stoichiometry of HSP70 protein to DNAJ protein in the cell is critical. 
Usually HSP70 levels within a cell are higher than DNAJs (Kampinga and Craig, 
2010). In vitro, stimulation of client protein folding is most efficient when HSP70 
concentrations are 10-20 times higher than DNAJ protein (Diamant and Goloubinoff, 
1998). However, there are usually a higher number of different DNAJ proteins in a 
cellular compartment compared to HSP70 proteins. For example, mammals have one 
type of HSP70 in mitochondria and one type in the endoplasmic reticulum, while these 
organelles have 4 and 6 DNAJ proteins, respectively. Hence, HSP70 proteins interact 
with multiple DNAJ proteins (Craig et al., 2006; Hageman and Kampinga, 2009). 
The ability of DNAJ proteins to recruit HSP70 to specific cellular locations is important 
for functional diversity, for example, the DNAJ homolog auxilin, which is expressed in 
neurons, is required for HSC70 to uncoat clathrin from clathrin-coated vesicles 
(Barouch et al., 1994). Also, the ribosome associated J-protein DNAJC2 recruits 
HSC70 to the ribosome to act on nascent polypeptides (Hundley et al., 2005). 
Additionally, DNAJC5, which encodes cysteine string protein α (CSPα), recruits 
HSC70, along with the small glutamine-rich tetratricopeptide repeat-containing protein 
(SGT), to form a functional chaperone complex on synaptic vesicles (Tobaben et al., 
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2001; Zhang et al., 2012). CSPα directly binds folded dynamin 1 and promotes its 
oligomerisation, thereby facilitating synaptic vesicle endocytosis (Zhang et al., 2012).  
To date, mutations in seven DNAJ proteins have been linked to distinct diseases in 
humans (Table 1.4, (Koutras and Braun, 2014)).  
 
Table 1.4. DNAJ mutations and resulting human diseases 
Gene  Protein Disease  Reference 
DNAJB2 HSJ1 Distal Motor Neuropathy (Blumen et al., 2012) 
DNAJB6 MRJ Limb-girdle Muscular 
Dystrophy Type 1D 
(Harms et al., 2012; 
Sarparanta et al., 2012)  
DNAJC5 CSPα Adult-onset Neuronal 
Ceroid Lipofuscinosis 
(Benitez et al., 2011; 
Noskova et al., 2011)  
DNAJC6  Auxilin Childhood Parkinsonism (Edvardson et al., 2012) 
DNAJC13 RME-8 Parkinsons Disease (Vilarino-Guell et al., 
2014) 
DNAJC19  TIM14 Ataxia Dilated 
Cardiomyopathy 
(Davey et al., 2006; 
Ojala et al., 2012) 
DNAJC29 Sacsin Autosomal Recessive 
Spastic Ataxia of 
Charlevoix-Saguenay 
(Bouchard et al., 1978; 
Engert et al., 2000) 
HSJ1: Homo sapiens DnaJ 1, MRJ: mammalian relative of DnaJ, CSPα: Cysteine string 
protein alpha, RME-8: receptor-mediated endocytosis 8, TIM14: translocase of the 
inner membrane 14 
 
 
1.4.3.3. HSP90/HSPC     
The HSP90 protein family has members localised to most organelles of eukaryotic cells 
(Taipale et al., 2010). The majority of eukaryotic genomes encode organelle-specific 
isoforms, including ER (GRP94) and mitochondrial forms (TRAP1, (Pearl and 
Prodromou, 2006). Under normal cellular conditions, HSP90 is highly abundant in the 
cytoplasm, constituting 1-2% of total protein levels (Borkovich et al., 1989). Under 
cellular stress, some HSP90 translocates to the nucleus, most likely by co-transport with 
client proteins, as HSP90 does not contain a nuclear localisation sequence (Taipale et 
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al., 2010). In a similar way to HSP70, the HSP90 client binding-release cycle is 
dependent on ATP hydrolysis and is facilitated by co-chaperones (Taipale et al., 2010).  
Constitutively expressed and inducible forms of cytosolic HSP90 exist. Inducible 
transcription is controlled by heat shock factor 1 (HSF1). Under normal conditions, 
HSF1 is a client of HSP90 and is held in an inactive complex with HSP90 and HSP70. 
Under cellular stress, HSF1 is released to allow transcriptional activation of inducible 
HSP90. Thus, HSP90 has an important role in regulating its own transcription (Nadeau 
et al., 1993). HSP90 can also be regulated by post-translational modifications such as 
acetylation, phosphorylation and nitrosylation (Taipale et al., 2010). 
Structurally, HSP90 is a homodimer consisting of three domains, the N-terminus, 
middle and C-terminus. The 25 kDa N-terminal domain is involved in nucleotide 
binding. This is connected to a middle domain by a charged linker (Hainzl et al., 2009; 
Tsutsumi et al., 2009). Mutations in the linker region impair client activation and 
prevent regulation by certain co-chaperones (Hainzl et al., 2009). The middle domain is 
thought to be required for client recognition. A 12 kDa C-terminal domain is involved 
in dimerisation of HSP90 (Ali et al., 2006; Minami et al., 1994). Five C-terminal 
residues make up the MEEVD motif (Met-Glu-Glu-Val-Asp), which is a highly 
conserved tetratricopeptide repeat (TPR) domain-binding site that mediates interaction 
with over 20 co-chaperones (Taipale et al., 2010; Young et al., 1998), such as HOP and 
CHIP, via their TPR domains.  
 
Members of the different chaperone families, HSP40, HSP70 and HSP90, function 
together in proteostasis networks, with co-chaperones mediating interaction between 
them. For example, the multiple TPR domains in the co-chaperone HSP70-HSP90-
organising protein (HOP) mediate interactions between HSP70 and HSP90. HOP also 
modulates the ATPase activity of both HSP70 and HSP90, thus facilitating client 
transfer between the two, allowing client maturation. HSP90 ATPase activity can be 
inhibited by co-chaperones, for example HOP, CDC37 and p23 (Prodromou et al., 
1999; Siligardi et al., 2002), or can be enhanced by co-chaperones, such as AHA1 and 
CPR6 (McLaughlin et al., 2002; Panaretou et al., 2002).  
Two main classes of HSP90 clients are protein kinases, such as CDK4 and ERBB2, and 
nuclear steroid receptors, such as glucocorticoid receptor and progesterone receptor. 
Additional client proteins include transcription factors, such as AHR, HIF1A, HIF2A 
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and HIF3A, telomerase reverse transcriptase (TERT, (Holt et al., 1999)) and endothelial 
nitric oxide synthase (eNOS, (Garcia-Cardena et al., 1998)). More recently, the 
intermediate filament protein vimentin was identified to be a client protein of HSP90 
(Zhang et al., 2006). HSP90 protects vimentin from apoptotic cleavage (Zhang et al., 
2006). 
HSP90 generally assists in the maturation of client proteins, but it can also promote 
protein degradation, for example it is essential for the degradation of the von Hippel-
Lindau (VHL) tumor suppressor protein (McClellan et al., 2005). The E3 ubiquitin 
ligase, C terminus of HSP70-interacting protein (CHIP), interacts with the C-terminus 
of both HSP90 and HSP70 through its TPR domain. CHIP knockdown in cultured cells 
stabilises some HSP90 clients, and CHIP overexpression promotes their degradation 
(Xu et al., 2002).  
 
1.4.4. Protein Degradation  
When a native protein folding state cannot be achieved, molecular chaperones direct 
misfolded proteins for degradation. This is important to prevent disruption to other 
cellular processes, for amino acid recycling, and for the regulation of individual protein 
levels. The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathways 
(ALP) are the two main routes of protein and organelle clearance in eukaryotic cells 
(Figure 1.2). The proteasome predominately degrades short-lived nuclear and cytosolic 
proteins (Ciechanover, 2006), as well as misfolded proteins from the ER, whereas 
autophagy is responsible mainly for the degradation of long-lived proteins and 
organelles (Henell et al., 1987; Mizushima et al., 2008).  
Autophagy refers to the degradation of cytosolic components in lysosomes, regardless 
of the mechanism by which the cargo is delivered to lysosomes. In most mammalian 
cells, the deliver occurs by three different ways that distinguish the subtypes of 
autophagy: macroautophagy, microautophagy and chaperone-mediated autophagy 
(CMA). All three subtypes coexist in cells, and alterations in both macroautophagy and 
CMA have been associated with neurodegenerative disorders (Cuervo et al., 2010). 
Macroautophagy is the main type of autophagy and this is discussed in more detail 
below. 
The signal for targeting proteins for degradation via macroautophagy or the UPS is 
polyubiquitination, which is the covalent attachment of a chain of four or more 
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ubiquitin molecules to a substrate protein at a lysine residue (Hershko and Ciechanover, 
1998). Ubiquitin itself has seven lysines (e.g. K48 and K63) and linkage of other 
ubiquitin molecules to these lysines then forms the polyubiquitin chain. Ubiquitination 
of proteins involves an E1-E2-E3 ubiquitin enzyme cascade (Figure 1.4). E1 (ubiquitin-
activating enzyme) hydrolyses ATP and forms a thioester-linked conjugate between 
itself and ubiquitin, E2 (ubiquitin-conjugating enzyme) receives ubiquitin from E1 and 
forms a similar thioster bond with ubiquitin, and E3 (ubiquitin ligase) binds both E2 and 





Figure 1.4. Schematic of the ubiquitination pathway. (1) An E1 ubiquitin-activating 
enzyme charges a single ubiquitin (Ub) molecule via ATP hydrolysis, before (2) 
transferring the ubiquitin to an E2 ubiquitin-conjugating enzyme. (3) An E3 ubiqutin-
ligase then transfers the ubiquitin to the substrate protein, and (4) the ubiquitin chain is 
extended by E3 ligases. 
 
 
Polyubiquitin chains, linked by lysines at residue 48 (K48-linked polyubiquitination), 
are the signal for proteasomal degradation. The K48-linked ubiquitinated proteins are 
recognised and degraded by the 26S proteasome, which is a complex structure 
comprising two regulatory 19S subunits and a 20S catalytic core subunit (Navon and 
Ciechanover, 2009). The targeted protein travels through a channel in the 26S 
proteasome and is enzymatically degraded. During degradation, ubiquitin is removed 
from the proteins by deubiquitinating enzymes and recycled (Bhattacharyya et al., 2014; 
Finley, 2009; Navon and Ciechanover, 2009).  
Polyubiquitin chains, linked by lysines at residue 63 (K63-linked polyubiquitination), 
target proteins for macroautophagy (Tan et al., 2008), particularly larger protein 
complexes, organelles and protein aggregates, which are too large to pass through the 
narrow pore of the proteasome (Mizushima et al., 2008; Yorimitsu and Klionsky, 2005). 
p62/SQSTM1 binds to K63-ubiquitin linked proteins, via its ubiquitin-associated (UbA) 
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domain, targeting them for autophagic degradation (Long et al., 2008; Pankiv et al., 
2007). The proteins or protein aggregates are engulfed within a double-membrane, 
which is proposed to form from the fusion of vesicles from a variety of membrane 
sources, including plasma membrane-derived endosomal intermediates (Ravikumar et 
al., 2010), the ER (Hayashi-Nishino et al., 2009; Yla-Anttila et al., 2009), the Golgi 
(van der Vaart and Reggiori, 2010; Yen et al., 2010), and mitochondria (Hailey et al., 
2010). This forms the autophagosome (Figure 1.5). Fifteen autophagy-related (ATG) 
proteins mediate the formation of the autophagosome, including the initiation of 
autophagy, and the expansion and closure of autophagosomal membranes (Mizushima 
et al., 2011). Mature autophagosomes are trafficked by dynein motors along 
microtubules, in a retrograde manner, to the perinuclear region where they fuse with 
lysosomes (autolysosomes) to degrade their contents by acidic lysosomal hydrolases 





Figure 1.5. Schematic of macroautophagy. Following the induction of autophagy, 
autophagic substrates and/or damaged organelles are engulfed by an isolation 
membrane known as a phagophore. This elongates to form an autophagosome, which 
has a double membrane. Autophagosomes fuse with lysosomes (autolysosome) to 
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Polyglutamine-expansion proteins, such as mutant huntingtin and ataxin-3, and mutant 
forms of α-synuclein and tau, are strongly dependent on macroautophagy for their 
clearance (Iwata et al., 2005b; Qin et al., 2003; Webb et al., 2003). 
Dysfunction of macroautophagy prevents efficient nutrient recycling, enhances 
susceptibility to apoptosis (Boya et al., 2005), and leads to the formation of 
ubiquitinated inclusions (Rideout et al., 2004). Dynein-dynactin function is also 
important for autophagosome-lysosome fusion, and autophagic clearance is impaired by 
loss of dynein-dynactin function (Ravikumar et al., 2005). Mutations in the dynactin 
subunit p150Glued lead to protein aggregation and a motor neuron disease (Levy et al., 
2006). 
 
1.4.4.1. Chaperone-mediated autophagy (CMA)  
CMA is a selective autophagy pathway for cytosolic protein clearance directly through 
lysosomes, without being trafficked via autophagosomes (Figure 1.2). This pathway is 
independent of ubiquitin, as substrates do not require ubiquitination prior to 
degradation. It involves the recognition of a targeting motif on substrates, Lys-Phe-Glu-
Arg-Gln (KFERQ, (Dice, 1990; Massey et al., 2004)). This motif is present in around 
30% of cytosolic proteins (Wing et al., 1991) and is recognised by the HSC70 
chaperone. HSC70 targets substrates to the lysosomal membrane where they bind to the 
receptor lysosome-associated membrane protein 2A (LAMP2A), to be translocated in to 
the lysosome for degradation. Wild-type α-synuclein, which contains a KFERQ-like 
motif (VKKDQ, (Liu et al., 2009)), has been shown to be selectively translocated into 
lysosomes for degradation by the CMA pathway (Cuervo et al., 2004). Mutation of the 
sequence VKKDQ by replacing DQ with AA prevents α-synuclein from binding to 
LAMP2A, which leads to dramatically reduced translocation of α-synuclein into the 
lysosomal lumen (Cuervo et al., 2004). 
 
1.4.4.2 Mitophagy 
Several types of cargo-specific autophagy have been reported and widely studied, 
including mitophagy, which selectively removes dysfunctional or excessive 
mitochondria. In functional mitochondria that are able to maintain their mitochondrial 
membrane potential, phosphatase and tensin homologue-induced putative kinase 1 
(PINK1) is imported via the translocase of the outer membrane (TOM) complex and the 
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translocase of the inner membrane (TIM23) complex. It is then cleaved by 
mitochondrial processing peptide (MPP) and presenilins-associated rhomboid-like 
protein (PARL) in the inner membrane before being translocated back to the cytoplasm 
for degradation by the proteasome (Becker et al., 2012; Greene et al., 2012; Jin et al., 
2010). However, in the absence of a mitochondrial membrane potential, PINK1 
accumulates on the mitochondrial outer membrane where it recruits the E3-ubiquitin 
ligase parkin (Geisler et al., 2010; Matsuda et al., 2010; Vives-Bauza et al., 2010), 
resulting in the targeting of mitochondria for degradation by mitophagy. Interruptions in 
the normal mechanisms of mitophagy have been implicated in the pathogenesis of 
neurodegenerative diseases. For example, mutations in the genes encoding PINK1 or 
parkin lead to defects in mitophagy and are the leading cause of recessive parkinsonism 
(Kitada et al., 1998; Michiorri et al., 2010; Valente et al., 2004).  
 
1.5. Disrupted proteostasis in neurodegeneration 
When the lines of defence against misfolded proteins fail or become overwhelmed, 
misfolded proteins can form aggregates. These protein aggregates are transported on 
microtubules, in a retrograde manner, to the microtubule organising centre (MTOC) 
where they accumulate and may form inclusion bodies or aggresomes (Garcia-Mata et 
al., 1999; Johnston et al., 1998; Kopito, 2000).  
Neurons are particularly vulnerable to the toxicity of misfolded proteins. This is 
believed to be, in part, because they are post-mitotic cells so are unable to dilute 
misfolded or aggregated proteins through cell division (Muchowski and Wacker, 2005). 
Consequently, many neurodegenerative disorders are characterised by the presence of 
inclusion bodies. For example, Alzheimer’s disease is characterised by the presence of 
extracellular amyloid plaques, which consist of aggregated β-amyloid peptide, and 
intracellular neurofibrillary tangles, containing aggregated, hyperphosphorylated tau 
protein (Glenner and Wong, 1984; Grundke-Iqbal et al., 1986). Similarly, sporadic 
Parkinson’s disease features intracellular inclusions known as Lewy bodies, which 
contain aggregated α-synuclein (Spillantini et al., 1997). Huntington’s disease has the 
presence of intranuclear inclusions of aggregated huntingtin protein, which contain 
polyglutamine (polyQ) expansion (DiFiglia et al., 1997). This is similar to what occurs 
in other polyQ disorders, such as spinocerebellar ataxias (SCAs), which are all caused 
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by expansions in the CAG tract of the affected gene, leading to polyQ expansion, 
misfolding and inclusion body formation (Bates, 1996; Trottier et al., 1995).  
Interestingly, most of these disease-specific inclusions contain proteins that are 
ubiquitinated, along with other proteostasis components, such as molecular chaperones 
and components of the proteasome (Muchowski and Wacker, 2005; Ross and Poirier, 
2004; Sherman and Goldberg, 2001). This suggests that the accumulated proteins with 
abnormal conformation have been detected by the protein quality control system, but 
due to inefficent or impaired clearance, they remain within cells and are sequestered to 
inclusions. 
Mutations in certain proteins that are involved in UPS and ALP function are known to 
lead to neurodegenerative diseases. Many of these proteins contain domains that 
mediate interactions with polyubiquitinated proteins or the proteasome, such as an 
ubiquitin-like domain (UbL), ubiquitin-associated domain (UbA), or ubiquitin-
interacting motifs (UIM, (Grabbe and Dikic 2009, Su and Lau 2009)). An example is 
parkin, which contains an N-terminal UbL-domain and is involved in transferring 
ubiquitin to substrates, targeting them for degradation via the UPS or ALP (Shimura et 
al., 2000). Interestingly, wild-type parkin is found in Lewy bodies in sporadic PD 
(Schlossmacher et al., 2002). 
 
1.5.1. HSP70 and HSP40 as modulators of neurodegeneration 
Molecular chaperones are particularly associated with protein aggregates (Barral et al., 
2004; Johnston et al., 1998; Verhoef et al., 2002). For example, HSP70 is found in 
nuclear inclusions of mutant huntingtin (Muchowski et al., 2000; Wyttenbach et al., 
2000) and in Lewy bodies (Lee and Lee, 2002), and the DNAJ/HSP40 protein DNAJB6 
is associated with Lewy bodies (Durrenberger et al., 2009). 
Recent studies have demonstrated that activation of the heat shock response (HSR), and 
in particular elevation of HSP70 levels, inhibits aggregate formation and prevents cell 
toxicity in several models of neurodegeneration. For example, HSP70 overexpression 
reduced α-synuclein accumulation and toxicity in mouse and Drosophila models of 
Parkinson Disease (Auluck et al., 2002; Klucken et al., 2004). Also, in a model of 
Alzheimer’s disease, HSP70 overexpression rescued primary neuronal cultures from the 
toxic effects of intracellular β-amyloid (Aβ) accumulation (Magrane et al., 2004). The 
ability of HSP70 to reduce the severity of polyQ-mediated degeneration has also been 
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demonstrated in mouse models. For example, when a spinocerebellar ataxia type 1 
(SCA1) transgenic mouse was crossed with a hemizygous mouse overexpressing 
HSP70 at around 10-fold normal levels, behavioural and neuropathological symptoms 
improved (Cummings et al., 2001). 
HSP40 proteins also have a neuroprotective role. In a cellular model of spinocerebellar 
ataxia type 1 (SCA1), overexpression of the HSP40 protein HDJ2 (DNAJA1) caused a 
significant decrease in the incidence of ataxin-1 inclusions (Cummings et al., 1998). 
Additionally, the overexpression of either HDJ1 (DNAJB1) or HDJ2 (DNAJA1) in a 
cell model of spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease (MJD) 
suppressed the aggregation and toxicity of polyQ-expanded full-length or truncated 
mutant ataxin-3 (Chai et al., 1999). HSP40 proteins that are enriched in neuronal tissues 
or have a neuronal specific expression profile may be particularly relevant in 
neurodegenerative diseases. For example, HSJ1a (DNAJB2a) has been shown to 
increase ubiquitylation and reduce the incidence of polyQ protein aggregation in 
cellular and in vivo models of polyQ and protein misfolding diseases (Gao et al., 2011; 
Howarth et al., 2007; Novoselov et al., 2013; Westhoff et al., 2005). Therefore, HSP70 
and its co-chaperones appear to have a protective effect against misfolded proteins. 
 
1.6. Sacsin Domains  
Sacsin contains multiple domains that suggest a role in proteostasis. If this is the case, 
then like many other neurodegenerative diseases, disrupted proteostasis may also be a 
molecular pathogenic mechanism in ARSACS.  
 
1.6.1 Sacsin Repeating Region (SRR)  
Sacsin consists of three repeated regions, known as the sacsin-repeating region (SRR, 
(Anderson et al., 2010; Romano et al., 2013)). These repeating regions are much larger 
than originally described (Anderson et al., 2010; Engert et al., 2000), with each repeated 
region being ≥1100 amino acids, covering ~84% of the protein sequence, and this 
repeated architecture is conserved in all vertebrate sacsins (Romano et al., 2013). The 
three repeated regions have a low overall similarity (16-18%), but they contain discrete 
sub-repeats based on there degree of local similarity, the first of which is homologous to 
the HATPase_c (Histidine kinase-like ATPases; SMART acc. no. SM00387) domain of 
HSP90 (Figure 1.1. (Anderson et al., 2010; Romano et al., 2013)).  
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Anderson et al (2010) demonstrated, by biochemical characterisation, that the first SRR 
has ATPase activity. A disease causing mutation (D168Y) within the first sub-repeat 
region, homologous to HSP90, abolished the full proteins ability to hydrolyse ATP 
(Anderson et al., 2010). From this, it was suggested that ATPase activity is a 
requirement for sacsin function, as this mutation lead to essentially the same clinical 
phenotype as nonsense mutations close to the N-terminus of the protein that result in 
truncations of the protein (Anderson et al., 2010). In HSP90, the middle domain 
contains an arginine residue that accepts phosphate after ATP hydrolysis (Pearl and 
Prodromou, 2006). This arginine is conserved in each of the second sub-repeats and a 
mutation occurring in one of these conserved arginines, namely c.1420C>T (p.R474C), 
leads to a severe clinical phenotype (Romano et al., 2013).  
The functional nature of the sub-repeating regions is also implicated by the observation 
that sacsin pathogenic missense mutations are found to be over-represented in the 
SRRs, and particularly in conserved positions (Romano et al., 2013). Previously, HSP90 
and the HDJ2 HSP40/DNAJ protein have been implicated to function together in 
folding pathways, for example in the maturation of the glucocorticoid receptor (Kimura 




J-domains are the defining feature of the DNAJ/HSP40 family of HSP70 co-
chaperones.  A region of over 30 residues near the C-terminus of sacsin (Figure 1.1) 
shares ~60% identity to the J-domain of HSP40 proteins and is highly conserved (Parfitt 
et al., 2009), suggesting a role with the HSP70 chaperone machinery. Sacsins J-domain 
is similar to that of other DNAJ proteins, for example DNAJB6, which is an HSP40 
homolog that has been associated with several neurodegenerative disorders, such as 
Parkinson’s disease (Durrenberger et al., 2009) and Huntington disease (Chuang et al., 
2002; Gillis et al., 2013). The sacsin J-domain was found to be able to function with the 
bacterial HSP70, DnaK, by an in vivo complementation assay (Parfitt et al., 2009). 
Also, a recombinant version of the J-domain from mouse sacsin increased the ATPase 
activity of HSP70 (Anderson et al., 2010). This confirmed that sacsin is a type III 
HSP40 protein and it is thus also known as DNAJC29 (Kampinga et al., 2009). Other 
type III HSP40 proteins are known to recruit HSP70s for specialised roles (examples in 
section 1.4.3.2).  
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The sacsin J-domain contains the highly conserved histidine-proline-aspartic acid 
(HPD) motif, which is important for HSP70 interaction (Parfitt et al., 2009). A 
histidine-to-glutamine substitution within the HPD motif disrupts the ability of J-
domains to functionally interact with HSP70 (Hennessy et al., 2005). To date, the only 
identified ARSACS-causing mutation in the sacsin J-domain is the heterozygous 
missense mutation R4331Q. The Dutch family with this SACS mutation are compound 
heterozygotes (K1715*/R4331Q (Vermeer et al., 2008)). The arginine occupies a 
position critical for J-domain function and this mutation is predicted to be intolerant and 
probably leads to loss of function of the protein (Vermeer et al., 2008). However, the 
R4331Q mutation alone did not affect the ability of the sacsin J-domain to rescue the 
function of mutant bacterial DnaJ with non-functional J-domain (Parfitt et al., 2009). 
Vermeer et al., (2008) suggest that both mutations (K1715*/R4331Q) may need to be 
present to affect the function of sacsin’s J-domain. However, this is unlikely as these 
two mutations are located far from each other and the result may be different when 
inserting this mutant sacsin J-domain into a non-functional human DNAJ. The K1715* 
mutation resides within the second SRR, and Li (2013) suggests that the function of the 
sacsin J-domain may require its interaction with the SRR, whose ATPase activity may 
contribute to J-domain’s recruitment and stimulation of HSP70 (Li, 2013).  
 
1.6.3. HEPN domain 
At the C-terminus of sacsin is a higher eukaryotes and prokaryotes nucleotide-binding 
(HEPN) domain. This was first described by Grynberg et al. (2003) and has been shown 
to bind to various nucleotides, such as ATP, ADP, and GTP, but does not exhibit any 
GTPase or ATPase activity (Kozlov et al., 2011). Crystal structure of the human sacsin-
HEPN domain revealed that it exists as a dimer, which interacts with nucleotides 
electrostatically via a large positively charged cavity at the dimer interface (Kozlov et 
al., 2011). An ARSACS patient mutation, N4549D, at the dimer interface was shown to 
hinder protein folding and dimerisation of the domain, which is likely responsible for its 
loss of function (Kozlov et al., 2011). HEPN domains are widely distributed in 
eubacteria and archaea but are restricted to animals in eukaryotes (Grynberg et al., 
2003). In humans, the HEPN domain occurs only in the protein sacsin.  
Very recently, it has been confirmed that the HEPN domain of sacsin binds nucleotides 
with low micromolar affinities using fluorescence polarisation (FP) assays (Li et al., 
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2015b). This is consistent with the HEPN domain contributing to the functional activity 
of sacsin by binding to nucleotides.  
It has been suggested that the close proximity of the sacsin J-domain and HEPN domain 
could be important for the hypothesised function of sacsin as a co-chaperone. The 
HEPN domain may increase the local concentration of ATP to promote nucleotide 
exchange onto HSP70 (Kozlov et al., 2011).  
 
1.6.4. UBL-domain, XPCB domain, and UIM domain 
The ubiquitin-proteasome pathway of protein degradation is a major mechanism for 
maintenance of cellular protein levels. Proteins containing UbL and UbA domains are 
implicated in proteasomal degradation through associations with proteins destined for 
degradation and with subunits of the proteasome (Su and Lau, 2009). The N-terminus of 
sacsin contains a UbL domain (Figure 1.1), which shares 43% homology to the 
RAD23A UbL domain over 65 residues (Parfitt et al., 2009), and has been shown by co-
immunoprecipitation to interact with the 20S proteasomal alpha subunit C8 (Parfitt et 
al., 2009).  
Towards the C-terminus is the Xeroderma pigmentosum complementation group C 
binding (XPCB) domain (Figure 1.1), which shares 35% homology with the hHR23 
XPCB domain (Kamionka and Feigon, 2004). Interestingly, the hHR23 protein also 
contains a UbL domain which, similar to sacsin, interacts with the 19S regulatory 
subunit of the 26S proteasome (Mueller and Feigon, 2002). The sacsin-XPCB domain 
was recently identified as a potential binding domain for the E3 ubiquitin ligase 
UBE3A, which is non-functional in the neurodevelopmental disorder Angelman’s 
syndrome (Greer et al., 2010). In Ube3A knockout mice levels of ubiquitinated sacsin 
were severely reduced, suggesting Ube3A is responsible for ubiquitinating sacsin (Jana, 
2012). Bioinformatic analyses also potentially identified two ubiquitin-interaction 
motifs (UIM) in sacsin, located either side of the XPCB domain (Parfitt, 2011). UIMs 
interact with ubiquitin itself.  
The presence of the UbL domain and XPCB domain, and possible UIM motifs, all point 
towards a function for sacsin in a ubiquitin-mediated degradation pathway. This, along 
with the presence of the J-domain and HSP90 like chaperone domains, suggests that 
sacsin plays a role in proteostasis. Interestingly, other proteins that function in the 
ubiquitin-proteasome pathway are linked to ataxias, for example, ataxin-3 contains a 
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UIM and functions as a deubiquitination enzyme (Burnett et al., 2003).  
 
1.7. Mitochondrial Dynamics  
Mitochondrial disruption is another key molecular pathogenic mechanism implicated in 
neurodegenerative disorders (Chen and Chan, 2009; Knott and Bossy-Wetzel, 2008; 
Liesa et al., 2009) and in particular, cerebellar ataxias, such as SCA3 (Laco et al., 2012; 
Ramos et al., 2015) and ataxia telangiectasia (Eaton et al., 2007; Valentin-Vega et al., 
2012). 
Mitochondria are highly dynamic; double-membrane bound organelles that contain their 
own genome and protein synthesis machinery. They migrate throughout the cell, and 
constantly fuse and divide, changing the length, shape, size and number of 
mitochondria. This is crucial to regulate many cellular processes (Chan, 2006) and is 
termed mitochondrial dynamics (Bereiter-Hahn, 1990; Bereiter-Hahn and Voth, 1994).  
Mitochondrial division, or fission, produces numerous mitochondrial fragments, and is 
important to distribute the organelles inside the cell (Collins et al., 2002). Fission is also 
required to sequester damaged mitochondrial fragments, which become engulfed by 
autophagosomes and are degraded through mitophagy (Lee et al., 2010; Tanaka et al., 
2010). Mitochondrial fusion generates interconnected mitochondria, enabling the 
exchange of contents between mitochondria, such as the sharing of mitochondrial DNA 
(mtDNA), dissipation of energy through transmission of a membrane potential 
(Skulachev, 2001; Westermann, 2010b), and transport of solutes, metabolites, and 
proteins (Twig et al., 2008).  
At steady state, the frequencies of fusion and fission events are balanced (Nunnari et al., 
1997); however when this balance is perturbed, dramatic changes in mitochondrial 
morphology occur. A high fusion-to-fission ratio leads to few mitochondria, which are 
long and highly interconnected (Bleazard et al., 1999; Chen et al., 2003a; Smirnova et 
al., 2001). Conversely, a low fusion-to-fission rate leads to numerous small 
mitochondria that have a spherical or rod like morphology.  
Mitochondria accumulate in sites of high-energy demand or where calcium buffering is 
required; hence certain cell types, such as neurons, are especially dependent on having 
the correct balance between mitochondrial fission and fusion. In the cerebellum, 
mitochondrial fission generates mitochondria of the correct size for transport along 
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dendritic processes of Purkinje neurons, to meet significant energy demands at locations 
distant from the cell body (Bereiter-Hahn, 2014; Chen et al., 2007).  
Mitochondrial fission and fusion are controlled by four large dynamin-related GTPases. 
These effectors of mitochondrial dynamics are conserved from yeast to mammals. Outer 
mitochondrial membrane (OMM) fusion is controlled by mitofusin 1 (MFN1) and 
mitofusin 2 (MFN2, (Chen et al., 2003a; Santel and Fuller, 2001)), inner mitochondrial 
membrane (IMM) fusion by optic atrophy protein 1 (OPA1, (Alexander et al., 2000; 
Delettre et al., 2000)), and mitochondrial fission by dynamin-related protein 1 (DRP1, 





Figure 1.6. Schematic representation of mitochondrial fission and fusion. 
Mitochondria dynamically alter their morphology through fission (left) and fusion 
(right) to maintain cellular homeostasis. For mitochondrial fission to occur, DRP1 is 
recruited from the cytosol to the OMM. FIS1 and MFF are located on the OMM and are 
adapter proteins for DRP1. For mitochondrial fusion to occur, MFN1 and MFN2 are 
located on the OMM to coordinate fusion of the outer membrane of adjacent 
mitochondria, and OPA1 is located on the IMM to coordinate inner membrane fusion. 
MFF: mitochondrial fission factor, FIS1: fission protein-1. 
 
 
1.7.1. Mitochondrial Fusion 
The first known mediator of mitochondrial fusion, fuzzy onions (FZO), was discovered 
in 1997 in Drosophila, and is an OMM GTPase required for the fusion of mitochondria 
during spermatogenesis (Hales and Fuller, 1997). FZO is the first identified member of 
the mitofusin family of proteins found in yeast (Fzo1, (Hermann et al., 1998; Rapaport 
et al., 1998), worms (Kanazawa et al., 2008), and mammals (Santel and Fuller, 2001). 
The mammalian homologues are mitofusins MFN1 and MFN2, which form homo-
oligomeric and hetero-oligomeric complexes that tether and possibly fuse OMMs of 
mitochondria (Chen et al., 2003a; Koshiba et al., 2004). MFN1 and MFN2 are anchored 
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to the OMM and have a large N-terminal GTPase domain and a C-terminal domain 
containing a heptad repeat region, both of which are exposed to the cytosol. Mutations 
in the GTPase domain or the heptad repeat region, which forms coiled-coil structures, 
prevent mitochondrial fusion (Chen et al., 2003a; Santel et al., 2003). Mutations in 
MFN2 cause Charcot-Marie-Tooth disease type 2A (CMT2A), with patients having a 
loss of peripheral nerve function (Lawson et al., 2005; Zuchner et al., 2004). The 
majority of mutations identified in MFN2 cluster in or near the GTPase domain of the 
protein. Mitochondria in the sural nerve of two patients with CMT2A showed structural 
aberrations in their outer and inner membranes and mitochondrial dysfunction 
(Verhoeven et al., 2006). Due to the ability of MFN1 and MFN2 to form hetero-
oligomeric complexes, MFN1 can partially compensate for loss of functional MFN2. 
For example, in mouse embryonic fibroblasts (MEFs), expression of Mfn2 mutants that 
cause CMT2A leads to lack of mitochondrial fusion activity. This phenotype can be 
partially rescued when wild-type Mfn1 is co-expressed due to the formation of 
heterotypic complexes (Chen et al., 2003a). It has been suggested that tissues with low 
MFN1 expression are vulnerable in patients with CMT2A and that methods to increase 
MFN1 expression in the peripheral nervous system may be beneficial.  
Mice lacking Mfn2 show highly specific degeneration of Purkinje neurons in the 
cerebellum, leading to cerebellar ataxia (Chen et al., 2007). These mutant Purkinje cells 
have fragmented mitochondria that fail to distribute effectively along dendrites, and 
show loss of respiratory activity.  
OPA1 is essential for IMM fusion in mammals, the yeast orthologue being Mgm1 
(Meeusen et al., 2006). OPA1 is present in eight isoforms that are generated by 
alternative splicing and alternative processing at two cleavage sites located between the 
N-terminal transmembrane domain and the first heptad repeat. Heterozygous mutations 
in OPA1 cause autosomal dominant optic atrophy (ADOA), the most common form of 
optic neuropathy (Alexander et al., 2000; Delettre et al., 2000). Over 100 OPA1 
mutations have been identified, most commonly occurring in the GTPase domain of the 
protein (Ferre et al., 2005). Fibroblasts depleted of OPA1 have fragmented 
mitochondria, defects in respiration, mitochondria with aberrant cristae structure and 
increased susceptibility to apoptosis (Cipolat et al., 2004; Olichon et al., 2003). 
However, defects in diseased tissue from ADOA patients seem to be less severe, with 
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patients having aggregated, fragmented, or normal mitochondria (Delettre et al., 2000; 
Olichon et al., 2003). 
A lack of mitochondrial fusion results in a reduction in the exchange of contents 
between mitochondria and thus, reduced exchange of mtDNA-encoded electron 
transport proteins. This in-turn leads to defects in oxidative phosphorylation (Chen and 
Chan, 2010). 
 
1.7.2. Mitochondrial Fission 
The dynamin-related protein DRP1, or Dnm1 in yeast, is an ~80 kDa soluble, cytosolic 
protein containing an N-terminal GTPase domain, a middle domain necessary for 
oligomerisation and a C-terminal GTPase effector domain (GED) that is involved in 
self-assembly (Westermann, 2010a). In addition, humans have an alternatively spliced 
brain-specific isoform of DRP1 with an insertion between the middle domain and the 
GED, known as the variable domain. This contains post-translational modification sites 
(Chen et al., 2000; Smirnova et al., 1998; Wilson et al., 2013). The role of DRP1 in 
mitochondrial fission is thought to be similar to that of the GTPase dynamin in scission 
of clathrin-coated endocytic vesicles (Hoppins et al., 2007; Praefcke and McMahon, 
2004). Dynamin oligomerises and self-assembles around endocytic vesicles, which 
stimulates its GTPase activity and mediates scission of vesicles from the plasma 
membrane. 
Mitochondrial fission requires the recruitment of DRP1 from the cytosol to the OMM. 
DRP1 exists in the cytosol as small oligomers (dimers and tetramers), which are thought 
to self-assemble into large multimeric structures at the OMM, wrapping around the 
mitochondrial membrane forming ring-like structures, which constrict and sever the 
mitochondrion (Figure 1.7, (Seo et al., 2010; Shaw and Nunnari, 2002; Smirnova et al., 
2001; Yoon et al., 2001b)). Recent data suggests that DRP1 exists in a dynamic, dimer-
oligomer equilibrium in solution (Macdonald et al., 2014). The minimal functional 
assembly subunit of DRP1 on the mitochondrial membrane for fission to occur is 
thought to be a dimer, and not a tetramer, as previously suggested (Macdonald et al., 
2014).  
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Figure 1.7. Schematic of mitochondrial fission through oligomerisation of DRP1 on 
the outer mitochondrial membrane. DRP1 (green) self-oligomerises and assembles 
around the OMM, constricting and severing the mitochondrion. Fis1 and Mff are 
involved in recruitment of DRP1 from the cytosol to the OMM in mammalian cells.   
 
 
DRP1 localisation to mitochondria can be seen as punctate spots on mitochondrial 
tubules at prospective sites of fission (Labrousse et al., 1999; Smirnova et al., 2001), 
and often at the ends of mitochondria where fission has occurred. This can be seen by 
time-lapse imaging of GFP-tagged DRP1 showing that mitochondrial tubules divide at 
sites where these DRP1 punctate structures are found (Benard and Karbowski, 2009; 
Smirnova et al., 2001), although not all mitochondrial-associated DRP1 sites undergo 
division. Electron microscopy studies reveal that DRP1 oligomers on the mitochondrial 
membrane have an approximate diameter of 100-150 nm (Macdonald et al., 2014). 
Cells deficient for DRP1 contain highly interconnected mitochondria due to ongoing 
fusion in the absence of fission (Otsuga et al., 1998; Smirnova et al., 1998). In addition, 
Drp1 knockout in mice leads to embryonic lethality (Ishihara et al., 2009; Wakabayashi 
et al., 2009). A lethal, dominant-negative mutation in the middle domain of DRP1 
(A395D) was reported in a neonate with microcephaly, abnormal brain development, 
optic atrophy and hypoplasia. In addition, mitochondrial elongation was seen in the 
cells of this patient (Waterham et al., 2007). Functional analysis revealed that this 
A395D mutation impaired higher order assembly, GTPase activity and mitochondrial 
localisation of DRP1 (Chang et al., 2010). Another dominant-negative mutation, K38A, 
located in the GTP-binding domain, impedes fission and leads to elongated 
mitochondria (Smirnova et al., 2001; Smirnova et al., 1998). 
The mitochondrial fission machinery is best understood in yeast. Dnm1 is recruited to 
the mitochondrial membrane by the proteins mitochondrial fission 1 (Fis1), 
mitochondrial division protein 1 (Mdv1) and Caf4. Fis1 is an 18kDa mitochondrial 
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integral outer membrane protein that is essential for fission (Fekkes et al., 2000; Mozdy 
et al., 2000; Tieu and Nunnari, 2000). Fis1 binds indirectly to Dnm1 through the 
molecular adaptors, Mdv1 or Caf4 (Griffin et al., 2005). Mdv1 and Caf4 both contain an 
N-terminal domain that dimerises and binds to Fis1 and a C-terminal domain containing 
WD40 repeats that binds to Dnm1 (Cerveny and Jensen, 2003; Griffin et al., 2005). 
Loss of Fis1 leads to failed recruitment of Dnm1 from the cytosol to the mitochondrial 
membrane and hence, results in a severe mitochondrial fission defect (Fekkes et al., 
2000; Mozdy et al., 2000). In humans, less is known about the recruitment of DRP1 
from the cytosol onto mitochondria. Fis1 exists in mammalian cells, but no homologues 
of Mdv1 or Caf4 are currently known. Currently, the four strongest candidates for 




Human FIS1 may be involved in recruiting DRP1 to mitochondria, although the 
evidence is conflicting. FIS1 localises throughout the OMM in contrast to the punctate 
localisation of DRP1 (Lee et al., 2004; Otera et al., 2010). Early studies found that 
overexpression of FIS1 in mammalian cells resulted in fragmentation of mitochondria 
(Stojanovski et al., 2004; Yoon et al., 2001b; Yu et al., 2005), and loss of FIS1 resulted 
in elongation of mitochondria (Koch et al., 2005; Stojanovski et al., 2004; Yoon et al., 
2001b). However, FIS1 inhibition does not affect recruitment of DRP1 to mitochondria 
(Lee et al., 2004) and a more recent study failed to show an effect of FIS1 knockdown 
on mitochondrial morphology in HeLa cells (Otera et al., 2010). Also, targeted deletion 
of FIS1 from human carcinoma HCT116 cells does not disrupt mitochondrial 
morphology or DRP1 recruitment to mitochondria (Otera et al., 2010). It may be 
possible that FIS1 is involved in mitochondrial fission only in specific cell types. 
 
1.7.2.2. MFF 
Mitochondrial fission factor (MFF) is a C-tail anchored protein on the OMM, which is 
conserved in metazoans but does not exist in yeast. It was identified in a small 
interfering RNA (siRNA) screen for Drosophila genes whose knockdown resulted in 
mitochondrial elongation (Gandre-Babbe and van der Bliek, 2008). A mammalian MFF 
homologue exists, and similarly, knockdown reduces DRP1 recruitment to 
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mitochondria, leading to mitochondrial elongation (Otera et al., 2010).  In contrast, 
MFF overexpression induces mitochondrial fragmentation, concomitant with increased 
DRP1 recruitment to mitochondria (Otera et al., 2010). Additionally, 
immunoprecipitation experiments have shown MFF and DRP1 to transiently associate 
with each other (Lee et al., 2004; Otera et al., 2010), and MFF co-localises with DRP1 
foci on the OMM (Otera et al., 2010). Currently, MFF is the best established receptor 
for DRP1.  
 
1.7.2.3. MiD49 and MiD51 
Mitochondrial dynamics protein of 49kDa (MiD49) and mitochondrial dynamics 
protein of 51kDa (MiD51, also known as mitochondrial elongation factor 1 (MIEF1)) 
are located on the OMM. Overexpression of MiD49 or MiD51 in mammalian cells 
results in mitochondrial elongation and collapse of the network. However, 
unexpectedly, this also leads to increased recruitment of DRP1 to the mitochondria 
(Palmer et al., 2011; Zhao et al., 2011). The suggested explanation for this is that 
although excessive MiD production results in increased DRP1 recruitment, the recruited 
DRP1 is not active, thereby resulting in a fission defect (Palmer et al., 2011; Zhao et al., 
2011). Moreover, co-immunoprecipitation and yeast two-hybrid experiments show an 
interaction between DRP1 and these two proteins (Palmer et al., 2011). 
MID knockdown studies are less clear and show conflicting results. In one study, 
MID49 or MID51 knockdown had no effect on mitochondrial morphology, but double 
knockdown of both resulted in elongated mitochondria (Palmer et al., 2011). Another 
study found that knockdown of MID51 resulted in mitochondrial fragmentation (Zhao 
et al., 2011). It seems that the MID proteins are important regulators of DRP1 function, 
but more studies are required to understand their precise roles.  
 
1.7.3. DRP1 post-translational modifications 
Overexpression of wild-type DRP1 does not lead to mitochondrial fragmentation. This 
suggests that a change in levels does not directly alter mitochondrial fission, and it is 
activation of DRP1 that is required for mitochondrial fission. Implicated mechanisms 
for activation of DRP1 include the post-translational modifications: phosphorylation, S-
nitrosylation, ubiquitination, and sumoylation. These may influence mitochondrial 
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translocation of DRP1, higher order assembly or GTPase activity (Otera and Mihara, 
2011).  
 
1.7.3.1. Phosphorylation of DRP1 
Several protein kinases have been identified that phosphorylate different DRP1 serine 
residues, for example, cyclin B dependent kinase (CDK1, (Taguchi et al., 2007)), cyclic 
AMP-dependent protein kinase (PKA, (Chang and Blackstone, 2007)), and 
calcium/calmodulin-dependent kinase 1α (CaMK1α, (Han et al., 2008)). Calcineurin 
(CaN), a calcium-dependent phosphatase, dephosphorylates DRP1 (Han et al., 2008). 
Two main phosphorylation sites in DRP1 are at serine residues 616 and 637 (Ser616 
and Ser637), which are conserved residues in the GTPase effector domain (GED, or 
variable domain, (Chang and Blackstone, 2007; Cribbs and Strack, 2007; Slupe et al., 
2013; Taguchi et al., 2007)). CDK1 phosphorylates DRP1 at Ser616 (Ser635 in rat) 
during mitosis, promoting fission to facilitate the proper distribution and segregation of 
mitochondria into daughter cells (Taguchi et al., 2007). However, this modification does 
not directly affect GTPase activity (Taguchi et al., 2007). Other kinases, including 
ERK1/2 (Yu et al., 2011) and PKCδ (Qi et al., 2011), also phosphorylate DRP1 at 
Ser616, which enhances DRP1 activity under high glucose or oxidative stress 
conditions, respectively, leading to mitochondrial fragmentation. Also, CDK5 was 
recently identified to phosphorylate DRP1 at Ser616, which induces mitochondrial 
fragmentation by the mobilisation of DRP1 to mitochondria from microtubules (Cho et 
al., 2014; Strack et al., 2013). 
Reversible phosphorylation of DRP1 occurs at Ser637 (also noted as residue 617 or 656 
depending on the DRP1 transcript and species of origin). Two different protein kinases, 
PKA and CaMK1α, phosphorylate DRP1 at Ser637. However, contradictory results are 
reported for the effect of these two kinases on mitochondrial dynamics. PKA 
phosphorylation inhibits mitochondrial fission by preventing an interaction between the 
GTPase and GED domains of DRP1, leading to reduced GTPase activity and eventually 
mitochondrial recruitment of DRP1 (Chang and Blackstone, 2007; Cribbs and Strack, 
2007). Conversely, CaMK1α–dependent phosphorylation of DRP1 at Ser637 leads to 
translocation of DRP1 to mitochondria and increased mitochondrial fission in response 
to calcium influx through voltage-dependent calcium channels (VDCCs, (Chang and 
Blackstone, 2010; Han et al., 2008; Otera et al., 2013)). 
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Calcineurin (CaN) dephosphorylates DRP1 at Ser637, which activates DRP1 and 
stimulates translocation to mitochondria, leading to increased mitochondrial fission 
(Cereghetti et al., 2008; Cribbs and Strack, 2007). Calcineurin is activated by calcium; 
hence a rise in intracellular calcium levels would lead to increased dephosphorylation of 
DRP1 at Ser637 and increased mitochondrial fission (Cereghetti et al., 2008). Similar to 
the transcription factor, nuclear factor of activated T cells (NFAT, (Martinez-Martinez 
et al., 2006; Rodriguez et al., 2009)); a conserved LXVP motif within DRP1 was 
recently identified to mediate the interaction with CaN (Slupe et al., 2013). Disrupting 
the CaN-DRP1 signalling axis blocks the translocation of DRP1 to mitochondria, 
leading to mitochondrial elongation (Cereghetti et al., 2008; Slupe et al., 2013). It seems 
that intracellular calcium levels are important for the phosphorylation status of DRP1, 
and hence control of mitochondrial dynamics.  
 
1.7.3.2. S-Nitrosylation of DRP1 
S-nitrosylation is a redox-related modification of thiols (such as cysteine residues) by 
nitric oxide (NO). A study suggested that NO produced in response to β-amyloid 
protein, a key mediator of Alzheimer’s disease, triggers excessive mitochondrial fission, 
followed by synaptic loss and neuronal damage, in part via S-nitrosylation of DRP1 at 
Cys644 within the GED domain (Cho et al., 2009), which enhances the GTPase activity 
of DRP1 and oligomer formation. A Cys644Ala mutation prevented S-nitrosylation of 
DRP1, blocking the neurotoxicity (Cho et al., 2009). 
 
1.7.3.3. Sumoylation of DRP1 
Post-translational modification of DRP1 also occurs by the covalent attachment of small 
ubiquitin-like modifier (SUMO) proteins (Harder et al., 2004), termed sumoylation, 
which like phosphorylation, seems likely to occur within the variable domain of DRP1 
(Guo et al., 2013a). Sumoylation often alters subcellular localisation of proteins or 
protects them from ubiquitin-mediated destruction. There are four human SUMO 
isoforms (SUMO1-4), which are conjugated to lysine residues in target proteins, such as 
DRP1, via an E1 complex (SAE1/SAE2), a single E2 (Ubc9), and various E3 ligases 
(Wilkinson and Henley, 2010). DRP1 was shown to interact with Ubc9 and conjugation 
competent forms of SUMO1, -2, and -3, demonstrating that DRP1 is a direct target of 
sumoylation (Figueroa-Romero et al., 2009).  
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Mitochondrial-anchored protein ligase (MAPL) is a mitochondrion-anchored SUMO E3 
ligase that attaches SUMO to DRP1, stabilising the mitochondrial pool of DRP1 and 
stimulating mitochondrial fission (Braschi et al., 2009; Harder et al., 2004). SUMO 
proteins are removed from substrates by the sentrin-specific protease (SENP) family of 
isopeptidases. There are six SENPs in mammals, with SENP3 and SENP5 involved in 
removing SUMO from DRP1 (Guo et al., 2013a; Zunino et al., 2007). The dynamic 
balance between Ubc9-mediated SUMO conjugation and SENP-mediated SUMO 
removal determines the sumoylation state of proteins. SENP3 and SENP5-mediated 
desumoylation of DRP1 facilitates DRP1 localisation at mitochondria, formation of 
functional oligomers, and increased fission (Guo et al., 2013a; Zunino et al., 2007). 
Following SENP3 knockdown, DRP1 localisation at the mitochondria was reduced in 
HeLa cells, as determined by immunocytochemistry. Conversely, SENP3 
overexpression promoted mitochondrial localisation of DRP1 (Guo et al., 2013a). This 
indicates that enhanced DRP1 sumoylation, facilitated by reduced levels of SENP3, 
reduces mitochondrial localisation of DRP1. 
 
1.7.3.4. Ubiquitination of DRP1 
The mitochondrial E3 ubiquitin ligase MARCH5, also known as MITOL, is essential 
for mitochondrial fission (Karbowski et al., 2007). Loss of MARCH5 by gene 
knockdown or overexpression of a MARCH5 mutant lacking ubiquitin ligase activity 
both induce accumulation of DRP1 on OMM, yet they lead to the opposite effect of 
mitochondrial elongation (Karbowski et al., 2007) or fragmentation (Nakamura et al., 
2006; Yonashiro et al., 2006), respectively. These contradictory results are due to the 
multiple effects of MARCH5 in promoting MFN2-mediated mitochondrial fusion, 
while also ubiquitinating DRP1 and promoting degradation (Nakamura et al., 2006). 
Parkin is an E3 ubiquitin ligase, which has an essential role in removing damaged 
mitochondria from the cell via mitophagy (Narendra et al., 2008; Pallanck, 2010; Youle 
and Narendra, 2011). Parkin ubiquitinates DRP1, targeting it for degradation by the 
proteasome (Wang et al., 2011). Loss of Parkin or overexpression of a pathogenic 
mutant inhibits the ubiquitination and degradation of DRP1, leading to increased DRP1 
levels and aberrant mitochondrial fragmentation (Wang et al., 2011).  
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1.7.4. Dynamin and DRP1 
Much of what is attributed to DRP1’s mechanism of action in mitochondrial fission 
parallels that of dynamin in endocytic vesicle scission. Dynamin is also regulated 
through post-translation modifications, such as sumoylation (Mishra et al., 2004), 
phosphorylation (Ahn et al., 2002; Shajahan et al., 2004) and S-nitrosylation (Kang-
Decker et al., 2007; Wang et al., 2006). For example, the GED domain of dynamin 
interacts with SUMO-1, UBC9, and PIAS-1, all of which are members of the 
sumoylation machinery (Mishra et al., 2004). SUMO-1 and UBC9 were shown to 
inhibit the oligomerisation of dynamin, and their expression in mammalian cells down-
regulated the dynamin-mediated endocytosis of transferrin (Mishra et al., 2004). Also, 
phosphorylation of dynamin by the non-receptor protein tyrosine kinase c-Src induces 
its self-assembly and increases its GTPase activity (Ahn et al., 2002; Shajahan et al., 
2004). Nitric oxide (NO) has also been shown to activate dynamin GTPase activity 
through S-nitrosylation, promoting dynamin self-assembly and endocytosis (Kang-
Decker et al., 2007; Wang et al., 2006). Hence, novel findings on the regulation and 
function of dynamin may also be relevant to DRP1.   
 
The GTP-bound form of dynamin specifically binds to HSC70 and its DNAJ co-
chaperone auxilin (Newmyer et al., 2003), which remove the clathrin coat from 
endocytic vesicles that have budded from the plasma membrane (Schlossman et al., 
1984, Ungewickell et al., 1995, Greener et al., 2000). Two domains within auxilin were 
identified that interact with dynamin, and these domains inhibit endocytosis when 
overexpressed in HeLa cells (Newmyer et al., 2003). Like auxilin, sacsin may be a co-
chaperone, interacting with DRP1 and a HSP70 protein via its J-domain, to perform a 
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1.8. Mitochondrial Transport 
Mitochondria travel from the cell body to regions of the cell where they are required to 
deliver ATP and other metabolites, and then return. This is most strikingly seen in 
highly elongated cells such as neurons, where mitochondria travel to the synaptic 
terminals of axons and dendrites where the demand for energy is high. 
Mitochondrial transport in mammalian cells is largely microtubule based, via kinesin 
and dynein motors (Hollenbeck and Saxton, 2005), although it also occurs via the actin 
cytoskeleton, through myosins (Ligon and Steward, 2000; Morris and Hollenbeck, 
1995). Anterograde microtubule-based movement is driven by three kinesin motor 
proteins, KIF1Bβ, KIF5 and KLP-6 (Nangaku et al., 1994; Tanaka et al., 1998), which 
interact with mitochondria through the Milton/TRAK family of proteins, which in-turn 
interact with the outer mitochondrial membrane Ras GTPases Miro1 and Miro2 
(Brickley and Stephenson, 2011; Glater et al., 2006; Macaskill et al., 2009; Reis et al., 
2009). Loss of this Miro-dependent pathway in neurons results in depletion of 
mitochondria from dendrites and axons, resulting in neurotransmission defects (Guo et 
al., 2005).  
Miro is necessary for basal mitochondrial transport as well as acting as a calcium 
responsive switch for mitochondrial transport. Through Miro, increases in cytosolic 
calcium lead to mitochondrial transport arrest and this is recovered following a return to 
basal cytosolic calcium levels (Macaskill et al., 2009; Saotome et al., 2008; Wang and 
Schwarz, 2009). In addition, Miro mediates mitochondrial fission in response to 
elevated cytosolic calcium, and mitochondrial elongation when calcium levels are low 
(Saotome et al., 2008).  
Retrograde movement of mitochondria along microtubules is driven by the dynein-
dynactin complex. Interestingly, this complex has been shown to play a role in 
regulating mitochondrial morphology by controlling the recruitment of the fission factor 
DRP1 to the outer mitochondrial membrane (Varadi et al., 2004). Functional disruption 
of this complex results in perinuclear, elongated mitochondria (Varadi et al., 2004). No 
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1.8.1. Dynein-Dynactin complex  
Dynein is the cytoplasmic motor protein that drives retrograde transport of vesicles and 
organelles along microtubules; that is from the periphery towards the nucleus, to their 
subcellular locations (Schnapp and Reese, 1989). Dynein function in vivo depends on 
dynactin; a multi-subunit complex which binds and activates dynein, driving the 
retrograde movement (Eckley et al., 1999; Gill et al., 1991; Schroer and Sheetz, 1991). 
There are nine subunits of the dynactin complex, which are arranged into distinct sub-




Figure 1.8. Schematic representation of the dynactin complex. Figure taken from 
(Parfitt, 2011).   
 
 
The Arp1 rod is the core of the dynactin complex and this is capped at one end by the 
actin-binding protein, CapZ α/β, and at the other end by four subunits, Arp11, p62, p27, 
and p25 (pointed-end complex). This sub-complex is involved in cargo binding. The 
projecting arm, which contains the p150Glued, dynamitin, and p24 subunits, binds 
microtubules and dynein (Figure 1.8, (Eckley et al., 1999; Schafer et al., 1994)). 






CHAPTER 1: INTRODUCTION 
	   50 
Table 1.5. Dynactin subunits 
Subunit Gene Name 







The projecting arm  
p150Glued DCTN1 




Dynactin is ubiquitously expressed in vertebrates and typically exhibits small punctae, 
corresponding to microtubule plus ends (Levy et al., 2006; Valetti et al., 1999), which 
are distributed throughout the cell (Gill et al., 1991; Paschal et al., 1993). 
The dynein-dynactin complex is required for mitosis, particularly nuclear envelope 
breakdown and spindle formation (Echeverri et al., 1996; Schroer, 2004), and in protein 
degradation via autophagy and aggresome formation (Johnston et al., 2002; Kimura et 
al., 2008). Other cellular roles suggested are in retrograde signalling from the axon to 
the cell body in neurons, in neurofilament transport, and in neuronal migration (Schroer, 
2004). Dynactin has also been shown to interact with the anterograde microtubule-based 
motor, kinesin II (Deacon et al., 2003), and in vitro studies suggest that dynactin 
contributes to the anterograde movement of kinesin II (Berezuk and Shroer 2007). 
The pointed-end complex, which comprises Arp11, p62, p27, and p25, binds neither 
dynein nor microtubules, and its p62, p27, and p25 subunits are not present in yeast, 
indicating that they are not required for dynactin’s most fundamental role as a dynein 
activator (Schroer, 2004). Yeh et al (2012) demonstrated that the pointed-end complex 
dissociates into two heterodimers, p62/Arp11 and p27/p25. Depletion of each subunit 
using RNA interference (RNAi) showed that Arp11 and p62 were essential for dynactin 
stability and they allow dynactin to bind the nuclear envelope prior to mitosis, 
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contributing to dynein recruitment and nuclear envelope breakdown. On the other hand, 
p27 and p25 were not essential for dynactin stability, but were required for binding of 
dynactin and recruitment of dynein to early and recycling endosomes for their 
movement (Yeh et al., 2012; Zhang et al., 2011).  
Disruption of dynein-dynactin function has been causally linked to multiple 
neurodegenerative diseases (Perlson et al., 2010). For example, mutations in p150Glued 
cause amyotrophic lateral sclerosis (ALS, (Munch et al., 2004)). 
Overexpression of dynamitin (p50) in HeLa cells results in redistribution of 
mitochondria from the cell periphery towards the nucleus and the formation of long, 
interconnected mitochondria (Varadi et al., 2004). This suggests a disruption in the 
balance between mitochondrial fission and fusion and is associated with a large 
decrease in localisation of DRP1 at the outer mitochondrial membrane. Dynamitin and 
p150Glued were also shown to interact with DRP1 by co-immunoprecipitation (co-IP 
(Varadi et al., 2004)).  
 
1.8.1.1. Dynactin-6/p27 subunit 
Interestingly, the dynactin-6 subunit, also known as p27, of the dynein-dynactin 
complex was found to interact with sacsin by a yeast-two-hybrid (Y2H) screen using 
residues 1-649 of sacsin as bait (Parfitt, 2011). Dynactin-6 (DCTN6) encodes a protein 
product of 190 amino acids with a molecular weight of 25 kDa (Eckley et al., 1999). 
The exact molecular function of DCTN6 is still unknown. However, the mouse homolog 
of DCTN6, which shares extensive sequence homology with the human protein, has 
been suggested to be involved in mitochondrial biogenesis (Murdock et al., 1999). 
Since DCTN6 exists as a heterodimer with DCTN5, siRNA-mediated depletion of one 
also leads to depletion of the other. Conversely, expression of siRNA-resistant DCTN6 
results in recovery of both DCTN6 and DCTN5 (Yeh et al., 2012).  
DCTN5 and DCTN6 are also reported to exist in a freely soluble pool in cells, so are 
available to provide functions outside of dynactin and may serve as adapter proteins that 
target dynactin to more subcellular structures (Schroer, 2004). 
Interestingly, like DRP1, DCTN6 is phosphorylated by CDK1 at the conserved 
consensus site Thr186, which generates a binding site for the mitotic kinase, polo kinase 
1 (PLK1, (Yeh et al., 2013)). This phosphorylation of DCTN6 occurs during mitosis 
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and depletion of DCNT6 leads to accelerated mitotic progression. The crystal structure 
of DCTN6 reveals an unusual left-handed parallel β-helix (LβH) domain and the CDK1 
phosphorylation site is in an unstructured C-terminal segment (Yeh et al., 2013). 
 
1.9. Mitochondrial Dysfunction and Neurodegeneration  
The central nervous system (CNS) is dependent on efficient mitochondrial function, 
since brain tissue has a high energy demand. Mutations in mitochondrial DNA 
(mtDNA), defects in mitochondrial dynamics, generation and presence of reactive 
oxygen species (ROS), and environmental factors, contribute to loss of mitochondrial 
energy production, which in turn may lead to neurodegenerative diseases (Filosto et al., 
2011). Previously, functional defects in mitochondria were considered to be 
downstream effects of neurodegenerative disease. However, in recent years it has been 
realised that impaired mitochondrial function is an important factor in the onset and 
progression of neurodegenerative diseases. Remarkably, more than one-third of the 
genes linked to neurodegeneration so far are associated with mitochondrial function 
(Schon and Przedborski, 2011).  
Interestingly, neurons have high expression levels of proteins involved in mitochondrial 
dynamics (Li et al., 2004). In vitro, expression of the dominant-negative DRP1 mutant 
K38A in rat hippocampal neurons, which leads to mitochondrial elongation, reduces the 
number of dendritic spines (Figure 1.9C, (Li et al., 2004)). Also, neuronal mitochondria 
lacking functional DRP1 tend to aggregate in the soma (Ishihara et al., 2009; Li et al., 
2004), Figure 1.9C). These observations show the importance of mitochondrial fission 
for neuronal morphogenesis and mitochondrial trafficking to neuron synaptic terminals. 
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Figure 1.9. Schematic representation of the defects in mitochondrial dynamics that 
lead to abnormal mitochondrial distribution in neurons. (A) Wild-type 
mitochondria are evenly distributed in the cell body, dendritic and axonal termini. (B) 
Absence of mitochondrial fission can lead to elongated mitochondria that branch out 
into the neurites and are they are protected from mitophagy, hence an accumulation of 
abnormal mitochondria (Cheung et al., 2007; Costa et al., 2010; Dagda et al., 2009). (C) 
Others have found elongated mitochondria to be coupled with impaired mitochondrial 
trafficking. Mitochondria aggregate within the perinucleur region, which is 
accompanied by decreased numbers of neurites and synapses (Ishihara et al., 2009; Li et 
al., 2004).  
 
 
Impaired mitochondrial dynamics is an important factor in the pathogenesis of many 
neurodegenerative diseases, some of which are discussed below.  
 
1.9.1. Alzheimer’s Disease 
Alzheimer’s disease (AD) is a late-onset neurodegenerative disease characterised by 
progressive decline in cognitive functions and memory. Recently, evidence indicates 
that impaired mitochondrial dynamics may be an important component in the 
pathogenesis of AD. Studies of AD patient brains report abnormal expression levels of 
the mitochondrial fission and fusion proteins DRP1, OPA1, MFN1 and MFN2 
(Manczak et al., 2011; Wang et al., 2009b). In addition, neurons overexpressing APP or 
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exposed to toxic Aβ peptides display abnormal levels of mitochondrial fission and 
fusion proteins and a perinuclear aggregation of mitochondria (Barsoum et al., 2006; 
Manczak et al., 2011; Wang et al., 2009b; Wang et al., 2008). Furthermore, a study in 
Aβ transgenic AD mice showed increased mitochondrial fragmentation (Calkins and 
Reddy, 2011). 
Tau is a microtubule-associated protein, abundantly present in the central nervous 
system and is predominantly expressed in neuronal axons (Brandt et al., 2005). Its 
physiological role is to stabilise the microtubule network. In AD, tau is 
hyperphosphorylated and loses its capability to bind with microtubules, which 
destabilizes the microtubule network and disturbs the transport of vesicles and 
organelles, such as mitochondria (Ebneth et al., 1998; Kopeikina et al., 2011; Roy et al., 
2005). Stable overexpression of the pathogenic tau mutation P301L in SH-SY5Y 
neuroblastoma cells leads to perinuclear aggregation of mitochondria due to impaired 
mitochondrial transport and motility, which is accompanied by a reduced rate of 
mitochondrial fission and fusion (Schulz et al., 2012).  
Expression of human tau carrying the R406W mutation in Drosophila leads to 
elongated mitochondria in the neurons of brains from the flies. This is accompanied by 
reduced localisation of DRP1 at mitochondria. It is suggested that hyperphosphorylation 
of tau leads to excess stabilisation of the actin cytoskeleton, which in-turn inhibits the 
association of DRP1 with mitochondria (DuBoff et al., 2012). 
DRP1 has also been shown to interact with Aβ and hyperphosphorylated tau in brain 
specimens from AD patients. This increases the GTPase activity of DRP1, leading to 
excessive mitochondrial fragmentation, along with mitochondrial and synaptic 
deficiencies, possibly leading to neuronal damage and cognitive decline (Manczak and 
Reddy, 2012).  
Specific post-translational DRP1 modifications have also been implicated in AD. For 
example, increased levels of DRP1 phosphorylation at Ser616 and S-nitrosylation, 
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1.9.2. Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease and is 
characterised by progressive loss of dopaminergic neurons in the substantia nigra pars 
compacta and the formation of intraneuronal inclusions known as Lewy bodies 
(Fearnley and Lees, 1991). PD symptoms include resting tremor, rigidity, bradykinesia 
and unsteady gait. Mitochondrial dysfunction has long being regarded as a primary 
cause in the pathogenesis of PD, and more specifically, dysregulation of mitochondrial 
dynamics has more recently been linked to the pathogenesis of PD (Chaturvedi and 
Beal, 2013; Santos and Cardoso, 2012; Van Laar and Berman, 2013). Around 10% of 
all cases of PD are associated with mutations in different PARK genes, such as PARK2, 
which encodes Parkin, and PTEN-induced kinase 1 (PINK1), which play important 
roles in the removal of damaged mitochondrial organelles via mitophagy (Dodson and 
Guo, 2007; Narendra et al., 2008; Narendra et al., 2010). DRP1 has been identified as 
one of the targets of the E3 ubiquitin ligase, Parkin (Wang et al., 2011).  
PINK1 is found in both the inner and outer mitochondrial membranes (Jin et al., 2010; 
Silvestri et al., 2005; Zhou et al., 2008a). Mitochondrial PINK1 is present in two forms, 
long and short, with the long form (PINK1-L, 64 kDa) cleaved to the short form 
(PINK1-S, 52 kDa) within the mitochondrial inner membrane by presenilin-associated 
rhomboid-like protein (PARL), an intramembrane protease (Deas et al., 2011; Jin et al., 
2010). PD patient fibroblasts are reported to contain fragmented mitochondria (Exner et 
al., 2007), and knockdown of PINK1 in HeLa cells and SH-SY5Y neuroblastoma cells 
also causes mitochondrial fragmentation, which can be reversed by over-expression of 
Parkin (Dagda et al., 2009; Exner et al., 2007). PINK1 has also been shown to form a 
complex with Milton and Miro (Weihofen et al., 2009), suggesting a role in 
mitochondrial transport. 
 
1.9.3. Huntington’s Disease 
Huntingdon’s disease (HD) is an autosomal dominant progressive neurodegenerative 
disease characterised by involuntary movements, psychiatric disturbances and cognitive 
decline. It is caused by an intragenic CAG-triplet expansion within the huntingtin (HTT) 
gene on chromosome 4 leading to an abnormal stretch of polyglutamine residues, which 
determines age of onset and disease severity. Patients have progressive neuronal loss 
affecting particular striatal GABAergic spiny neurons, as well as atrophy and gliosis of 
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the basal ganglia, cortex, and hippocampus. Abnormal mitochondrial dynamics have 
also been associated with this disease (Bossy-Wetzel et al., 2008). Studies in HD patient 
lymphoblasts and in primary striatal neurons isolated from HD mouse models revealed 
fragmented mitochondria (Guo et al., 2013b; Quintanilla et al., 2013). Likewise, 
mitochondria in HeLa cells overexpressing mutant HTT with a 74 glutamine repeat 
(Htt74Q) show fragmentation, reduced fusion, reduced ATP levels and increased cell 
death (Wang et al., 2009a). Additionally, HD patient cells have increased activity of 
calcineurin, which dephosphorylates DRP1 and increases its translocation to 
mitochondria, leading to mitochondrial fragmentation (Costa et al., 2010). 
Overexpression of OPA1, a dominant-negative DRP1 mutant K38A, or a dominant-
negative calcineurin mutant, can rescue the mitochondrial fragmentation (Costa et al., 
2010). Cellular models of HD, aswell as striatal and cortical specimens from HD 
patients, were also shown to have higher mRNA and protein expression levels of DRP1 
and FIS1, whereas OPA1, MFN1 and MFN2 fusion proteins are decreased (Cartelli et 
al., 2010; Kim et al., 2010a; Shirendeb et al., 2011).  
In transfected primary rat cortical neurons, mutant, but not wild type Htt blocked 
mitochondrial movement (Chang et al., 2006). Also, expression of mutant Htt in 
transgenic mice impaired trafficking of vesicles and mitochondria (Trushina et al., 
2004). Mutant Htt was found to bind DRP1 and increase its mitochondrial fission 
activity (Song et al., 2011). 
 
1.9.4. Hereditary Optic Atrophy 
Autosomal dominant optic atrophy (ADOA) is characterised by loss of retinal ganglion 
cells (RGCs) leading to optic atrophy. A subset of ADOA is caused by OPA1 mutations 
(Alexander et al., 2000; Delettre et al., 2000). Patients have a slow progressive loss of 
bilateral visual function, with onset typically within the first two decades of life. 
Symptoms include a decrease in visual acuity, colour vision deficiency, and visual field 
defects (Hoyt, 1980; Kline and Glaser, 1979). 
ADOA patient dermal fibroblasts have an inhibition of mitochondrial fusion in about 
50% of cells, accompanied by a significant impairment in mitochondrial ATP synthesis 
(Zanna et al., 2008). In addition, RNAi experiments show that loss of OPA1 leads to 
excessive fragmentation of the mitochondrial network and increased cell apoptosis 
(Cipolat et al., 2004; Lee et al., 2004; Olichon et al., 2003).  
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1.9.5. Charcot-Marie-Tooth Neuropathy (CMT) 
Charcot-Marie-Tooth Disease type 2A (CMT2A) is an autosomal dominant peripheral 
neuropathy characterised by axonal degeneration and is caused by mutations in the 
mitochondrial fusion protein MFN2 (Zuchner et al., 2004). Other types of CMT disease 
affect Schwann cells, resulting in demyelination of peripheral nerves. However, 
CMT2A affects the axons of the longest sensory and motor peripheral nerves, with a 
subset showing additional degeneration in the optic nerve (Zuchner and Vance, 2005). It 
is not known why mutations in MFN2, which is ubiquitously expressed, lead to such a 
highly cell type-specific defect.  
Expression of MFN2 mutants in cultured dorsal root ganglion (DRG) neurons led to 
disruption of mitochondrial transport in axons. Cellular ATP levels, mitochondrial 
potential, and respiratory chain function were unaltered (Baloh et al., 2007). Given that 
the peripheral sensory and motor axons are the longest in the body, they are likely to be 
particularly sensitive to mitochondrial transport defects, hence this could be the reason 
for the cell type-specific defect. MFN2 mutant zebrafish were also shown to have 
perturbed axonal mitochondrial transport. Phenotypically this resulted in progressive 
motor dysfunction and pathological alterations to the neuro-muscular junction 
(Chapman et al., 2013). 
 
1.9.6. Mitochondrial dysfunction in ARSACS 
Since sacsin is localised at mitochondria, the effect of loss of sacsin on mitochondrial 
morphology and function has been investigated. Using three-dimensional confocal 
reconstructions along with fluorescence recovery after photobleaching (FRAP) studies 
in SH-SY5Y cells, siRNA-mediated sacsin knockdown was shown to lead to a more 
interconnected mitochondrial network (Girard et al., 2012). Similarly, fibroblasts from 
ARSACS patients display a hyperfused mitochondrial phenotype indicated by the 
presence of balloon-like or bulbed mitochondria (Blumkin et al., 2015; Girard et al., 
2012; Pilliod et al., 2015). This mitochondrial phenotype parallels that seen in models 
of DRP1 knockdown (Estaquier and Arnoult, 2007; Lee et al., 2004) or when mutant 
forms of DRP1 are overexpressed (Frank et al., 2001; Smirnova et al., 1998). This 
suggests that loss of sacsin function leads to a disruption in normal mitochondrial 
dynamics. Furthermore, a decrease in mitochondrial fission seems more likely than 
enhanced fusion due to the identification of a putative interaction between a 
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heterologously expressed N-terminal portion of sacsin (amino acids 1-1368) and DRP1 
by co-immunoprecipitation (Girard et al., 2012), along with co-localisation of the 
proteins seen by confocal microscopy (Girard et al., 2012).  
More recently, motor neurons cultured from Sacs-/- knockout mice also show an 
elongation of mitochondria, along with a significant reduction in mitochondrial motility 
(Lariviere et al., 2015). It has been hypothesised that larger, unusually shaped 
mitochondria cannot distribute into the narrow dendrites to reach synapses and instead 
accumulate in the soma and proximal dendrites (Girard et al., 2012). This leads to 
striking alterations in the organisation of dendritic fields in the cerebellum of Sacs-/- 
mice, which precedes Purkinje cell death (Girard et al., 2012). Additionally, cultured rat 
hippocampal neurons transduced with lentivirus encoding shRNA targeting sacsin show 
an accumulation of mitochondria in the soma and proximal dendrites (Girard et al., 
2012). Neurons are very sensitive to changes that disturb mitochondria because of their 
high metabolic activity and significant energy demand at locations distant from the cell 
body. Moreover, sacsin knockdown cells and neurons from Sacs-/- mice have a loss of 
mitochondrial membrane potential, which is generated by oxidative phosphorylation, 
thereby indicating a loss in mitochondrial function (Girard et al., 2012). In line with 
this, a very recent study has shown that ARSACS patient fibroblasts have reduced 
mitochondrial respiration and increased reactive oxygen species, which indicates 
mitochondrial dysfunction and oxidative stress due to loss of sacsin (Criscuolo et al., 
2015).	   Likewise, our group has demonstrated functional impairment of oxidative 
phosphorylation in ARSACS patient fibroblasts and in SH-SY5Y neuroblastoma cells 
transfected with siRNA targeting SACS (Bradshaw et al., 2016). Along with this, 
reduced transcript levels of genes involved in oxidative phosphorylation and increased 
transcript levels of oxidative stress genes were observed in sacsin deficient cells 
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1.10. Intermediate Filaments  
Cytoskeletal dysfunction has also been identified as a key feature of several 
neurodegenerative diseases, including AD, tauopathies and polyQ disorders 
(Gunawardena and Goldstein, 2005; McMurray, 2000). 
The mammalian cytoskeleton is composed of three interconnected filaments: 
microtubules (25 nm in diameter), actin microfilaments (7-10 nm in diameter), and 
intermediate filaments (10-12 nm in diameter), which together control the shape and 
mechanics of eukaryotic cells. Neurons are particularly dependent on the cytoskeleton 
to deliver proteins synthesised in the cell body to the axons and nerve terminals.  
Intermediate filaments (IF) are found in nearly all eukaryotic cells, although different 
cell types possess different types of IF protein (Table 1.6). In epidermal cells and the 
axons of neurons, they are at least 10 times more abundant than microfilaments or 
microtubules. IFs are very stable structures that are assembled from one or more 
proteins encoded by a large multigene family of >70 members (Herrmann et al., 2009). 
There are six types of IF proteins, which are classified by gene structure and sequence 
homology (Table 1.6). All IF proteins have a common domain structure: a central α-
helical core flanked by globular N- and C-terminal domains, but they vary greatly in 
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Table 1.6. Intermediate filament proteins in mammals 
Intermediate filament protein Molecular Weight (kDa) Tissue Distribution 
Type I 
Acidic keratins 40 - 57 Epithelia 
Type II   
Basic keratins 53 - 67 Epithelia 
Type III   
Desmin 53 Muscle 
Glial fibrillary acidic protein 
(GFAP) 
50 Glial cells and astrocytes 
Peripherin 57 Peripheral and central neurons 
Vimentin 57 Mesenchyme 
Type IV   
α-Internexin 66 Developing central nervous 
system 
Neurofilament - Light 68 Mature neurons 
Neurofilament - Medium 145 Mature neurons	  
Neurofilament - Heavy 200 Mature neurons	  
Type V   
Nuclear lamins 67 - 70 Nucleus of all cells 
Type VI   
Nestin 240 Developing central and 
peripheral nervous system 
 
 
IF proteins are differentially expressed throughout the development of the nervous 
system. Undifferentiated cells express vimentin, a type III IF protein (Bignami et al., 
1982; Cochard and Paulin, 1984), whereas at later developmental stages, neuroblasts 
express nestin, α-internexin, and peripherin (Kaplan et al., 1990; Parysek and Goldman, 
1987; Portier et al., 1983). Upon differentiation into neurons, the neurofilament proteins 
become expressed (Carden et al., 1987; Nixon and Shea, 1992; Shaw and Weber, 1982).  
 
CHAPTER 1: INTRODUCTION 
	   61 
1.10.1. Neurofilaments (NFs) 
NFs constitute the major IF proteins in adult neurons, and they are a heteropolymer, 
composed of the three type IV proteins, NF-L, NF-M, and NF-H. NFs are synthesised in 
the perikaryon, before being assembled into filaments and actively transported along 
microtubules in axons by the kinesin and dynein motors, where they move at a net slow 
velocity of 0.2-1 mm/day (Lariviere and Julien, 2004). Hence, IFs are dependent on an 
intact microtubule network for extension throughout the cell. They are responsible for 
the radial growth of large myelinated axons and thus determine axonal diameter, which 
in turn is directly related to the speed of impulse conduction. Hence, disruption in the 
assembly of NFs results in hypotrophy of myelinated axons and a reduction in the 
velocity of nerve conduction (Kriz et al., 2000; Zhu et al., 1997). 
NFs within the perikaryon and proximal segments of axons and dendrites are normally 
hypophosphorylated, while NFs in axons are heavily phosphorylated (Carden et al., 
1987; Lee and Johnston, 1997). 
 
1.10.2. Intermediate filaments and mitochondria 
There is growing evidence indicating a contribution of IFs to the tethering of 
mitochondria (Anesti and Scorrano, 2006; Milner et al., 2000; Tang et al., 2008). This 
has been shown in muscle cells (Milner et al., 2000; Stone et al., 2007), nerve cells 
(Straube-West et al., 1996; Wagner et al., 2003), and fibroblasts (Mose-Larsen et al., 
1982; Summerhayes et al., 1983). There is also evidence that vimentin and NFL-H bind 
directly to mitochondria in vitro and that mitochondrial function requires IFs (Milner et 
al., 2000; Tao et al., 2009; Tolstonog et al., 2005; Wagner et al., 2003). A recent study 
demonstrated that mitochondria associate with the non-α-helical N-terminal domain of 
vimentin and that this binding inhibits their motility (Nekrasova et al., 2011). In 
cultured fibroblasts, mitochondria are distributed throughout the perinuclear region and 
they are frequently orientated parallel to vimentin IFs. 
Mitochondria can also associate with IFs through interactions with the cytolinker, 
plectin (Reipert et al., 1999; Rezniczek et al., 2003; Winter et al., 2008). Plectin-1b acts 
as a direct linker between vimentin IFs and the mitochondrial network, with loss of 
plectin-1b resulting in mitochondrial elongation (Winter et al., 2008). 
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Disruptions to the IF network have also been shown to disrupt the morphology, 
distribution and functions of mitochondria. For example, mutations in the small heat 
shock protein, αB-crystallin, which lead to desmin aggregation in desmin-related 
myopathies (Vicart et al., 1998), also lead to alterations in mitochondrial organisation 
and function. Specifically, a reduced maximum rate of oxygen consumption and a 
compromised inner membrane potential ensue (Maloyan et al., 2005). Furthermore, 
mutations in desmin itself lead to changes in the distribution and function of 
mitochondria in skeletal muscles and the heart (Capetanaki, 2002; Milner et al., 2000). 
Similarly, morphological and functional changes in mitochondria have been reported in 
vimentin-null fibroblasts (Tolstonog et al., 2001), and mutations in the NF-L gene, 
which cause Charcot-Marie-Tooth neuropathy type 2E (CMT2E), result in the 
clustering of mitochondria in the cell bodies of neurons (Brownlees et al., 2002). 
Collectively, this highlights the importance of the normal localisation and function of 
IFs for the normal distribution and function of mitochondria. 
	  
1.11. Intermediate Filament Abnormalities and Neurodegeneration 
Abnormal accumulations and disorganisation of IFs has been observed in many 
neurodegenerative disorders such as ALS, CMT2E, AD and PD (Al-Chalabi and Miller, 
2003; Forno et al., 1986; Perrot and Eyer, 2009). This may be due to factors such as 
deregulation of IF protein synthesis, defective axonal transport, abnormal 
phosphorylation and proteolysis. In ALS, abnormal accumulations of phosphorylated 
NF proteins are present in the perikaryon of affected neurons, swollen axons and 
spheroids (Manetto et al., 1988; Schmidt et al., 1987). In addition, the IF protein 
peripherin is present in ubiquitinated inclusions in motor neurons from ALS patients 
(He and Hays, 2004).  
Mutations in genes encoding neurofilament proteins have also been linked to 
neurodegenerative diseases. Codon deletions or insertions in the lysine-serine-proline 
(KSP) phosphorylation motif of NF-H have been reported in a small number of sporadic 
cases of ALS (Al-Chalabi et al., 1999; Figlewicz et al., 1994; Tomkins et al., 1998). In 
addition, mutations in the NF-L gene have been reported in many cases of CMT2E (De 
Jonghe et al., 2001; Georgiou et al., 2002; Jordanova et al., 2003; Mersiyanova et al., 
2000). This directly implicates disruption of the IF cytoskeleton in the molecular 
pathogenesis of some neurodegenerative diseases. 
CHAPTER 1: INTRODUCTION 
	   63 
Insoluble neurofibrillary tangles (NFTs) are a predominant feature in the pyramidal 
cells of the hippocampus and in the cerebral cortex of those with AD. 
Hyperphosphorylated tau, a microtubule-associated protein, was identified as a core 
protein in NFTs, and more recently, NF-L, NF-M, and NF-H have also been shown to 
be integral components of NFTs (Rudrabhatla et al., 2011). 
 
1.11.1. Intermediate filament abnormalities in ARSACS 
Morphological and functional changes in mitochondria have been widely reported in 
different ARSACS disease models (Criscuolo et al., 2015; Girard et al., 2012; Lariviere 
et al., 2015; Pilliod et al., 2015). More recently, Sacs-/- knockout mice were shown to 
display early abnormal accumulations of non-phosphorylated neurofilament (NF) 
bundles, specifically the heavy molecular weight subunit (NFH), in the somatodendritic 
regions of vulnerable neuronal populations, a phenotype also observed in an ARSACS 
brain (Lariviere et al., 2015). Motor neurons cultured from Sacs-/- embryos also exhibit 
a similar NF rearrangement.  
So like many other neurodegenerative diseases, both mitochondrial and cytoskeletal 
defects have been reported in ARSACS, and this is not suprising since mitochondria 
rely on microtubules (Anesti and Scorrano, 2006; Hollenbeck and Saxton, 2005; 
Karbowski et al., 2001) intermediate filaments (Chernoivanenko et al., 2015; Milner et 
al., 2000; Nekrasova et al., 2011) and actin (Boldogh and Pon, 2006; Hatch et al., 2014; 
Li et al., 2015a) for their normal morphology, motility and distribution. Also, since 
sacsin contains domains linking to proteostasis pathways, such as a DNAJ domain and 
HSP90-like domains, loss of its function may affect proteostasis. Thus, like other 
neurodegenerative diseases, a combination of proteostasis, mitochondrial and 
cytoskeletal defects likely contribute to the pathophysiological basis of ARSACS, and 
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1.12. Aims and Objectives  
This thesis aims to elucidate the cellular role of sacsin by determining how loss of its 
function leads to impaired mitochondrial dynamics and function, along with defects in 
the intermediate filament cytoskeleton. This may shed light on the mechanism of 
disease in ARSACS and potentially other neurodegenerative or ataxia-related diseases. 
Chapter 3 aimed to delineate the mechanisms leading to an elongated and hyperfused 
mitochondrial network in cells lacking sacsin. Putative interactions have previously 
been identified between sacsin and both the mitochondrial fission protein DRP1 (Girard 
et al., 2012), and DCTN6, a component of the dynein-dynactin motor complex (Parfitt, 
2011). Interestingly, the dynein-dynactin complex has been identified to have a role in 
translocation of DRP1 to mitochondria (Varadi et al., 2004). This led to the hypothesis 
that sacsin and DCTN6 may function together in the recruitment of DRP1 to 
mitochondria. To test this hypothesis, interactions between sacsin, DRP1 and DCTN6 
were further investigated using co-immunoprecipitation (co-IP). Following this, the 
effect of either sacsin or DCTN6 siRNA knockdown on DRP1 mitochondrial 
localisation was examined using confocal microscopy and image analysis to quantify 
the incidence of DRP1 foci associated with mitochondria. The measurements were 
performed under basal conditions and after mitochondrial fission had been induced by 
treatment with a mitochondrial uncoupler. Furthermore, it was hypothesised that loss of 
sacsin may lead to a reduction in DRP1 complex formation. This was examined through 
the chemical cross-linking of proteins, followed by immunoblotting for DRP1 under 
non-reducing conditions. 
Chapter 4 addresses the intermediate filament defect observed in ARSACS. The 
organisation of the intermediate filament network (vimentin) in ARSACS patient 
fibroblasts and sacsin knockdown cells was analysed by confocal microscopy and image 
analysis. Since the intermediate filament network is important for the localisation and 
organisation of other cellular structures, including actin and microtubules, the Golgi 
complex, endosomes, and mitochondria, the distribution of these organelles was also 
characterised.  
Leading on from this, the impact of loss of sacsin on the dynamic assembly of the 
vimentin network was assessed by fluorescence recovery after photobleaching (FRAP). 
This involved the transient transfection of SH-SY5Y cells with vimentin-targeted GFP, 
in combination with either SCRM or SACS siRNA. 
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Moreover, the subcellular localisation of sacsin was further defined using super 
resolution microscopy and image analysis, along with cellular fractionation studies.  
Chapter 5 investigates the possibility that, similar to other neurodegenerative diseases, 
the intermediate filament defects observed in ARSACS may be the result of disrupted 
proteostasis. The expression and localisation of key proteostasis components, namely 
ubiquitin, HSP70, HSP90, p62 and LAMP2, were analysed by confocal microscopy and 
image analysis, along with biochemical approaches. Evidence for an accumulation of 
misfolded proteins in cells with loss of sacsin would support a role for sacsin in 
proteostasis and would provide a novel factor contributing to disease pathogenesis in 
ARSACS.  
Conclusions and details of potential future directions are detailed in Chapter 6. The 
findings indicate a role for sacsin in maintaining mitochondrial and protein quality 
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2.1. Cell Culture  
 
2.1.1. Cell lines and Maintenance 
The neuroblastoma-derived cell line SH-SY5Y (Biedler et al., 1978) was purchased 
from the European Collection of Authenticated Cell Cultures (ECACC) at the Health 
Protection Agency (HPA; Salisbury, UK). Cells were grown in 50% Dulbecco’s 
Minimum Eagle Medium (DMEM)/50% F12 (Sigma, Poole, UK) supplemented with 
10% (v/v) heat-inactivated foetal bovine serum (FBS; Life Technologies, Paisley, UK) 
and 50U/ml penicillin and 50µg/ml streptomycin (Pen/Strep; Life Technologies, 
Paisley, UK; final concentration in media 1% (v/v)).  
ARSACS patient dermal fibroblasts were a gift from Dr Sascha Vermeer (Radboud 
University, Nijmegen, Netherlands) and Dr Paola Giunti (UCL Institute of Neurology, 
London). The cells were collected as part of a project approved by the Medical Ethics 
Committee of the Radboud University (CMO-nr 2014/155), and Giunti has ethical 
approval for dermal fibroblast collection through a European integrated project on 
spinocerebellar ataxias (REC Ref - 04/Q0505/21). Written informed consent to 
participate in this study was obtained from all patients.  
Control human dermal fibroblasts were purchased from PromoCell (Heidelberg, 
Germany) or were kindly provided by Dr Tristan McKay (Biomedical Sciences, St 
George’s, University of London), or Dr Sascha Vermeer (Radboud University, 
Nijmegen, Netherlands). Control and ARSACS patient fibroblasts used in this work 
were not closely age matched but were all between passage 3 and 8. Cells were grown 
in DMEM supplemented with 10% (v/v) heat-inactivated FBS and 50U/ml penicillin 
and 50µg/ml streptomycin (Pen/Strep; final concentration in media 1% (v/v)). Cells 
were kept in a constant humidified atmosphere of 5% CO2 at 37ºC. 
 
2.1.2. Subculturing  
All reagents were warmed to 37ºC before use. Media was removed from the culture 
flask or dish and cells washed with DPBS (Dulbecco’s Phosphate Buffered Saline). 
Trypsin-EDTA (0.5g/l trypsin, 0.2g/l Ethylenediaminetetraacetic acid; Life 
Technologies, Paisley, UK) was used to detach the cells for 2-5 minutes, and then 
inactivated by adding media containing 10% (v/v) FBS. The cell suspension was 
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centrifuged at 125g for 5 minutes and the supernatant was removed. The cell pellet was 
then re-suspended in fresh media and cells were re-plated as required. 
 
2.1.3. Freezing down cells 
Cells were grown until confluent, then trypsinised and transferred to a 15ml Falcon 
tube. From here on, Falcon tubes were spun using a Sorvall legend RT centrifuge with a 
four-piece swinging bucket rotor (75006445). Falcon tubes were centrifuged at 125g for 
5 minutes and the media removed. The cell pellet was then re-suspended in a freezing 
solution containing 90% FBS and 10% (v/v) DMSO (Dimethyl Sulphoxide, Sigma, 
Poole, UK), and cooled at a maximum of 1oC/min to -80ºC in 1ml cyrotubes. The tubes 
were transferred to liquid nitrogen for long-term storage. When necessary, the cells 
were revived from frozen by quickly thawing in a 37ºC water bath. The 1ml aliquot was 
transferred to a 15ml Falcon tube and centifuged at 125g for 5 minutes. The supernatant 
was removed and the cells were resuspended in 10ml of complete medium and plated 
into a new flask. Flasks were incubated in a 5% CO2, 37ºC incubator and the growth 
media was changed the following day.  
 
2.1.4. Cell counting 
Cells were washed with DPBS and trypsinised to detach the cells as if sub-culturing, 
before transferring them to a 15ml Falcon tube. 10µl of cell suspension was combined 
with 10µl of trypan blue (to identify dead cells) and pipetted into either end of a 
haemocytometer. Cells were counted, using a hand tally counter, in all four red corners 
of one grid (Figure 2.1) using a Leica DMIL light microscope with 10x objective, 
ignoring dead cells stained with trypan blue. The concentration of cells and volume of 
the suspension needed to acquire the desired cell density were determined using the 
following calculations: 
 
Number of cells counted/number red corners counted = number of cells/100ml  
Multiply by 2 to adjust for 1:2 trypan blue dilution 
x 104 = Number of cells/ml (y) 
Number of cells required/y = volume of cell suspension to seed (ml) 
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Figure 2.1. Schematic of haemocytometer grid 
 




2.2. Transient Transfections  
 
2.2.1. Lipofectamine and Plus Reagent 
Cells were seeded either in 8 well chamber slides (Nunc, VWR, Leicester, UK), 12 well 
plates, 6 well plates, 10cm dishes, or 25cm3 (T25) cell culture flasks (VWR, Leicester, 
UK) until 60-70% confluent. Cells for live imaging were seeded in 35mm glass-
bottomed cell culture dishes (Mat-Tek, Ashland, MA, USA). Cells were transfected 
with plasmid DNA and/or small interfering RNA (siRNA) using the Lipofectamine and 
Plus reagent system (Life Technologies, Paisley, UK) as follows: 
 
For an 8 well chamber slide, 100ng of DNA was incubated at room temperature with 
1µl Plus reagent in 12.5µl serum free media (Opti-MEM; Life Technologies, Paisley, 
UK) for 20 minutes. 1µl Lipofectamine and 100µl Opti-MEM were added to the 
mixture and incubated for 15 minutes. Cells were washed twice with serum free media 
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before the transfection mixture was added to the cells. Transfection reagents were 
scaled up or down depending on the culture vessel (Table 2.1). After incubation for 3 
hours at 37ºC, an equal volume of 2x serum media containing 20% FBS/2% PenStrep 
was added to cells, followed by further incubation at 37ºC for 24-48 hours. Cells were 
then processed for immunocytochemistry or immunoblot analysis.  
 





DNA Opti-MEM Lipofectamine 
8-well slide 12.5 µl 1 µl 100ng 100 µl 1 µl 
Mat-Tek dish 100 µl 4 µl 1µg 400 µl 4 µl 
12-well plate 50 µl 2 µl 500ng 200 µl 2 µl 
6-well plate 100 µl 4 µl 1µg 700 µl 4 µl 
T25 flask 250 µl 10 µl 2µg 1.5ml 10 µl 
Volumes shown are for a single well for each vessel indicated. 
 
2.2.2. Lipofectamine 3000 
Cells were seeded either in 12 well plates, 6 well plates, or 10cm dishes (VWR, 
Leicester, UK) until 70-90% confluent. Cells for live imaging were seeded in 35mm 
glass-bottomed cell culture dishes (Mat-Tek, Ashland, MA, USA). Cells were 
transfected with plasmid DNA and/or siRNA using the Lipofectamine 3000 system 
(Life Technologies, Paisley, UK) as follows: 
 
For a standard 12 well plate, 500ng of DNA and/or 20pmol siRNA was diluted in 50µl 
serum free media (Opti-MEM) at room temperature. In a separate Eppendorf tube, 2µl 
Lipofectamine 3000 was diluted in 50µl Opti-MEM. The diluted DNA was added to the 
diluted Lipofectamine 3000 reagent (1:1 ratio), mixed by pipetting, and incubated for 5 
minutes at room temperature. The DNA-lipid complexes were then added to the cells in 
1ml of growth medium. Transfection reagents were scaled up or down depending on the 
culture vessel (Table 2.2). Cells were incubated for 48 hours at 37ºC before visualising 
and processing them for immunocytochemistry or immunoblot analysis. 
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Mat-Tek dish 125 µl 1.5 µg 50 pmol 125 µl 5 µl 2 ml 
12-well plate 50 µl 500 ng 20 pmol 50 µl 2 µl 1 ml 
6-well plate 125 µl 1.5 µg 50 pmol 125 µl 5 µl 2 ml 
10 cm dish 500 µl 10 µg 350 pmol  500 µl 30 µl 10 ml 
Volumes shown are for a single well for each vessel indicated. 
 
For transfection of siRNA, three custom SACS siRNAs to exons 7, 8 and 10, and two 
DCTN6 siRNAs to exons 3 and 6 were previously validated by our group (Ambion, Life 
Technologies, Paisley, UK, Table 2.3). The three SACS siRNAs were combined to make 
a stock solution of 20µM concentration. The same was done for the two DCTN6 
siRNAs. The final concentration of siRNA in each transfection was 20nM. 
 
Table 2.3. siRNA sequences 
Primer name Sequence (5’ - 3’) 
SACS exon 7 - sense GGAUGAUCCUCUGAAGGUC 
SACS exon 7 - antisense GACCUUCAGAGGAUCAUCC 
SACS exon 8 - sense GCGGCCGAAUUCUAUAAAG 
SACS exon 8 - antisense CUUUAUAGAAUUCGGCCGC 
SACS exon 10 - sense CGUAAGAUUUCUAGAUGAC 
SACS exon 10 - antisense GUCAUCUAGAAAUCUUACG 
DCTN6 exon 3 - sense GCCCUUAUCAUAAAUGCUU 
DCTN6 exon 3 - antisense AAGCAUUUAUGAUAAGGGC 
DCTN6 exon 6 - sense GGCAGAAAUGUAAUAUUGA 
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2.3. RNA Extraction 
RNA was extracted and purified from cells using an RNeasy mini kit (Qiagen). Cells 
were washed with cold PBS and lysed directly from plates using 350µl buffer RLT 
(lysis buffer) containing 10µl/ml of 2-mercaptoethanol (2-ME, Sigma), a reducing 
agent. Cells were homogenised by passing the lysate ten times through a 23G needle. 
To each 350µl lysate, one volume of 70% (v/v) ethanol was mixed in by pipetting, and 
the solution was transferred to an RNeasy spin column over a 2 ml collection tube. 
From here on, 1.5/2ml Eppendorfs were spun using a Sorvall legend micro 17 
centrifuge with a 24 x 1.5/2ml rotor (Thermo scientific). Lysates were centrifuged at 
13000g for 30 seconds through the column. The flow-through was discarded and the 
column washed with 700µl buffer RW1. Flow-through was discarded again, and the 
column washed with 500µl buffer RPE by centrifuging at 13000g for 30 seconds. This 
step was repeated with a centrifugation time of 2 minutes. The column was then 
transferred to a clean collection tube and centrifuged at 13000g for 1 minute to dry the 
membrane. The column was placed in a 1.5ml Eppendorf and RNA was eluted with 
30µl RNase-free water by centrifugation at 13000g for 1 minute. The RNA yield was 
quantified using the Nanodrop ND-1000 spectrophotometer, measuring absorbance at 
260 nm. Purity of RNA was determined by the OD260/OD280 ratio, which should be 






















CHAPTER 2: MATERIALS AND METHODS 
	   73 
2.4. cDNA Synthesis 
Complementary DNA (cDNA) was produced using the QuantiTect reverse transcription 
kit (Qiagen). First a reaction was carried out to remove genomic DNA (gDNA). 1µg of 
RNA was mixed with 7x gDNA wipeout buffer and RNase-free water to a final volume 
of 14µl. This was incubated at 42ºC for 2 minutes, then immediately placed on ice. 
Reverse transcription was subsequently carried out by creating a master mix, as detailed 
in table 2.4.  
 
Table 2.4. Reverse-transcription reaction components 




Quantiscript RT buffer, 5x1 4µl 1x 
RT primer mix 1µl  
gDNA elimination reaction 14µl  
Total volume 20µl  
1Contains Mg2+ and dNTPs. 
 
This was incubated for 15 minutes at 42ºC, followed by a 3-minute incubation at 95ºC 
to inactivate the reverse transcriptase. cDNA was then stored at -20ºC or used in real-
time PCR reactions. cDNA was amplified with GAPDH primers (Table 2.7) to identify 
successful reverse transcription, which should reveal a PCR product of approximately 
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2.5. Polymerase Chain Reaction (PCR) 
PCR was used to amplify specific regions of genes of interest. A series of temperature 
steps are repeated: Denaturation of DNA at 94ºC to separate the double helix, annealing 
at 50-60ºC to bind sequence specific primers to the template strand, and elongation of 
complementary strands by DNA polymerase in a 5’ to 3’ direction at 72ºC. Newly 
synthesised DNA is used as a template in subsequent cycles, leading to exponential 
amplification. 
cDNA was incubated with DNA polymerase from Thermus aquaticus (Taq), primers to 
the gene of interest (sequences given in table 2.7) and dNTPs to allow amplification 
(Table 2.5). 
 
Table 2.5. Standard PCR Mastermix 
Reagents 50µl reaction Final Concentration at 1x 
10x Standard Taq buffer1,2 5µl 1x 
dNTPs (10mM) 1µl 0.2mM 
Forward primer (10µM) 1µl 0.2mM 
Reverse primer (10µM) 1µl 0.2mM 
dH20 40.75µl To final volume 50µl 
Taq polymerase (5000U/ml)1 0.25µl  
cDNA 1 µl 0.5-1ng/µl 
1 New England BioLabs. 210mM Tris-HCl, 50mM KCl, 1.5mM MgCl2, pH8.3.  
 
Mastermix (49µl) and DNA (1µl) were mixed in a PCR tube to a total volume of 50µl. 
PCR reactions were carried out on a G-storm GS1 thermocycler (G-storm, somerset, 
UK) and the PCR thermocycle was programmed as indicated in table 2.6. PCR products 
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Table 2.6. PCR cycling conditions  
Phase Time Temperature 
Initial denaturation 5 min 94ºC 
Denaturation* 30 secs 94ºC 
Anneal*1 30 secs ~55ºC 
Extension* 1min/kb 72ºC 
 10 min 72ºC 
Cooling ∞ 4ºC 




Table 2.7. Primer sequences 
Primer name Sequence (5’ - 3’) 
GAPDH-F TGCACCACCAACTGCTTAG 
GAPDH-R GGATGCAGGGATGATGTTC 
SACS exon 6-7 - F ACAACAACGCGGTTTTCACC 
SACS exon 6-7 - R GCCTGATTCATGTGGGCCAA 
SACS exon 8-9 - F TTTAAAGGAAGCTGCCCAAA 
SACS exon 8-9 - R CCAAACCATCTTAAGCCATCA 
DCTN6-F GGATCCCATGGCGGAGAAGACTCAAAAGAGT 
DCTN6-R GGATCCGTTCTTTACTGGAGTTGAGCTT 
T7 sequencing primer TAATACGACTCACTATAGGG 
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2.6. Agarose Gel Electrophoresis 
Amplified DNA samples were loaded into the wells of an agarose gel and an electrical 
field was applied. Negatively charged DNA molecules migrate through the gel towards 
the anode. The speed of migration depends on the size of PCR products, with larger 
molecules migrating more slowly as they incur more resistance passing through the 
agarose. The size of a PCR product is estimated by comparison to a DNA ladder 
containing fragments of known sizes, run in an adjacent lane.  
To prepare a 1% w/v agarose gel, 1g of agarose was dissolved in 100ml of 1x TAE 
buffer by heating in a microwave for 3 minutes. After cooling slightly, 10µl of Gel Red 
(10,000x; Life Technologies, Paisley, UK) was added to the solution before pouring 
into a gel casting frame with a comb inserted and left to solidify for around 40 minutes. 
The gel was then placed in an electrophoresis tank containing 1x TAE buffer. 6x 
loading dye containing bromophenol blue (Promega) was added to samples at a 1:6 
dilution to track DNA migration during electrophoresis. GeneRuler DNA ladder mix 
(Thermo Scientific) was used as a DNA size marker. The gel was run at 100 volts for 
around 40 minutes and DNA bands were visualised under a UV-light using a Kodak 
Electrophoresis and Documentation analysis system UV transilluminator (Uvitec, 
Cambridge, UK).  
 
2.7. Gel Extraction 
To purify DNA from an agarose gel, the bands were visualised under UV light, cut out 
with a clean blade and transferred to a 1.5ml Eppendorf. The QIAquick gel extraction 
kit (Qiagen, Manchester, UK) was used as described. The weight of the gel slice was 
determined, and 3 volumes of Buffer QG were added to 1 volume of the gel. The 
mixture was incubated at 50ºC for 10 minutes to dissolve the gel, vortexing 
intermittently. One gel volume of 100% isopropanol was added and mixed to precipitate 
the DNA. The sample was then transferred to the QIAquick column and centrifuged for 
1 minute at 13000g to bind the DNA to the silica membrane. Through-flow was 
discarded and the column was washed with 500µl Buffer QG and centrifuged for 1 
minute to remove further agarose. Through-flow was removed and another wash step 
followed. 750 µl Buffer PE was applied to the column and centrifuged for 1 minute to 
remove salt. Through-flow was discarded and the column was centrifuged for an 
additional minute to remove traces of Buffer PE. The column was placed in a clean 
CHAPTER 2: MATERIALS AND METHODS 
	   77 
collection tube, and DNA was eluted with 25µl nuclease free water, centrifuging for 1 
minute at 13000g. DNA concentration in ng/ml was determined using a Nanodrop ND-
1000, measuring absorbance at 260 nanometers (nm). The purity of the DNA was 
determined by calculating the ratio of absorbance at 260 nm and 280 nm. A ratio of 




2.8.1. Generation of Dynactin-6 vectors 
Dynactin-6 (DCTN6) vectors were created by recombinant DNA cloning. The DCTN6 
sequence was amplified by PCR from an adult human brain cDNA library using the 





An aliquot of the amplified product was analysed on an agarose gel to verify that the 
reaction produced the desired product of 583bp, which was subsequently gel-purified 
(as section 2.7). This product was then ligated into a pGEMT-Easy vector (Promega, 
Southampton, UK) with blue-white selection indicating insertion. Restriction digest 
using BamHI restriction enzyme (NEB, Hitchen, UK) confirmed the insertion of the 
correct region (as section 2.8.2). 
The DCTN6 constructs were subcloned into the p3xFLAG-CMV-14 vector (Sigma, 
Poole, UK) and the pEGFP-N3 vector (Clontech, Oxford, UK) to generate FLAG-
tagged and GFP-tagged dynactin-6 constructs, respectively (Figure 2.2). Restriction 
digest using BseRI and Xba1 restriction enzymes (NEB, Hitchen, UK) confirmed in-
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Figure 2.2. Constructs used in this thesis. (A) Vector map of pEGFP-N3, into which 
dynactin-6 was cloned into the BamHI site within the multiple cloning site (MCS). (B) 
Vector map of p3xFLAG-CMV-14, into which dynactin-6 was cloned into the BamHI 
site within the MCS. (C) Vector map of pDsRed2-Mito, which contains a mitochondrial 
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2.8.2. Restriction Digest 
Restriction enzymes were used to digest inserts and vectors in order to prepare insert 
sticky ends (3’- or 5’-overhangs of 1 to 4 nucleotides) and linearise vectors before 
ligation. Restriction digests were also used at the end of the cloning process to screen 
transformed colonies for release of an insert. Those with the correct size insert after 
digestion were sent for Sanger sequencing to confirm the insert was in-frame with the 
correct orientation.  
DNA was digested using appropriate restriction enzymes for 2 hours, in a 10µl reaction 
for checking insert release, and a 30µl reaction for digesting inserts and vectors before 
ligation, as indicated in table 2.8. 
 
Table 2.8. Restriction digest reaction mix 
 Screening colonies for 
insert 
Preparing insert and vector 
for ligation 
Vector DNA 100ng 1µg 
Enzyme (NEB Biolabs) 1µl 1µl 
NEBuffer 1-4 (10x) 1µl 3µl 
BSA (100x) 0.1µl 0.3µl 
ddH20 to total volume of 10µl 30µl 
 
Digested products were analysed by gel electrophoresis. If preparing DNA for ligation, 
an additional step was required before gel electrophoresis. Reaction mixes containing 
linearised vectors were treated with Alkaline Phosphatase, Calf Intestinal (CIAP; 
Promega) to dephosphorylate the 5’ end, preventing religation of the empty vector. 1µl 
CIAP was added to restriction digest reactions and incubated for 30 minutes at 37ºC, 
followed by heating at 65ºC for 10 minutes to deactivate the enzyme. After gel 
electrophoresis, digested inserts and vectors were gel extracted and purified for ligation.  
 
2.8.3. Ligation 
The concentration of PCR product (insert) required for ligation was calculated using the 
following equation:  
(ng vector x kb insert/kb vector) x insert: vector ratio = ng insert 
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Various insert to vector ratios were used to increase the likelihood of successful 
ligation. Ligation reaction mixes were prepared as in table 2.9. 
 







2x Rapid Ligation Buffer 5 µl 5 µl 5 µl 
Vector 1 µl 1 µl 1 µl 
PCR product 1 µl - - 
Control insert DNA - 2 µl - 
T4 DNA ligase (3 Weiss units/ µl) 1 µl 1 µl 1 µl 
Deionised water  2 µl 1 µl 3 µl 
Final volume 10 µl 10 µl 10 µl 
 
A Promega control insert DNA was used as a positive control to give an indication of 
the number of colonies to expect after transformation. A negative background control 
was used to assess background due to re-ligation of linear vectors, which should 
produce few colonies after transformation. Tubes were briefly centrifuged, and 
reactions were incubated overnight at 4ºC on slushy ice.  
 
2.8.4. Preparation of LB agar plates 
10g of Luria broth (LB) and 7.5g of agar were dissolved in 500ml of deionised water, 
autoclaved to sterilise, and cooled to around 37ºC. Once cooled, antibiotic was added to 
the solution at a concentration of 100µg/ml for ampicillin or 30µg/ml for kanamycin, 
and poured into 10cm2 plates under sterile conditions. Plates were left to set at room 
temperature, and then stored at 4ºC.  
For plates being used to grow competent cells transformed with pGEMT-Easy vectors, 
50mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside; Promega) and 
200mg/ml of IPTG (Isopropyl β-D-1-thiogalactopyranoside; Promega) were pipetted 
onto plates and spread using a sterile Pasteur pipette. Plates were left to set at room 
temperature. 
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The pGEMT-Easy vector contains a portion of the LacZ gene within the multiple 
cloning site, which encodes the N-terminal fragment of β-galactosidase. This 
metabolises X-Gal to produce a blue product. IPTG triggers the transcription of LacZ. 
Thus, competent cells transformed with an empty pGEMT-Easy vector will turn blue. 
However, when a DNA fragment is inserted into the multiple cloning site of the 
pGEMT-Easy vector, the LacZ gene is disrupted, preventing β-galactosidase activity, so 
there will be no action upon X-gal and the cells will not turn blue. This blue-white 
screening identifies colonies containing the DNA insert.  
 
2.8.5. Transformation 
JM109 E.coli highly competent cells (>108 cfu/µl; Promega) were defrosted on ice until 
just thawed, mixed by gently flicking the tube, and 50µl transferred to a 1.5ml 
Eppendorf along with the 10ul ligation reaction.  Tubes were mixed by gentle flicking 
and incubated on ice for 20 minutes. The competent cells were then heat-shocked at 
42ºC for 50 seconds in a water bath, then immediately returned to ice for 2 minutes. 
This allows DNA to enter the cell membrane. 950µl of room temperature S.O.C 
medium (Life Technologies, Paisley, UK) was added to cells transformed with the 
ligation reactions, then incubated for 1.5 hours at 37ºC with shaking at 150rpm. 100µl 
of transformation culture was spread onto pre-prepared LB agar plates containing the 
appropriate antibiotic with a sterilised glass rod. The remaining 900µl was centrifuged 
at 1000g for 10 minutes to pellet cells, which were then re-suspended in 200µl S.O.C 
medium to concentrate the remaining cells. 100µl was spread onto a second LB agar 
plate for each ligation. Plates were incubated overnight at 37ºC to allow colony 
formation.  
In a sterile environment, individual colonies were picked using a sterile pipette tip, and 
transferred to a 50ml Falcon tube containing 10ml LB with the appropriate antibiotic. 
For pGEMT-Easy cloning, white colonies were selected and blue colonies were 
disregarded. Cells were grown for 16 hours at 37ºC with shaking at 300rpm, and then 
centrifuged at 4000rpm for 20 minutes at room temperature to pellet cells. Supernatent 
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2.8.6. Plasmid Purification  
Plasmid DNA was extracted and purified using a QIAprep Spin Miniprep Kit (Qiagen, 
UK). Pelleted bacterial cells were resuspended in 250µl of cold buffer P1 by vortexing 
and transferred to a 1.5ml Eppendorf, ensuring no cell clumps were visible. Cells were 
lysed by adding 250µl of alkaline buffer P2 and inverting the tubes to mix. 350µl of 
acidic neutralisation buffer N3 was added to tubes and mixed by inversion. Samples 
were then centrifuged for 10 minutes at 13000rpm and supernatant was collected and 
transferred to a QIAprep Spin column, which was centrifuged for one minute to bind 
DNA to the silica membrane. The QIAprep spin column was washed by adding 500µl 
buffer PB and centrifuging for one minute, discarding the flow-through, followed by a 
second wash with 750µl buffer PE to rid the column of endonucleases and salt, again 
centrifuging for one minute. Flow-through was discarded and the column was 
centrifuged for one minute to remove residual buffer. The column was placed in a clean 
1.5ml Eppendorf and DNA was eluted in 30ul nuclease free water by centrifuging for 
one minute at 13000rpm. For purification of larger plasmid preps, the HiSpeed Plasmid 




2.9.1. Cell lysate preparation 
For preparation of cell lysates, cells were washed twice with PBS at 4ºC, then harvested 
in RIPA (Radio-Immunoprecipitation Assay, Sigma, Poole, UK) Buffer: 150 mM NaCl, 
1.0% w/v IGEPAL® CA-630, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, and 50 
mM Tris, pH 8.0, supplemented with protease and phosphatase inhibitors (Roche, 
Burgess Hill, UK) at 4ºC. Cell lysates were transferred to a 1.5ml Eppendorf and 
incubated on ice for 30 minutes, then were spun at 13000g at 4ºC for 12 minutes. The 
supernatant was transferred to a fresh Eppendorf and an equal volume of 2x sample 
buffer containing SDS and 2-ME (Sigma, Poole, UK) was added. The samples were 
boiled at 100ºC for 10 minutes and centrifuged at 13000g for 1 minute before gel 
loading. For non-reducing sample conditions, no 2-ME was added to the 2x sample 
buffer and samples were not boiled prior to gel loading.  
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2.9.2. Bradford Protein Assay 
The Bio-Rad Protein Assay (Bio-Rad) was used to determine protein concentrations. A 
differential colour change of the protein assay dye, Coomassie Brilliant blue G-250, 
occurs as the absorbance maximum shifts from 465 nm to 595 nm when protein binding 
occurs. Measurement at 595 nm with a spectrophotometer or microplate reader and 
comparison to a standard curve provides a relative measurement of protein 
concentration. 
Serial dilutions of bovine serum albumin (BSA) ranging in concentration from 0 to 
1mg/ml were used as protein standards. Test proteins were diluted 1 in 2 and the protein 
assay dye was diluted 1 in 5 with dH20. 10µl of standard or test sample were added to a 
96-well plate in duplicate, followed by 200µl protein assay dye, and mixed by gentle 
pipetting. The samples were left to incubate at room temperature for 5 minutes, then 
absorbance at 595 nm was read using a standard plate reader. A standard curve was 
produced by plotting OD595 against the concentration of the BSA standard, and the 




The samples were run on precast 4-12% polyacrylamide NuPAGE Bis-Tris gels (Life 
Technologies, Paisley, UK). The gels were run in 1x 3-(Nmorpholino) propanesulfonic 
acid (MOPS) running buffer (Life Technologies, Paisley, UK), consisting of 50mM 
MOPS, 50mM Tris, 0.1% w/v SDS, 1mM EDTA, pH 7.7. High Molecular Weight 
Marker protein ladder or Novex Sharp Pre-stained Protein Standard (Life Technologies, 
Paisley, UK) were run alongside all samples. 20-25µl of sample per well was loaded 
and the samples were run at 100-150V for 1.5-3 hours. 
 
2.9.4. Immunoblotting 
After separation by electrophoresis, the samples were transferred to a nitrocellulose 
membrane (Whatman) by either semi-dry transfer using a Trans-Blot SD semi-dry 
transfer cell (Bio-Rad, Hemel Hempstead, UK) or wet transfer using a mini Trans-Blot 
cell (Bio- Rad, Hemel Hempstead, UK), depending on the size of the protein. 
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Semi-dry transfer was carried out at 15V for 40 minutes using a transfer buffer 
containing 20mM Tris base, 120mM glycine and 20% (v/v) methanol. Wet transfer was 
carried out at 45V overnight (16 hours) at 4ºC using a transfer buffer containing 20mM 
Tris base, 120mM glycine, 0.1% (w/v) sodium dodecyl sulfate (SDS) and 10% (v/v) 
methanol.  
After transfer the membrane was blocked with 5% milk powder in PBS with 0.1% 
Tween20 (PBST) for 1 hour to prevent non-specific binding of the antibody, then 
incubated in 5ml 5% (w/v) milk in PBST containing appropriate primary antibodies 
(Table 2.10) for 3 hours or overnight. After washing in PBST three times for 10 minutes 
the membranes were incubated with appropriate species-specific infrared secondary 
antibodies (Licor, Cambridge, UK, Table 2.11) at a dilution of 1:5000 for 1 hour. After 
three washes in PBST, the membranes were scanned using the Licor Odyssey infrared 
scanner. This system involves direct scanning of the membrane by two independent 
lasers, allowing detection of the infrared fluorescence emitted by two different 
secondary antibodies. The two colour detection system uses a 700 nm red channel, and 
800 nm green channel. Images of the blots were quantified using the Licor Odyssey 
imaging systems software. 
 
2.9.5. Coomassie Blue staining 
Coomassie brilliant blue is a triphenylmethane dye that stains proteins in 
polyacrylamide gels. Protein lysates were run on precast 4-12% polyacrylamide 
NuPAGE Bis-Tris gels. Gels were then washed briefly in sterile deionised ultrapure 
water prior to soaking in Coomassie Brilliant Blue staining solution (0.05% (w/v) 
Coomassie Brilliant Blue R-250, 50% (v/v) methanol and 10% (v/v) glacial acetic acid) 
at room temperature for 1 hour with gentle shaking. The gels were then destained in 
Coomassie destaining buffer (20% (v/v) methanol and 10% (v/v) glacial acetic acid) at 
room temperature with gentle shaking until the desired contrast was achieved 
(approximately 5 minutes). Gels were dried overnight between two moistened sheets of 
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SH-SY5Y cells were subjected to chemical cross-linking at 24 hours post-transfection. 
The cleavable, homo-bifunctional cross-linker dithiobis[succinimidylpropionate] (DSP; 
Pierce, Rockford, IL, USA) was diluted to a final concentration of 1mM in PBS and 
added to the cultured cells. After incubation for 1 hour at room temperature, cross-
linking was stopped by addition of Tris (pH 7.5) to a final concentration of 20mM. 
Cells were then lysed in preparation for immunoprecipitation and immunoblotting. 
 
2.10.2. Cell lysis 
SH-SY5Y cells in T25 culture flask were transfected with Dynactin-6-FLAG and/or 
DRP1-GFP, or empty vectors. After 24 hours the cells were washed twice in ice-cold 
PBS, before the cells were harvested in 750µl Lysis buffer (50mM Tris-HCl pH7.4, 
150mM NaCl, 1mM EDTA and 0.5% (v/v) Triton X-100) supplemented with protease 
inhibitors (Roche, Burgess Hill, UK) and incubated on ice for 15 minutes. The cells 
were homogenised by passing ten times through a 23G needle. The lysate was 
centrifuged at 17500g on a table top microcentrifuge to separate the nuclei, and the 
supernatant was used for immunoprecipitation. A small aliquot (120µl) of supernatant 
was removed for analysis by immunoblotting (input fraction).  
 
2.10.3. Tag-coupled bead immunoprecipitation 
40µl of anti-FLAG-M2 Magnetic beads (Sigma, Poole, UK) were washed twice in 
200ml lysis buffer, before being recovered in a magnetic separator. The remaining cell 
lysate was added to the washed beads and incubated overnight at 4ºC on a rotor. After 
approximately 16 hours the beads were placed in the magnetic separator and the 
supernatant was removed. The beads were then washed three times with 400µl lysis 
buffer. After washing the beads were eluted in 50µl 2x sample buffer (Sigma, Poole, 
UK) and heated at 100ºC for 3 minutes before being placed in the magnetic separator to 
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2.11. Subcellular fractionation 
 
2.11.1. Mitochondrial Isolation 
Cells were seeded in 10cm cell culture dishes and allowed to reach 90-100% 
confluence. The cells were washed twice in ice cold PBS, before being harvested in 1ml 
of ice cold trypsin and transferred to a 15ml Falcon. The cells were spun at 200g for 5 
minutes to pellet the cells, and the pellet was washed in 10ml of PBS. The cells were re-
pelleted at 200g for 5 minutes, before resuspending in 100µl of homogenisation buffer 
(10mM Tris-HCL (pH 7.4), 1mM EDTA, 250mM sucrose) with protease inhibitors 
(Roche, Burgess Hill, UK). The cells were frozen overnight at -80ºC. The 
homogenisation buffer containing the cell pellet was thawed on ice and transferred to an 
ice cold 1.5ml Eppendorf. The Falcon was washed with 300µl of homogenisation buffer 
and added to the Eppendorf. The cell pellet was resuspended by pipetting (around 20x 
titrations) before being frozen again at -80ºC for 1 hour. After thawing on ice, the lysate 
was spun at 1500g for 10 minutes at 4ºC to generate a supernatant (S1; homogenate 
fraction) and pellet (P1; nuclei and cell debris). The S1 fraction was transferred to a new 
Eppendorf and a 30µl aliquot taken before centrifugation at 11500g for 12 minutes to 
generate a supernatant (S2; cytoplasm) and pellet (P2; mitochondria). The S2 fraction 
was transferred to a new Eppendorf and a 30µl aliquot taken. 4x sample buffer (Life 
Technologies, Paisley, UK) was added to the S2 fraction and samples heated at 70ºC for 
10 minutes. The P2 fraction was washed by resuspension in 1ml of homogenisation 
buffer before being re-pelleted at 11500g for 12 minutes. The supernatant was discarded 
and the mitochondrial pellet resuspended in 50µl of homogenisation buffer. An equal 
volume of 2x sample buffer (Sigma, Poole, UK) was added to each sample and heated 
at 70ºC for 10 minutes. Additionally, the mitochondrial fraction was sonicated at 10,000 
kHz for 10 seconds to break up the DNA. All fractions were subsequently analysed by 
SDS-PAGE and immunoblotting.  
 
2.11.2. Cytoskeletal Fraction 
Cells were seeded in a 10cm cell culture dish and allowed to reach 90-100% confluence. 
The cells were washed three times with ice-cold PBS and incubated for 10 minutes with 
1ml of lysis buffer (50 mM HEPES, pH 7.4, 20 mM EGTA, 0.5% (v/v) Triton-X100), 
supplemented with protease and phosphatase inhibitors (Roche, Burgess Hill, UK), at 
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room temperature. Cell lysates were centrifuged at 15000g for 15 minutes at 4ºC to 
obtain a detergent-insoluble pellet. The supernatant (soluble fraction) was transferred to 
a 1.5 ml Eppendorf and the insoluble pellet was washed with lysis buffer and re-pelleted 
at 15000g for 10 minutes at 4ºC. Insoluble pellets were resuspended in 60µl of urea (6 
M). Fractions were mixed with equal volume of 2x concentrated Laemmli’s sample 
buffer, heated at 100ºC for 10 minutes, and subsequently analysed by SDS-PAGE. 
 
2.11.3. Intermediate-filament-rich-fractions  
Intermediate filaments (IFs) are extremely stable. Even after extraction in solutions 
containing detergents and high salt concentrations, most IFs in a cell remain intact, 
whereas microfilaments and microtubules depolymerise into their soluble subunits. 
Hence, IF purification methods use detergents and high salt concentrations to seperate 
IFs from other proteins. The IFs are then treated with urea, a denaturing solvent. 
Cells were seeded in 10cm cell culture dishes and allowed to reach 90-100% 
confluence. The cells were washed three times with ice-cold PBS, before being 
harvested in 1ml of homogenisation buffer containing 1% (v/v) Nonidet P-40, 10% 
(v/v) glycerol , 20 mM HEPES, pH 7.6, and 150 mM NaCl, supplemented with protease 
and phosphatase inhibitors (Roche, Burgess Hill, UK). Lysates were transferred to 
1.5ml Eppendorfs, homogenised by passing through a 23-gauge needle ten times, and 
incubated at 37°C for 30 minutes. The soluble (supernatant) and insoluble (pellet) 
fractions were collected after centrifugation at 5200 rpm for 30 minutes at 4ºC. The 
soluble supernatant was transferred to a 1.5 ml Eppendorf and the insoluble pellet 
washed once with homogensiation buffer and re-pelleted at 5200 rpm for 20 minutes at 
4ºC. Insoluble pellets were resuspended in 60µl of urea (6 M) and sonicated at 10,000 
kHz for 10 seconds. Fractions were mixed with equal volume of 2x concentrated 




SH-SY5Y and human dermal fibroblast cells were grown on glass 8-well Lab-Tek II 
chamber slides (Nalge Nunc International Corp.) or 12-well plates until 80% confluent 
or 24-48 hours post-transfection. After washing three times in PBS, cells were treated 
with 3.7% (v/v) paraformaldehyde for 20 minutes to fix the cells, followed by PBS with 
CHAPTER 2: MATERIALS AND METHODS 
	   88 
0.2% (v/v) Triton X-100 for 5 minutes to permeabilise the cell membranes. The cells 
were washed in PBS, and then blocked in 0.02% (v/v) Triton X-100 containing 10% 
(v/v) normal goat serum (NGS) and 1% (w/v) bovine serum albumin (BSA), hereafter 
called Buffer A, for 45 minutes. After blocking the cells were incubated with primary 
antibodies (Table 2.10) at the appropriate concentration in Buffer A for 2 hours. After 
incubation with primary antibodies the cells were washed three times in PBS and then 
incubated with species-specific secondary antibodies (Table 2.11) in Buffer A for 45 
minutes. After two washes in PBS, the cells were briefly (1 minute) incubated with 
2mg/ml 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI, Sigma, Poole, UK) to 
counterstain nuclei and then washed twice in PBS. Fluorescent mounting medium 
(Dako, Ely, UK) was used to apply coverslips to slides, or in the case of chamber slides, 
the chamber was removed from the slide and fluorescent mounting medium (Dako, Ely, 
UK) was used to apply cover glass. 
 
2.12.1. MitoTracker  
MitoTracker (Life Technologies, Paisley, UK) is a cell permeant mitochondrial probe 
that stains the mitochondria within cells. A stock solution was initially prepared by 
dissolving 50µg of lyophilised marker in DMSO to a concentration of 1mM. This was 
then stored at -20°C. The excitation and emission maxima are given as 579 nm and 599 
nm, respectively, by Life Technologies. The stock MitoTracker solution was diluted to a 
working concentration of 100nM in complete medium (DMEM, 10% (v/v) FBS, 1% 
(v/v) Pen/Strep). MitoTracker was added to the cells and incubated for 30 minutes at 
37ºC in 5% CO2 atmosphere. After washing twice in PBS, cells were treated with 3.7% 
(v/v) paraformaldehyde for 20 minutes to fix the cells. Immunocytochemistry was then 
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Table 2.10. Primary antibodies used in immunoblotting and immunocytochemistry 
Antibody Species Dilution Company 
Acetylated-α-tubulin 
(monoclonal, 6-11B-1) 
Mouse 1:2000 (IC) 
1:2000 (IB) 
Sigma, Poole, UK 
Arl13b (polyclonal) Rabbit 1:500 (IC) Proteintech, Manchester, UK 
β-actin (monoclonal, 
AC-15) 
Mouse 1:10000 (IB) Sigma, Poole, UK 
β-tubulin (monoclonal, 
TUB 2.1) 
Mouse 1:200 (IC) 
1:500 (IB) 
Sigma, Poole, UK 
BiP (monoclonal, 
C50B12) 
Rabbit 1:300 (IB) Cell Signaling Technology, 
Danvers, MA, USA 
Calnexin (monoclonal, 
37) 
Mouse 1:1000 (IB) BD Biosciences, Oxford, UK 
DRP1 (monoclonal, 
8/DLP1) 
Mouse 1:500 (IB) 
1:100 (IC) 
BD Biosciences, Oxford, UK 




Mouse 1:1000 (IB) 
1:250 (IC) 
Sigma, Poole, UK 
EEA1 (monoclonal, 14) Mouse 1:100 (IC) BD Biosciences, Oxford, UK 
GAPDH (polyclonal) Rabbit 1:5000 (IB) Abcam, Cambridge, UK 
GFP (monoclonal, 
GFP-20) 
Mouse 1:2000 (IB) Roche, Burgess Hill, UK 
GS28 (monoclonal, 
HFD9) 
Mouse 1:500 (IC) Enzo Life Sciences, Exeter, UK 
HSP60 (monoclonal, 
LK1) 
Mouse 1:500 (IB) Sigma, Poole, UK 
HSP70 (monoclonal, 
BRM-22) 
Mouse 1:5000 (IB) 
1:100 (IC) 
Sigma, Poole, UK 
HSP90 (polyclonal) Rabbit 1:100 (IC) Abcam, Cambridge, UK 
KDEL (monoclonal, 
10C3) 




Mouse 1:5000 (IB) 
1:100 (IC) 




Mouse 1:1000 (IB) 
1:100 (IC) 
Abcam, Cambridge, UK 
Sacsin (monoclonal, 
EPR11864) 
Rabbit 1:1600 (IB) 
1:100 (IC) 
Abcam, Cambridge, UK 
TOM20 (polyclonal) Rabbit 1:1000 (IB) Santa Cruz, Santa Cruz, CA, 
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1:500 (IC) USA 
Ubiquitin (polyclonal) Rabbit 1:500 (IB) 
1:100 (IC) 
Abcam, Cambridge, UK 
V5 (monoclonal, V5-
10) Mouse 1:1000 (IB) Sigma, Poole, UK 
Vimentin (monoclonal, 
Vim 3B4) 
Mouse 1:2000 (IB) 
1:100 (IC) 
Abcam, Cambridge, UK 
Vimentin (monoclonal, 
SP20) 
Rabbit 1:2000 (IB) 
1:100 (IC) 
Abcam, Cambridge, UK 
IB = Immunoblotting, IC = Immunocytochemistry 
 
 
Table 2.11. Secondary fluorescent antibodies used in immunoblotting and 
immunocytochemistry 
Antibody Emission Species Dilution Company 
Alexa Fluor 488 Green Mouse/rabbit 1:1000 Life Technologies, Paisley, UK 
Alexa Fluor 568 Red Mouse/rabbit 1:1000 Life Technologies, Paisley, UK 
Alexa Fluor 647 Far-red Mouse/rabbit 1:1000 Life Technologies, Paisley, UK 
DAPI1 Blue n/a 1:5000 Sigma, Poole, UK 
MitoTracker 




ReadyProbes Green n/a 2 drops/ml 
Life Technologies, 
Paisley, UK 
TMRM2 Red n/a 10nM Life Technologies, Paisley, UK 
IRDye®680LT Far-red Mouse 1:5000 Life Technologies, Paisley, UK 
IRDye®800CW Far-red Rabbit 1:5000 Life Technologies, Paisley, UK 
1 DAPI = 4’,’6-diamido-2-phenylindole stain 
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2.13. Confocal Microscopy 
Cells stained for various intracellular markers were visualised and imaged using the 
Zeiss LSM510 inverted laser scanning confocal microscope (Carl Zeiss Ltd, UK). Super 
resolution microscopy of sacsin localisation was performed using a Zeiss LSM710 
ELYRA PS.1 (Carl Zeiss Ltd, UK). Images were taken using a 63x oil immersion 
objective. The pinhole was set to 1 Airy unit, with Cy2 green fluorophore detected by 
the 458 nm Argon laser, Cy3 red fluorophore detected by the 543 nm HeNe laser, Cy5 
far-red fluorophore detected by the 633 nm HeNe laser, and blue wavelengths, such as 
that emitted by DAPI, detected by the 405 nm Diode laser. Images were acquired at 
1024 x 1024 pixels; 8-line averaging, and 12-bit depth. Image processing was 
performed using Zen 2009 software (Carl Zeiss Ltd, UK), and Imaris (Biplane, 
Switzerland). Maximum intensity projection images of Z-stacks were also produced 
using the Zen software. 
Fluorescence recovery after photobleaching (FRAP) was performed using the 63x oil 
immersion objective, a scan area of 512 x 512 pixels, 12-bit depth, 1-line averaging and 
the 458 nm argon laser power was 100%. Photobleaching of a 15 x 15 µm area was 
started after 2 or 3 scans. 
Tetramethylrhodamine methyl ester (TMRM) fluorescence analysis was performed 
using the 63x oil immersion objective, a scan area of 512 x 512 pixels, 12-bit depth, 2-
line averaging and the gain in the red channel was 405 and the digital offset -1.36. 
 
2.14. Statistics 
Where mean values are presented, error bars represent ± SEM. An unpaired two-tailed 
Student’s t-test was performed in excel to compare means between two conditions, for 
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3.1. Introduction and Aims 
Disruption to mitochondrial morphology has recently been implicated in ARSACS 
disease pathogenesis. Specifically, an elongated and interconnected mitochondrial 
network is observed in ARSACS patient fibroblasts (Criscuolo et al., 2015, Blumkin et 
al., 2015, Pilliod et al., 2015, Girard et al., 2012), SACS knockout mouse neurons 
(Lariviere et al., 2015), and SACS knockdown cells (Girard et al., 2012). This 
mitochondrial phenotype is suggestive of perturbed mitochondrial dynamics, more 
specifically reduced fission or enhanced fusion. Reduced fission seems a more likely 
mechanistic explanation of the ARSACS mitochondrial phenotype, since a co-IP 
experiment performed in our lab identified that a heterologously expressed N-terminal 
portion of sacsin (amino acids 1-1368) interacted with DRP1, the main mediator of 
mitochondrial fission in mammalian cells (Girard et al., 2012). Furthermore, 
immunocytochemistry analysis revealed that sacsin localisation partially overlaps with 
DRP1 foci at mitochondria (Girard et al., 2012). This data suggests a potential role for 
sacsin in mitochondrial fission. 
For mitochondrial fission to occur, DRP1, which mainly exists as small oligomers in the 
cytosol, is recruited to the outer mitochondrial membrane (OMM). The mechanisms and 
regulation of DRP1 recruitment to mitochondria are not yet fully understood in 
mammalian cells (Otera and Mihara, 2011). FIS1 and MFF are thought to be important 
in facilitating DRP1 recruitment onto mitochondria (Loson et al., 2013; Otera et al., 
2010; Yoon et al., 2001b). Other factors, such as, mitochondrial dynamics protein of 
49kDa and 51kDa (MiD49 and MiD51, respectively), and the mitochondrial E3 
ubiquitin ligase MARCH5 (Karbowski et al., 2007) are also known to regulate DRP1 
recruitment/activation (Palmer et al., 2011).  
Once recruited to the OMM, DRP1 self-assembles into larger multimeric structures at 
discrete foci and forms spirals around the outside of mitochondria (Chang and 
Blackstone, 2010; Yoon et al., 2001b; Smirnova et al., 2001). This is mediated by the 
coiled-coil domain (Okamoto et al., 1999) and is driven by GTP hydrolysis-dependent 
conformational change. Mitochondrial fission is then thought to occur through spiral 
constriction of the DRP1 ring (Hoppins et al., 2007; Mears et al., 2011; Smirnova et al., 
2001; Strack and Cribbs, 2012). This resembles the action of dynamin at sites of 
endocytosis. Dynamin, along with its accessory proteins, assembles into a fission 
complex, which begins constriction of the clathrin-coated pit neck. The assembled 
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dynamin polymer then undergoes GTP-dependent conformational changes that constrict 
the neck further and lead to plasma membrane fission (Hinshaw, 2000; Ingerman et al., 
2005; Sundborger and Hinshaw, 2014). 
To gain further mechanistic insights into how loss of sacsin function modulates 
mitochondrial dynamics, our lab has previously performed a yeast two-hybrid (Y2H) 
screen using residues 1-649 of sacsin as bait. This identified dynactin-6 (DCTN6) to be 
a putative sacsin interactor. DCTN6, also known as p27, is a component of the dynein-
dynactin motor complex, which drives retrograde transport of various cargoes, 
including mitochondria, on microtubules (section 1.8.1.1). Interestingly, this motor 
complex has previously been shown to be required for the recruitment of DRP1 to 
mitochondria (Varadi et al., 2004). Varadi et al (2004) found that overexpressing 
dynamitin (p50), another subunit of the dynein-dynactin complex, lead to a collapsed 
mitochondrial phenotype, with long, interconnected mitochondria, which is 
accompanied by a large reduction in the association of DRP1 with mitochondria. 
Additionally, mutations in another dynactin subunit, p150Glued, were shown to lead to a 
similar mitochondrial phenotype (Levy et al., 2006). These studies indicate that the 
dynein-dynactin complex is involved in DRP1 recruitment to mitochondria and thus, 
mitochondrial fission.  
Since putative interactions have been identified between both sacsin and DRP1, and 
sacsin with DCTN6; this indicates the potential for a joint function between sacsin and 
the dynein-dynactin complex in the recruitment of DRP1 to mitochondria. To test this 
hypothesis, several approaches were taken. Initially, interactions between sacsin, DRP1 
and DCTN6 were further investigated by co-immunoprecipitation (co-IP) experiments. 
Secondly, a role for sacsin in the mitochondrial translocation of DRP1 and its assembly 
into scission complexes was investigated through SACS siRNA knockdown 
experiments. Thirdly, it is hypothesised that changes in DCTN6 expression may also 
lead to alterations in mitochondrial morphology and dynamics like that shown for sacsin 
and other subunits of the dynein-dynactin complex. So, the effects of DCTN6 
overexpression and siRNA knockdown on mitochondrial morphology and DRP1 
localisation were investigated using confocal microscopy. The objective was to further 
establish the cellular mechanisms contributing to the highly elongated and 
interconnected mitochondrial network seen in ARSACS. 
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3.2. Results 
 
3.2.1. Identification of an interaction between DRP1 and DCTN6 
As it is hypothesised that sacsin and DCTN6 could form a complex, possibly with 
DRP1, interactions between these three proteins were further investigated. A direct 
interaction between sacsin and DCTN6 could not be verified by co-IP due to technical 
issues related to the available reagents. Specifically, a FLAG-tagged construct encoding 
residues 1–1368 of sacsin, which was used to detect a putative interaction with DRP1 
(Girard et al., 2012), was no longer available and attempts to reproduce this construct 
failed. Sacsin and DCTN6 antibodies were also not suitable for use in 
immunoprecipitation (IP) experiments. 
Full-length DCTN6 vectors with a GFP- or 3xFLAG-tag were constructed to carry out 
heterologous expression experiments to investigate a predicted interaction between 
DCTN6 and DRP1. An endogenous IP would be preferable but was not possible due to 
difficulties in the detection of DCTN6 using the available antibodies to the endogenous 
protein. 
 
3.2.1.1. Verification of DCTN6-FLAG and DCTN6-GFP construct expression 
Prior to using the DCTN6-FLAG and DCTN6-GFP constructs (generation of constructs 
is detailed in section 2.8.1), confirmation that cells expressed a protein of the predicted 
size was performed. SH-SY5Y cells were transfected with either construct, and after 48 
hours cell lysates were analysed by immunoblotting. Specific bands of approximately 
24 kDa and 48 kDa for DCTN6-FLAG and DCTN6-GFP (Figure 3.1), which are the 
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Figure 3.1. Verification of DCTN6-FLAG and DCTN6-GFP expression. 
Immunoblot analysis of SH-SY5Y cells transfected with DCTN6-FLAG (~24 kDa) or 
DCTN6-GFP (~48 kDa). The corresponding tagged empty vector (EV) constructs were 
transfected as controls.   
 
 
3.2.1.2. Co-immunoprecipitation between DRP1 and DCTN6 
SH-SY5Y cells were transiently transfected with a FLAG-tagged construct expressing 
DCTN6 and/or a GFP-tagged construct expressing DRP1, or were transfected with an 
empty FLAG or empty GPF vector (controls). 24 hours post transfection; cells were 
chemically crosslinked using dithiobis[succinimidylpropionate] (DSP; Pierce, 
Rockford, IL, USA) and lysed. Following this, cell lysates were incubated with anti-
FLAG magnetic beads overnight.  
Immunoblot analysis of inputs (Figure 3.2) shows specific bands corresponding to 
endogenous DRP1 (monomeric ~80 kDa, oligomeric ~240 kDa), along with successful 
transfection of DCTN6-FLAG (~24 kDa) and DRP1-GFP (monomeric ~107 kDa, 
oligomeric ~270 kDa). Immunoblot analysis of immunoprecipitated lysates (Figure 3.2) 
shows that the anti-FLAG magnetic beads successfully captured DCTN6-FLAG. 
Importantly, distinct bands were revealed, which correspond to monomeric DRP1-GFP 
(~107 kDa) and oligomeric DRP1-GFP (~270 kDa) in the immunoprecipitated sample 
that was dual transfected with DCTN6-FLAG and DRP1-GFP (indicated by arrows in 
figure 3.2). These bands are absent in the control samples. The DRP1 antibody 
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recognises some strong non-specific bands between 70-85 kDa (¶ in figure 3.2). This is 
unlikely to be the antibody heavy chain, which is approximately 50 kDa, but is possibly 
non-specific protein binding to the beads. This obscures endogenous monomeric DRP1 
in immunoprecipitated samples; hence an interaction between endogenous DRP1 and 
DCTN6-FLAG cannot be reliably determined here. In summary, this data shows an 
interaction between DCTN6-FLAG and DRP1-GFP by co-IP. This interaction may be 
transient, since the experiment was carried out under cross-linking conditions, which 







Figure 3.2. Co-IP of DCTN6-FLAG and DRP1-GFP. SH-SY5Y cells were 
transfected with a FLAG-tagged construct encoding DCTN6 and/or a GFP-tagged 
construct encoding DRP1. Transfections of empty vectors (EV) were also performed as 
controls. Immunoprecipitation (IP) was performed with FLAG-tagged magnetic beads, 
and immunoblots were performed with anti-FLAG or anti-DRP1 antibodies. The inputs 
of DCTN6-FLAG and DRP1 are indicated (endogenous monomeric and oligomeric 
DRP1 are ~80 kDa and ~240 kDa, respectively). Arrows indicate monomeric and 
oligomeric DRP1-GFP (~107 kDa and ~270 kDa, respectively). *Negative IP control, ♯ 
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3.2.2. A role for sacsin in the mitochondrial translocation of DRP1 
Since a putative interaction between sacsin and DRP1 has previously been identified, 
siRNA-mediated knockdown was used to investigate the effect of loss of sacsin on the 
mitochondrial localisation of DRP1 and on the assembly of DRP1 multimeric 
complexes.  
 
3.2.2.1. Sacsin expression can be reduced in SH-SY5Y cells by siRNA 
SH-SY5Y neuroblastoma cells were transiently transfected with a combination of 
previously validated siRNA molecules to sacsin exons 7, 8 and 10 (SACS) or a 
scrambled non-targeting siRNA (SCRM) control. Mito-DsRed was used to identify 
transfected cells. It is assumed that the cells expressing Mito-DsRed will also be 
transfected with siRNA. Immunocytochemistry followed by confocal imaging, reverse 
transcription PCR (RT-PCR) and immunoblot analyses of cell lysates transfected with 
each siRNA were used to confirm effective knockdown of sacsin (Figure 3.3). A 
commercially available sacsin antibody was used (this reagent was not used in previous 
work from our lab as it was not available), which binds to a specific sequence within 
amino acids 4100-4200 (Abcam). This antibody also detects a fainter band on 
immunoblotting, which is around 450 kDa (Figure 3.3B). This may be an alternatively 
spliced isoform of sacsin, although no experimental evidence exists for this. Originally, 
sacsin was thought to be encoded by a single gigantic exon (now exon 10), which 
contains an ATG initiation codon; hence this may be responsible for the lower 
molecular weight protein product. The confocal images also confirm the previously 
identified localisation of a proportion of sacsin at or near the cytoplasmic face of 
mitochondria (Figure 3.3A). 
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Figure 3.3. Cellular levels of sacsin can be significantly reduced by targeting SACS 
with siRNAs. SH-SY5Y cells were transfected with siRNA to SACS exons 7, 8 and 10, 
or a SCRM siRNA control, and after 48 hours cells were analysed for SACS mRNA and 
protein expression. (A) Representative images of cells transfected with Mito-DsRed and 
either SCRM or SACS siRNA. Cells were fixed and stained with a rabbit anti-sacsin 
antibody. Maximum intensity projections of z-stacks were taken via confocal 
microscopy. The white box in the merged panel is shown zoomed in the panel on the far 
right, and white arrows indicate sacsin puncta. Red dashed lines in the sacsin panels 
outline transfected cells. (B) Immunoblot analysis was performed using the rabbit anti-
sacsin antibody, along with β-actin as a loading control. Lane 1: HiMark pre-stained 
protein standard (Life Technologies). (C) Densitometric analysis of sacsin protein levels 
normalized to β-actin shows 0.9-fold reduction in SACS compared to SCRM siRNA 
treated cells. The full blot is shown to allow assessment of any non-specific binding by 
the antibody. (D) RT-PCR was performed using intron spanning primers for exons (ex) 
7-8 of SACS, which reveals a reduction in SACS mRNA in SACS compared to SCRM 
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3.2.2.2. Reduced levels of mitochondrial associated DRP1 in sacsin deficient cells 
DRP1 localisation in relation to the mitochondrial network was investigated in sacsin 
deficient cells compared to controls by immunocytochemistry. SH-SY5Y cells were 
transfected with Mito-DsRed and either SCRM or SACS siRNA. 48 hours after 
transfection, cells were treated with vehicle control or 20 µM of the mitochondrial 
uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) for 40 minutes. CCCP 
is one of the most widely used protonophore uncouplers, along with 2,4-Dinitrophenol 
(Kenwood et al., 2014). It causes dissipation of the proton gradient across the inner 
mitochondrial membrane, which is used to drive ATP synthesis in oxidative 
phosphorylation, leading to mitochondrial membrane depolarisation and mitochondrial 
fission. Possible off-target effects of these uncouplers are plasma membrane 
depolarisation, mitochondrial inhibition, and cytotoxicity (Kenwood et al., 2014; Park et 
al., 2002), which may interfere with the measurement of mitochondrial function. Other 
know inducers of mitochondrial fission include the mitochondrial complex I inhibitor, 
Rotenone (Barsoum et al., 2006; Hwang et al., 2014), and Oligomycin, an inhibitor of 
mitochondria ATP synthase (De Vos et al., 2005; Guillery et al., 2008).  
Following treatment, cells were processed for immunocytochemistry, as detailed in the 
methods, using an anti-DRP1 antibody. Cells were imaged using confocal microscopy 
(Figure 3.4) and the number of DRP1 foci per micrometer (µm) of mitochondrial length 
was measured using the line trace function of the LSM510 confocal ZEN software 
(Zeiss). This gives the intensity of both the red and green channel along individual 
mitochondria, with green intensity peaks representing DRP1 foci. The number of DRP1 
foci along the measured mitochondria length was then collated from the graphical and 
tabular output.  Ten cells per siRNA condition and six mitochondria per cell (total of 60 
mitochondria per condition) were measured. Two or three independent sets of cells, 
transfected on different days, were analysed. The number of DRP1 foci per µm of 
mitochondria significantly decreased in SACS cells compared to SCRM, decreasing 
from 0.91 ± 0.03 to 0.75 ± 0.02 (Figure 3.4). Inducing mitochondrial fission with CCCP 
significantly increased the number of DRP1 foci per µm of mitochondria in SCRM cells 
from 0.91 ± 0.03 to 1.41 ± 0.05, and hence mitochondrial fragmentation. Despite a 
significant increase in DRP1 foci per µm of mitochondria in SACS cells in response to 
CCCP mediated induction of mitochondrial fission, there was still a significant 
reduction in mitochondrial associated DRP1 foci incidence compared to SCRM siRNA 
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Figure 3.4. Reduced mitochondrial localisation of DRP1 in sacsin knockdown cells. 
Representative confocal images of SH-SY5Y cells transfected with Mito-DsRed and 
either (A, B) SCRM, or (C, D) SACS siRNA, all treated with either vehicle control or 20 
µM CCCP for 40 minutes. 48 hours post transfection; cells were fixed and stained with 
an anti-DRP1 antibody (green). The white box in the merged panel is shown zoomed in 
the panel on the far right. White arrows indicate DRP1 foci in close proximity to 
mitochondria. The number of DRP1 foci on mitochondria was measured using ZEN 
software. (E) Quantification of the mean number of DRP1 foci per µm of mitochondria 
in SCRM and SACS cells. Ten cells per siRNA condition and six mitochondria per cell 
(total of 60 mitochondria per condition) were measured in at least two independent 
experiments. Error bars represent SEM, *** = p<0.001, ** = p<0.01. Scale bars = 10µm 
and 1µm in merged and zoom panels, respectively. 
 
 
This observation of reduced DRP1 localisation to mitochondria in sacsin deficient cells 
was further investigated by subcellular fractionation of SH-SY5Y cells transfected with 
either SACS or SCRM siRNA. Briefly, 48 hours after transfection, cells were lysed and 
homogenized before centrifugation to separate nuclei and cell debris from the cytosol. 
The cytosolic fraction was then subjected to further centrifugation to create a 
mitochondrial pellet (detailed in section 2.11). After immunoblot analysis, total DRP1 
levels were found to be similar in cells treated with SCRM control or SACS siRNA. 
However, DRP1 was present in the mitochondrial fraction at a reduced level in cells 
treated with SACS siRNA compared to SCRM siRNA (Figure 3.5), which supports the 
immunocytochemistry data in figure 3.4. This result was consistently observed, 
however was difficult to quantify due to variability between immunoblots from 
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Figure 3.5. Reduced DRP1 in the mitochondrial fraction of sacsin knockdown cells.  
(A) Representative immunoblot of SH-SY5Y cells transiently transfected with SACS or 
SCRM siRNA and subjected to subcellular fractionation. Transfections were performed 
in duplicate. Analysis with antibodies to TOM20 (mitochondria) and GAPDH (cytosol) 
confirmed that the fractionation protocol had enriched mitochondrial (mito) proteins. 
(B) Densitometric analysis of DRP1 levels in the mitochondrial fraction relative to 
TOM20 shows a 0.35-fold reduction in SACS compared to SCRM siRNA treated cells 
(n = 2).  
 
 
3.2.2.3. Reduction in higher order DRP1 complexes in sacsin deficient cells 
Since a reduction in DRP1 mitochondrial localisation has been identified in sacsin 
deficient cells, it is hypothesised that there may be a reduction in DRP1 self-assembly 
into multimeric structures on the OMM. This was investigated in SH-SY5Y cells by 
siRNA knockdown. Following transfection of SACS or SCRM siRNA, cells were 
subjected to chemical cross-linking using DSP. Cells were lysed and a non-reducing 
sample buffer (without the reducing agent 2-Mercaptoethanol, 2-ME) was added to 
lysates. This approach was similar to that used by Cho et al. for detecting oligomeric 
DRP1 (Cho et al., 2014). Immunoblot analysis using an anti-DRP1 antibody revealed 
several high molecular weight DRP1 complexes (>230kDa, Figure 3.6). Cells 
transfected with SACS siRNA showed a reduction in the higher molecular weight DRP1 
complexes when compared to SCRM controls (Figure 3.6). Expression of monomeric 
(~80 kDa) and lower order oligomeric (dimer and tetramer) DRP1 shows similar levels 
in SCRM and SACS siRNA treated cells. The reduction in the higher molecular weight 
DRP1 complexes may reflect an absence of DRP1:sacsin complexes, but could also 
indicate that DRP1 higher order oligomers, or complexes between DRP1 and other 
components of the fission machinery are reduced.  
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Figure 3.6. Reduced higher molecular weight DRP1 complexes in sacsin 
knockdown cells. (A) Schematic of the method to detect DRP1 complexes. (B) 
Representative immunoblot showing high molecular weight DRP1 complexes are 
reduced in sacsin knockdown cells. SH-SY5Y cells were transfected with SACS or 
SCRM siRNA. After 48 hours cells were treated with the crosslinker DSP and lysed. 
Total cell lysates were immunoblotted under reducing (+ 2-ME) and non-reducing 
conditions (- 2-ME) for DRP1. GAPDH was used as a loading control. Arrow indicates 
high molecular weight DRP1 species. DSP: dithiobis[succinimidylpropionate]. (C) 
Immunoblotting for sacsin confirms effective SACS siRNA knockdown. β-actin was 
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3.2.3. A role for DCTN6 in the regulation of mitochondrial fission 
The identified interaction between DCTN6 and DRP1, along with previous data 
showing that loss of function of components of the dynein-dynactin complex leads to 
altered mitochondrial morphology and dynamics (Varadi et al., 2004; Levy et al., 2006), 
suggests that the dynein-dynactin complex may have a role in mitochondrial fission. 
The effect of DCTN6 expression on mitochondrial morphology has not yet been 
explored and was thus investigated here. Human dermal fibroblasts (HDFs) were 
selected for this imaging based analysis due to the mitochondrial network being more 
evenly distributed throughout the cell than that seen in SH-SY5Y cells. 
 
3.2.3.1. DCTN6 overexpression leads to mitochondrial fragmentation 
HDFs were transiently transfected with Mito-DsRed and either the empty vector 
pEGFP-N3 (indicated as EV-GFP from here on) or DCTN6-GFP. After 48 hours, live 
cell imaging was performed using a confocal microscope. Maximum intensity 
projections of z-stack images suggested that the mitochondrial network in cells 
transfected with DCTN6-GFP was more fragmented than in EV-GFP control cells 
(Figure 3.7). 
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Figure 3.7. The mitochondrial network appears more fragmented in DCTN6-GFP 
overexpressing cells. Representative confocal images of normal HDFs transfected with 
mito-DsRed and either (A, B) EV-GFP, or (C, D) DCTN6-GFP. After 48 hours, 
maxiumum intensity projections of z-stacks were obtained by live cell confocal 
imaging. The white box in the mito-DsRed panel is shown zoomed in the panel on the 
far right. Scale bar = 10µm.  
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3.2.3.2. DCTN6 siRNA knockdown leads to mitochondrial elongation 
HDFs were transfected with previously validated siRNAs targeting exons 3 and 6 of 
DCTN6, or a SCRM siRNA control, and incubated for 48 hours. Immunoblot analysis of 
cell lysates expressing each siRNA was used to confirm effective knockdown of 
DCTN6 protein compared to β-actin loading control. The predicted molecular weight of 
DCTN6 is 21 kDa (Figure 3.8). It is important to note that the anti-DCTN6 antibody 
used detects a non-specific band of approximately 75 kDa (Figure 3.8). The expression 
of this band does not reduce after DCTN6 siRNA knockdown, so is unlikely to be a 






Figure 3.8. DCTN6 expression can be reduced by RNA interference using siRNA.  
(A) HDFs were transfected with siRNA to DCTN6 exons 3 and 6, or SCRM siRNA 
control. After 48 hours cells were analysed for DCTN6 protein expression by 
immunoblotting using a rabbit anti-DCTN6 antibody (Proteintech). β-actin (Sigma) was 
used as a loading control. Arrowhead indicates the band corresponding to DCTN6 
protein. Sacsin levels were not reduced by siRNA targeting DCTN6. (B) Densitometric 
analysis of DCTN6 protein levels normalised to β-actin shows 0.7-fold reduction in 
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To study the effect of DCTN6 knockdown on mitochondrial morphology, HDFs were 
transfected with Mito-DsRed and either SCRM or DCTN6 siRNA, as detailed in the 
methods. After 48 hours, live cell imaging was performed using a confocal microscope. 
Maximum intensity projections of z-stack images showed the mitochondrial network in 
cells transfected with DCTN6 siRNA appeared to be much more elongated and 





Figure 3.9. DCTN6 knockdown leads to elongated and interconnected 
mitochondria. Representative confocal images of HDFs transfected with Mito-DsRed 
and either (A-C) SCRM, or (D-F) DCTN6 siRNAs. After 48 hours, maximum intensity 
projections of z-stacks were taken via confocal microscopy. The white boxes in the 
mito-DsRed panels are shown zoomed in the panels on the right of each image. Scale 
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Fluorescence recovery after photobleaching (FRAP) studies have been widely used as a 
measure of mitochondrial dynamics (Mitra and Lippincott-Schwartz, 2010; Tanaka et 
al., 2010). SH-SY5Y cells were transfected with a mitochondrial-targeted GFP, in 
combination with either SCRM or DCTN6 siRNA. After 48 hours FRAP analysis was 
performed on 15-20 cells for each treatment. Briefly, this involved photobleaching a 
small area of mitochondrial-targeted GFP (mitoGFP) within a cell and then monitoring 
the diffusion of the fluorescent signal within mitochondria back into the region of 
interest from the surrounding region. Confocal settings were kept constant for all 
imaging. There was a higher level of recovery from photobleaching in DCTN6 cells 
compared to SCRM control (Figure 3.10). The mitoGFP fluorescence recovers to 71 ± 
5.7 % of the initial intensity in DCTN6 siRNA transfected cells, whereas in SCRM 
siRNA transfected cells, the fluorescence recovers to only 58 ± 6.5 % of the initial 
intensity after 20 seconds (Figure 3.10). This indicates a more interconnected 
mitochondrial network in DCTN6 cells, as the mitoGFP can diffuse back into the 
bleached zone more rapidly than that seen in SCRM control cells.  
Additional methods for quantifying this alteration in mitochondrial morphology are 
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Figure 3.10. FRAP analysis of DCTN6 knockdown cells indicates a more 
interconnected mitochondrial network. (A) Representative images of SH-SY5Y cells 
co-transfected with mitoGFP and either SCRM or DCTN6 siRNA. A 15 x 15 µm area of 
the mitochondrial network corresponding to the white-boxed area was photobleached 
and the cells imaged every second for 20 seconds. Red boxes indicate a 15 x 15 µm area 
of the mitochondrial network not photobleached and fluorescence measurements of this 
area were used as a control for any loss of fluorescence over time that was not due to 
photobleaching. (B) Graphical representation of recovery after photobleaching from 15-
20 cells/siRNA condition/experiment (n=3). Fluorescent intensities of the 15 x 15 µm 
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3.2.4. DCTN6 knockdown leads to reduced mitochondrial localisation of DRP1  
Earlier in this chapter, sacsin knockdown was demonstrated to reduce the mitochondrial 
localisation of DRP1 (3.2.2), which could explain the elongation of mitochondria due to 
reduced fission. Here, DCTN6 knockdown also results in a more interconnected 
mitochondrial network, and evidence has been provided for an interaction between 
DCTN6 and DRP1 (Figure 3.2). Therefore, the effect of DCTN6 siRNA knockdown on 
DRP1 localisation was investigated, as a reduced mitochondrial localisation of DRP1 
could also explain the elongated mitochondria in this case.  
SH-SY5Y cells were transfected with Mito-DsRed and either SCRM or DCTN6 siRNA. 
48 hours after transfection, cells were treated with vehicle control or 20 µM of the 
mitochondrial uncoupler CCCP for 40 minutes to induce mitochondrial fission. Cells 
were processed for immunocytochemistry, as detailed in the methods, using an anti-
DRP1 antibody. Cells were visualized by confocal microscopy (Figure 3.11) and the 
number of DRP1 foci per µm of mitochondrial length was measured using the line trace 
function of the LSM510 confocal ZEN software, as in section 3.2.2. Ten cells per 
siRNA condition and six mitochondria per cell (total of 60 mitochondria per condition) 
were measured. At least two independent sets of cells, transfected on different days, 
were analysed. The number of DRP1 foci per µm of mitochondria significantly 
decreased in DCTN6 cells compared to SCRM, decreasing from 0.91 ± 0.03 to 0.61 ± 
0.02 (Figure 3.11). Inducing mitochondrial fission with CCCP significantly increased 
the number of DRP1 foci per µm of mitochondria in SCRM cells from 0.91 ± 0.03 to 
1.41 ± 0.05, and hence mitochondrial fragmentation. Despite a significant increase in 
DRP1 foci per µm of mitochondria in DCTN6 cells in response to CCCP mediated 
induction of mitochondrial fission, there was still a significant reduction in 
mitochondrial associated DRP1 foci incidence compared to SCRM siRNA controls 
(0.76 ± 0.03 for DCTN6, compared to 1.41 ± 0.05 for SCRM, Figure 3.11). 
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Figure 3.11. Reduced mitochondrial localisation of DRP1 in DCTN6 knockdown 
cells. Representative confocal images of SH-SY5Y cells transfected with mito-DsRed 
and either (A, B) SCRM, or (C, D) DCTN6 siRNA, all treated with either vehicle 
control (0 µM) or 20 µM CCCP for 40 minutes. 48 hours post transfection; cells were 
fixed and stained with an anti-DRP1 antibody. The white box in the merged panel is 
shown zoomed in the panel on the far right. White arrows indicate DRP1 foci in close 
proximity to mitochondria. The number of DRP1 foci on mitochondria was measured 
using ZEN software (Zeiss). (E) Quantification of the mean number of DRP1 foci per 
µm of mitochondria in SCRM and DCTN6 cells. Ten cells per siRNA condition and six 
mitochondria per cell (total of 60 mitochondria per condition) were measured in at least 




3.2.5. DCTN6 knockdown leads to reduced mitochondrial membrane potential 
Mitochondrial membrane potential (Δψm) is generated by oxidative phosphorylation and 
is thus an indicator of mitochondrial function. Loss of sacsin expression reduces Δψm, 
suggesting impaired mitochondrial function (Girard et al., 2012). The effect of loss of 
DCTN6 expression on Δψm was determined using the potential-sensitive dye, 
tetramethylrhodamine methyl ester (TMRM) in live cell imaging studies. SH-SY5Y 
cells were transfected with either SCRM or DCTN6 siRNA, along with EV-GFP to 
allow identification of transfected cells. After 48 hours the cells were incubated with 
10nM TMRM for 30 minutes before live cell imaging using the confocal microscope. 
TMRM fluorescence was quantified using LSM510 software, using GFP fluorescence 
to delineate the edge of the cell (Appendix 1). A total of 25 cells per treatment were 
analysed. Confocal settings were kept constant for all imaging. DCTN6 knockdown 
cells have a significantly reduced TMRM fluorescence intensity by 29 ± 7% compared 
to SCRM control cells (p<0.01, Figure 3.12), indicating that loss of DCTN6 expression 
leads to reduced Δψm. This reduction may be due to a disruption to electron transport 
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Figure 3.12. DCTN6 knockdown leads to reduced mitochondrial membrane 
potential. Representative images of SH-SY5Y cells transfected with either (A, B) 
SCRM or (C, D) DCTN6 siRNA, along with EV-GFP (images including GFP are shown 
in appendix 1). 48 hours post transfection; cells were incubated with 10nM TMRM for 
30 minutes before live cell imaging. Maximum intensity projection images from z-
stacks are shown. TMRM fluorescence was quantified using LSM510 software (Zeiss). 
White lines represent the edge of cells. (E) The mean TMRM intensity from at least two 
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3.3. Conclusions  
Previously, a putative interaction was identified between sacsin and DCTN6, a 
component of the dynein-dynactin motor complex. This complex has been shown to be 
an important modulator of DRP1 distribution, and therefore mitochondrial fission 
(Varadi et al., 2004). Thus, a role for sacsin in mitochondrial fission may involve 
DCTN6. In this chapter, evidence for a novel interaction was demonstrated between 
DCTN6 and DRP1 using heterologous expression vectors. Interactions have previously 
been identified between DRP1 and other dynactin subunits, namely p50 and p150Glued 
(Varadi et al., 2004) thus, the data presented here is in support of an interaction between 
DRP1 and the dynactin complex. This putative interaction between DRP1 and DCTN6, 
together with the previous data indicating that sacsin interacts with both of these 
proteins, suggests that sacsin, DCTN6 and DRP1 may function together in 
mitochondrial fission (Figure 3.13). However, verification of an interaction between 




Figure 3.13. Putative interactions identified between sacsin, DCTN6 and DRP1 
may provide a mechanistic link for sacsin in mitochondrial fission. Blue lines: 
previously identified interactions, red line: interaction identified in this thesis. 
 
 
Moreover, data produced in this chapter provides evidence for a reduction in the 
localisation of DRP1 at the OMM in cells with reduced levels of sacsin. Importantly, 
this is also the case after mitochondrial fission is induced by the uncoupler CCCP; 
indicating that DRP1 recruitment to mitochondria is impaired. Similar results have been 
reported due to loss of function of mitochondrial fission accessory proteins. For 
example, reduced MFF expression leads to a reduction in mitochondrial recruitment of 
DRP1 and elongation of the mitochondrial network (Otera et al., 2010). Likewise, loss 
of MiD49 or MiD51 expression has been shown to reduce DRP1 association with 
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mitochondria, leading to unopposed fusion (Palmer et al., 2011). This suggests that, like 
MFF, Mid49 and Mid51, sacsin may play a role in the recruitment or stabilisation of 
DRP1 at mitochondrial fission sites, hence maintaining normal mitochondrial dynamics. 
Sacsin may affect the function of an already known, or unknown mitochondrial fission 
accessory protein, thus exerting an indirect influence on DRP1 localisation and 
mitochondrial fission. However, this is unlikely due to the identification of an 
interaction between sacsin and DRP1 (Girard et al., 2012), which may indicate a more 
direct affect on DRP1 traffic.  
Additionally, diminished cellular levels of sacsin expression were shown to lead to a 
reduction in higher order DRP1 complexes. These high molecular weight complexes 
may be DRP1 in complex with another protein(s). Since an interaction has been shown 
between sacsin (520 kDa) and DRP1 (~80 kDa), this complex may include sacsin (~600 
kDa). Hence, loss of sacsin expression leads to reduced complex formation with DRP1. 
The size of the higher molecular weight protein(s) that are reduced in figure 3.6 
corresponds with this hypothesis. Alternatively, loss of sacsin may affect DRP1 
interactions with other proteins, possibly other mitochondrial fission accessory proteins. 
This may explain how loss of sacsin can lead to perturbations in mitochondrial fission. 
On the other hand, the high molecular weight complexes could be DRP1 oligomers, 
which suggests that the self-assembly of DRP1 into multimeric structures on the OMM 
may be impaired. The fission-promoting activity of DRP1 would thus be reduced, 
consequently leading to increased fusion of mitochondria. If the mitochondrial 
localisation of DRP1 is impaired, less DRP1 will be available to form a multimeric 
constriction complex. Alternatively, loss of sacsin may impair DRP1 self-assembly 
itself, perhaps through affecting GTP hydrolysis of DRP1, which is known to be 
important for DRP1 oligomerisation on the OMM (Chang et al., 2010). Defective self-
assembly of DRP1 at the OMM is likely to destabilise the mitochondrial pool of DRP1, 
hence reducing its mitochondrial localisation.   
Perturbed DRP1 self-assembly on the OMM was identified to be the cause of an 
elongated mitochondrial network in HDFs from a neonate with a lethal de novo 
mutation within the middle domain of DRP1 (A395D, (Chang et al., 2010; Pitts et al., 
1999)). On the other hand, disassembly of DRP1 complexes is also important for 
mitochondrial fission to occur. A dominant-negative DRP1 mutation, K38A, impairs 
GTP hydrolysis, which in turn prevents the disassembly of DRP1 complexes (Chang et 
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al., 2010), inhibiting OMM constriction, leading to mitochondrial elongation (Smirnova 
et al., 1998). This highlights that mitochondrial fission is dependent on having correct 
DRP1 cycling dynamics.  
It is also important to note that loss of sacsin does not eliminate mitochondrial fission. 
This is concordant with what is shown when the function of known mitochondrial 
fission accessory proteins are lost (Gandre-Babbe and van der Bliek, 2008; Palmer et 
al., 2011), and emphasises the complexity of the fission process and the multiple 
contributing factors. 
Also in this chapter, changes in DCTN6 expression levels were observed to alter 
mitochondrial morphology. Specifically, DCTN6 overexpression lead to a more 
fragmented mitochondrial network, whereas siRNA-mediated knockdown of DCTN6 
lead to a more elongated and interconnected mitochondrial network. FRAP analysis also 
supports the confocal imaging showing a more interconnected mitochondrial network 
due to reduced DCTN6 expression. Interestingly, this phenocopies the effect when 
sacsin function is perturbed (Blumkin et al., 2015; Criscuolo et al., 2015; Girard et al., 
2012; Lariviere et al., 2015; Pilliod et al., 2015), which further supports a joint role for 
sacsin and DCTN6 in mitochondrial dynamics.  
Like when reducing sacsin expression, impaired mitochondrial fission seems to be the 
cause of the elongated mitochondrial network in cells with reduced DCTN6 expression. 
siRNA-mediated knockdown of DCTN6 lead to a significant reduction in DRP1 foci 
localised with mitochondria. This is concordant with that shown by Varadi et al (2004) 
when disrupting dynein-dynactin function. They suggest that the dynein-dynactin 
complex is required for the correct targeting of DRP1 to mitochondria (Varadi et al., 
2004). This observation also further supports the interaction identified between DRP1 
and DCTN6 by co-IP. 
Finally, reducing DCTN6 expression significantly decreases Δψm. This again, is also a 
consequence of reducing cellular levels of sacsin (Girard et al., 2012), which further 
supports a joint role for sacsin and DCTN6, and indicates the potential involvement of 
these proteins in maintaining normal mitochondrial health. It is conceivable that the 
reduction in DRP1-mediated mitochondrial fission, which is required to maintain 
mitochondrial quality control, leads to an accumulation of dysfunctional mitochondria 
that cannot be degraded by mitophagy and thus, a reduction in Δψm is observed. This is 
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reflected in recent studies showing mitochondrial dysfunction in ARSACS (Girard et 
al., 2012, Criscuolo et al., 2015, Bradshaw et al., 2016). 
In summary, several observations suggest that DCTN6 and sacsin may function in the 
same pathway. Firstly, there is evidence that they both interact with DRP1, secondly, 
loss of function of either protein leads to elongated and overly interconnected 
mitochondria, and thirdly, loss of function of either protein leads to a reduction in the 
mitochondrial localisation of DRP1. Collectively, this data suggests that sacsin and 
DCTN6 may function together in the recruitment or stabilisation of DRP1 on 
mitochondria.  
Considering all of the data, it is plausible that the high molecular weight DRP1 
complexes in figure 3.6 could be a complex including DRP1, sacsin and DCTN6, and 
loss of sacsin leads to reduced formation of this complex, which ultimately results in 
reduced mitochondrial fission. Taking into account that sacsin is a putative co-
chaperone; sacsin may act as a co-chaperone, regulating complex assembly and/or 
disassembly, in order for DRP1 to be recruited to mitochondria via the dynein-dynactin 
motor. However, further research is required to investigate this.  
The data also supports that the alterations in mitochondrial dynamics observed in 
ARSACS are a consequence of impaired fission, rather than an increase in fusion. 
 
3.3.1. Further work 
It is essential that the protein interactions identified in this chapter, and previously, are 
now verified. For example, an interaction between the N-terminus of sacsin and 
DCTN6, identified by a Y2H screen, needs to be verified by performing a co-IP. Sacsin 
1-1368-FLAG, representing the N-terminus, would be heterologously expressed along 
with DCTN6-GFP, followed by incubation of cell lysates with anti-FLAG magnetic 
beads. 
The development of super-resolution microscopy allows for more accurate 
determination of the co-localisation of proteins, such as sacsin, DRP1 and DCTN6. This 
anaylsis is less reliable using confocal microscopy due to the limits in resolution. This 
data would provide further evidence to support interactions between these proteins.  
A proximity ligation assay using antibodies to sacsin, DRP1 and DCTN6 could also be 
performed to verify interactions between these proteins. 
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To further investigate whether the high molecular weight DRP1 complexes in figure 3.6 
include sacsin and DCTN6, the same experiment could be performed (as in section 
3.2.2), but for DCTN6 knockdown. If the high molecular weight DRP1 complexes are 
also reduced with loss of DCTN6 expression, this would add support to the hypothesis 
that DRP1, sacsin and DCTN6 work together in a complex.  
Further quantification of the changes in mitochondrial network morphology due to 
altered DCTN6 levels (figures 3.7 and 3.9) could be performed to verify this data. 
Methods include quantifying the number and length of mitochondria per cell and 
comparing between conditions. Also, the degree of branching of the mitochondrial 
network (form factor) in DCTN6 siRNA treated cells compared to controls could be 
quantified using the length of the mitochondria outline and area of mitochondrion 
(Grunewald et al., 2010; Koopman et al., 2005; Mortiboys et al., 2008).  
It has previously been found that mitochondrial dynamics, including DRP1-mediated 
fission, modulates oxidative phosphorylation complex assembly and function 
(Hroudova et al., 2014; Liu et al., 2011). The reduced mitochondrial membrane 
potential in cells with loss of DCTN6 (figure 3.12) is suggestive of disrupted oxidative 
phosphorylation, which may be mediated by reduced DRP1-mediated fission (figure 
3.11) and thus, disrupted assembly and function of electron transport chain (ETC) 
complexes. This could be assessed through blue native polyacrylamide gel 
electrophoresis (BN PAGE) to quantify the protein content and activities of the ETC 
complexes in DCTN6 siRNA treated cells compared to controls. Spectrophotometric 
enzyme assays can also be performed, for example, complex I (NADH dehydrogenase) 
activity can be measured by NADH oxidation, with or without the complex I inhibitor 
rotenone (Jung et al., 2000). Furthermore, a perturbation to oxidative phosphorylation 
could be confirmed using a seahorse extracellular flux (XF) analyser (Seahorse 
Biosciences) to measure bioenergetic function.  
Post-translational modifications are important in regulating DRP1 function and 
recruitment to mitochondria. The reduced localisation of DRP1 at the OMM seen in 
both sacsin and DCTN6 deficient cells may be mediated through a change in DRP1 
post-translational modifications. Therefore, it is important to investigate if there is a 
relationship between loss of these proteins and key regulatory modifications of DRP1, 
such as phosphorylation and SUMOylation. Phosphorylation of DRP1 at serine 637 is 
known to inhibit DRP1 activation leading to retention of the protein in the cytosol while 
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dephosphorylation of serine 637 promotes translocation of DRP1 to the mitochondria 
(Cereghetti et al., 2008; Knott and Bossy-Wetzel, 2008). Phosphorylation of DRP1 at 
serine 616 inhibits mitochondrial translocation and oligomerisation of DRP1 (Cho et al., 
2014). 
Preliminary experiments were performed to optimise detection of phosphorylated DRP1 
at Ser616 and Ser637 by immunoblotting (not shown). Cell lysates were analysed under 
both crosslinked and un-crosslinked, and reduced (+2-ME) and non-reduced (-2-ME) 
conditions. Interestingly, DRP1 appears to be phosphorylated at Ser616 at the 
monomeric and higher oligomeric levels, whereas phosphorylation at Ser637 is at the 
monomeric and dimeric levels, but not the higher oligomeric level. Comparisons now 
need to be made in the levels of DRP1 phosphorylation at Ser616 and Ser637 in cells 
transfected with SCRM, SACS or DCTN6 siRNAs.  
SUMOylation stabilizes the mitochondrial pool of DRP1 and stimulates mitochondrial 
fission (Braschi et al., 2009; Harder et al., 2004). This occurs via SUMO proteins 
(Figueroa-Romero et al., 2009), and E3 ligases such as MAPL (mitochondrial-anchored 
protein ligase). Hence, the phosphorylation and SUMOylation state of DRP1 could be 
compared between sacsin or DCTN6 deficient cells and controls, which would give 
further mechanistic insight into the reduced mitochondrial localisation of DRP1.  
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4.1. Introduction and Aims 
As described in the introduction to this thesis, the cytoskeleton is a heterogeneous 
network of filamentous structures, composed of microfilaments, intermediate filaments 
(IFs) and microtubules. This interconnected network of cytoskeletal elements allows 
eukaryotic cells to resist deformation, transport intracellular cargo, and change shape. 
Moreover, it is integral to the spatial organisation of organelles within the cell. Neurons 
are particularly dependent on the cytoskeleton to deliver the proteins and other 
components synthesised in the cell body to the axons and nerve terminals. Therefore, it 
is not suprising that dysfunction of cytoskeletal components is linked to 
neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Alzheimer’s, 
Parkinson’s, tauopathies, polyQ disorders and Charcot-Marie-Tooth disease (Al-Chalabi 
and Miller, 2003; Gunawardena and Goldstein, 2005; Lariviere and Julien, 2004; Liem 
and Messing, 2009; McMurray, 2000; Perrot and Eyer, 2009). 
One example of a neurodegenerative disease with multiple cytoskeletal components 
affected is Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph 
Disease (MJD), which is caused by expansion of a polyglutamine tract in ataxin-3 
(ATXN3). ATXN3 is a deubiquitinating enzyme, so binds to ubiquitinylated proteins, 
and is thought to modulate substrate degradation through the ubiquitin-proteasome 
pathway (Rodrigues et al., 2010). Depletion of ATXN3 using siRNA in both human and 
mouse cell lines leads to severely compromised and disorganised microtubule, 
microfilament and IF networks (Rodrigues et al., 2010). This cytoskeletal phenotype 
was found to be reversible and dependent on ATXN3 levels.  
A striking example of a neurodegenerative disease where IFs alone appear to be 
disrupted in isolation to other cytoskeletal elements is giant axonal neuropathy (GAN), 
which is caused by autosomal recessive mutations in GAN, resulting in loss of the 
gigaxonin protein. Peripheral nerves from patients show accumulations of 
neurofilaments within enlarged axons (Gordon, 2004), muscle fibres have 
accumulations of desmin, glial fibrillary acidic protein (GFAP) accumulates in 
astrocytes, and vimentin accumulates in multiple cell types, including dermal fibroblasts 
(Cleveland et al., 2009; Peiffer et al., 1977).  
Recently, disrupted neurofilament organisation was identified as a pathophysiological 
feature of ARSACS (Lariviere et al., 2015). Specifically, loss of sacsin function results 
in abnormal accumulations of non-phosphorylated neurofilament heavy chain (npNFH) 
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bundles in the somatodendritic region of various neuronal populations in sacsin 
knockout mice and ARSACS brains (Lariviere et al., 2015).  
This leads to the overarching aim of this chapter, which was to investigate the 
organisation of IFs in ARSACS patient dermal fibroblasts and SACS siRNA knockdown 
cells. IFs connect with many other cellular structures, including actin and microtubules 
(Chang and Goldman, 2004), the Golgi complex (Gao and Sztul, 2001; Gao et al., 
2002), endosomes (Sarria et al., 1992), and mitochondria (Nekrasova et al., 2011; 
Winter et al., 2008). Disorganisation of the IF network may effect the spatial 
organisation of these cellular components; hence the distribution of these organelles in 
cells with depleted sacsin function were also characterised. Moreover, the subcellular 
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4.2. Results 
 
4.2.1. Colocalisation of a proportion of sacsin with vimentin intermediate filaments 
Sacsin is expressed at detectable levels in SH-SY5Y cells and has a predominantly 
cytoplasmic distribution, with a clear punctate component. Previously, a proportion of 
sacsin has been shown to localise at or near the cytoplasmic face of the OMM (Parfitt et 
al., 2009; Girard et al., 2012), with defects in mitochondrial dynamics and function 
identified as an important factor in ARSACS disease pathogenesis (Girard et al., 2012). 
Due to the recent discovery of alterations in neurofilaments as an additional underlying 
pathophysiological feature of ARSACS (Lariviere et al., 2015), the subcellular 
localisation of sacsin in relation to IFs was investigated using immunocytochemistry in 
SH-SY5Y cells. These neuroblastoma-derived cells have vimentin as their primary IF 
rather than neurofilaments.  
Vimentin IFs were analysed for overlap with sacsin localisation using antibodies to 
vimentin and sacsin, followed by visualisation using confocal microscopy. As 
previously shown, sacsin displays a cytoplasmic localisation with a punctate 
component. Importantly, a proportion of sacsin punctate were identified to be on or near 
the vimentin cytoskeleton (Figure 4.1).  
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Figure 4.1. Sacsin localises in close proximity to vimentin intermediate filaments. 
Representative confocal images of SH-SY5Y cells fixed and permeabilised, followed by 
staining with antibodies to sacsin (green) and vimentin (magenta). White boxes in 
vimentin/sacsin panels are shown zoomed in the right panels. White arrows indicate 
sacsin punctate on or near vimentin filaments. Scale bars = 10µm. 
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The localisation of sacsin in relation to vimentin was further analysed using super-
resolution structured illumination microscopy (SR-SIM, LSM 710 ELYRA PS.1). This 
allows higher-resolution imaging, generating images of approximately 100 nm in lateral 
resolution compared to the 200 nm obtained by standard confocal microscopy (Figure 
4.2). Antibodies to vimentin and sacsin were used, along with MitoTracker Red to label 
mitochondria. Z-stacks were acquired and SIM processing performed. The previously 
identified localisation of a proportion of sacsin at or near the cytoplasmic face of 
mitochondria was also evident in these images (Figure 4.2D). In addition, the ability to 
visualise the cells in super-resolution identified areas where sacsin punctae are localised 
between mitochondria and vimentin filaments (indicated by white arrows in Figure 
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Figure 4.2. Sacsin localises in close proximity to both vimentin intermediate 
filaments and mitochondria. Representative super-resolution images of SH-SY5Y 
cells incubated with MitoTracker Red and stained with antibodies to sacsin (magenta) 
and vimentin (green). Panels B and D are zoomed in images of A and C. White arrows 
in panel B indicate sacsin puncta adjacent to vimentin. White arrows in panel D indicate 
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4.2.2. Cellular fractionation of SH-SY5Y cells and human dermal fibroblasts  
Given the strong overlap between sacsin and vimentin IF localisation, subcellular 
fractionation of SH-SY5Y cells and control human dermal fibroblasts (HDFs) was 
performed (see section 2.11.2) to investigate if sacsin purifies in the cytoskeletal 
fraction, and more specifically in an IF-enriched fraction of cell lysate. Immunoblot 
analyses showed sacsin to be enriched in an insoluble cytoskeletal fraction, as was the 





Figure 4.3. Sacsin is enriched in an insoluble cytoskeletal fraction. Subcellular 
fractionation of control HDFs to separate cytoskeletal proteins and subsequent 
immunoblot analysis reveals that although sacsin is present in the soluble (SOL) 
cytosolic fraction, it is significantly enriched in the insoluble (INS) cytoskeletal 
fraction. Analysis with antibodies to calnexin (ER), vimentin (IF), β-actin (actin 
filaments) and GAPDH (cytosol) confirmed that the fractionation protocol had enriched 
cytoskeletal proteins relative to other cellular components.  
 
 
Using an alternative fractionation protocol designed to specifically enrich IFs, sacsin’s 
cytoskeletal association was further investigated. Sacsin was present in an IF-enriched 
fraction generated from HDF and SH-SY5Y cell lysates (Figure 4.4). This is more 
evident in SH-SY5Y cells as sacsin has a higher abundance in these cells compared to 
HDFs. However, the fractionation of HDFs was cleaner with no detection of β-tubulin, 
GAPDH and HSP60 in the insoluble IF-enriched fraction (INS, Figure 4.4). This data is 
consistent with the immunocytochemistry data and further suggests that sacsin is 
associated with the cytoskeleton and specifically with IFs. 
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Figure 4.4. Sacsin is present in an insoluble IF-enriched fraction. IF fractionation of 
normal HDF and SH-SY5Y cells, followed by immunoblot analysis reveals that sacsin 
is present in the soluble cytosolic fraction and the insoluble intermediate filament 
fraction. The relative mobility of sacsin is the same across cell types and in soluble and 
insoluble fractions. Analysis with antibodies to vimentin (IF), β-actin (actin filaments), 
β-tubulin (microtubles), calnexin (ER), GAPDH (cytosol), HSP60 and TOM20 




4.2.3. Disorganisation of the vimentin IF network in ARSACS patient HDFs 
The discovery of alterations in the neurofilament cytoskeleton in neurons from Sacs-/- 
mice and in ARSACS brains (Lariviere et al., 2015), along with the identification that 
sacsin localises within close proximity of vimentin IFs, indicates a potential function of 
sacsin with IFs. Here, HDFs from ARSACS patients were analysed for evidence of 
alterations in IF networks. These patient HDFs contain pathological mutations in SACS, 
in the context of the genetic background of the affected individual, hence they are a 
useful cellular model to study ARSACS. It is also important to note that a mitochondrial 
phenotype has previously been observed in these patient HDFs. Details of the SACS 
mutations present in the five ARSACS HDF lines used, and the location of the 
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4 1 25 F p.2801delQ  In frame 
deletion 
Yes 






Table 4.1. ARSACS HDF lines used in this thesis. These were obtained from Dr. 
Sasha Vemeer, Radboud University, Nijmegen and Dr. Paola Giunti, UCL Institute of 
Neurology, London. Amino acid change to an * indicates a truncated protein, fs 
indicates a frameshift and del indicates a deletion. #Using an anti-sacsin antibody 
recognising a fragment within human sacsin amino acids 4100-4200 (abcam). ARSACS 






Figure 4.5. Schematic showing location of ARSACS patient mutations in sacsin. 
Schematic representation of the sacsin domains from N- to C-terminus. Amino acid 
residues are indicated in numbers.  sr1: subrepeat 1, sr2: subrepeat 2, sr3: subrepeat 3, 
srX: subrepeat X.  
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Sacsin expression in the HDFs was also analysed by immunoblotting. Three of the five 
ARSACS HDFs have no detectable sacsin protein, whereas two have reduced cellular 
levels of sacsin compared to WT controls (Figure 4.6). This is consistent with what is 
expected from the types of SACS mutations present in the patients. For example, patient 
5 in table 4.1 is a compound heterozygote, with one allele having a point mutation 
affecting residue 4331, which is beyond the region of antibody binding (4100-4200), 
hence this mutation does not affect binding and sacsin levels are detectable. The other 
allele has a mutation at residue 1715, which leads to a premature STOP codon and 
truncation of the protein, which is why they have reduced sacsin expression compared 
to wild-type (WT) controls. Patient 4 has a homozygous in-frame deletion of a single 
amino acid at residue 2801. This does not affect sacsin levels; hence this patient has 





Figure 4.6. Sacsin protein levels in WT control and ARSACS HDFs. 
Immunoblotting of lysates from ARSACS HDF lines and WT controls was performed 
using a rabbit monoclonal anti-sacsin antibody against an undefined sequence between 
residues 4100 and 4200. This detected a sacsin band in cells homozygous for the single 
amino acid deletion mutation 2801delQ, which was of similar intensity to that seen in 
WT control HDFs (patient 4). In cells with the K1715*/R4331Q mutation a 
significantly fainter sacsin band was just visible (patient 5). This is consistent with the 
K1715*/R4331Q HDF line expressing detectable levels of protein from a single allele. 
No sacsin was detected in the other three ARSACS HDF lines, although we could not 
preclude expression of a truncated protein. The relative mobility of sacsin was the same 
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4.2.3.1 Collapsed and bundled vimentin IFs in ARSACS 
The vimentin network of the five ARSACS patient and five WT control HDF lines was 
visualised by immunocytochemistry, using antibodies to sacsin and vimentin, along 
with MitoTracker Red to label the mitochondria. Confocal imaging identified a striking 
collapse and perinuclear bundling of the vimentin network in all ARSACS HDF lines 
compared to WT controls (Figure 4.7). Interestingly, a perinuclear ‘hole’ in the 
mitochondrial network occurs where the vimentin bundles, and in the two patient cells 
with some remaining sacsin protein detected (p.2801delQ, K1715* and R4331Q), there 
is a re-localisation of sacsin from being throughout the cytoplasm, to the perinuclear 
area where the vimentin is bundling and mitochondria are excluded (as indicated by 
white arrows in figure 4.7).  
 
	  CHAPTER 4: INTRACELLULAR DISORGANISATION IN ARSACS 
	   134 
 
	  CHAPTER 4: INTRACELLULAR DISORGANISATION IN ARSACS 






	  CHAPTER 4: INTRACELLULAR DISORGANISATION IN ARSACS 
	   136 
 
 
Figure 4.7. Collapsed and bundled vimentin IFs in ARSACS patient HDFs. 
Representative confocal images of five ARSACS patient HDF and WT control lines. 
Fibroblasts were incubated with MitoTracker Red and were stained with rabbit anti-
sacsin and mouse anti-vimentin antibodies. Confocal analysis showed collapsed and 
bundled vimentin IFs in all five ARSACS patient HDFs. Arrows indicate areas of 
vimentin network distruption. The mitochondrial network is disrupted and sacsin 
accumulates in the same location. Scale bars = 10 µm. Further images for ARSACS 
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The incidence of HDFs with vimentin bundling was compared by quantifying the 
phenotype in each ARSACS patient and each WT control line. This was done blind to 
experimental status. The total number of cells counted per cell line was >120 from at 
least two different cover slips. This revealed that, on average, 79.6 ± 1.9 % of cells from 
the five ARSACS patients have a collapsed vimentin network, which is a highly 
significant increase from control cells (p<0.001, Figure 4.8). These results indicate that 






Figure 4.8. Quantification of the collapsed and bundled vimentin IF phenotype in 
ARSACS patient HDFs. (A) The vimentin phentoype was quantified by counting the 
number of cells with a collapsed vimentin network for each cell line, blind to 
experimental status. The total number of cells counted per cell line was >120 from two 
cover slips. Results are expressed as mean ± SEM for each control and patient cell line. 
(B) Results from all five WT and five patient cell lines were combined to give an 
overall mean ± SEM,***p<0.001. Statistics were carried out using an unpaired two-tailed 
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The compound heterozygote ARSACS patient with SACS mutations K1715* and 
R4331Q has some remaining sacsin expression (patient 5 in table 4.1 and figure 4.6). 
Interestingly, sacsin localisation mirrors the collapsed vimentin network in HDFs from 
this patient (Figure 4.9). The same is observed in HDFs from another patient with some 
remaining sacsin expression (patient 4 in table 4.1 and figure 4.6), which can be seen in 
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4.2.3.2 Vimentin protein levels were unchanged in ARSACS patient HDFs  
Due to the re-localisation of vimentin in ARSACS patient HDFs, the total levels of 
vimentin protein were analysed for any change compared to controls by immunoblotting 
using an anti-vimentin antibody. There were no significant differences in total vimentin 
protein levels, normalised to β-actin, in ARSACS patient HDFs compared to WT 





Figure 4.10. Total cellular levels of vimentin were unchanged in ARSACS patient 
HDFs. (A) Immunoblot analysis of protein lysates from five ARSACS patient and five 
WT control HDFs probed with an anti-vimentin antibody. β-actin was used as a loading 
control. (B) Densitometric analyses were performed and mean relative vimentin protein 
levels calculated for the ARSACS patient and WT control HDF lines. Data were 
normalised to β-actin. Total cellular protein levels of vimentin did not significantly 
differ.  
 
Together this data suggests that loss of sacsin function leads to a significant remodeling 
of the vimentin network, but overall cellular levels of the protein are unchanged. 
 
4.2.4. Organisation of the microtubule and microfilament network in ARSACS 
patient HDFs 
Due to the striking changes in both the mitochondria and IF network organisation in 
ARSACS HDFs, the distribution of microtubules and microfilaments were also 
analysed. This was by immunocytochemistry, using either a fluorescent marker of actin 
(ActinGreen 488 ready probes, Life Technologies), or an antibody to β-tubulin, along 
with MitoTracker Red to label the mitochondria. Confocal imaging revealed that the 
distribution of the microfilament network did not appear to be significantly altered in 
ARSACS HDFs compared to controls (Figure 4.11).  
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Figure 4.11. Organisation of the F-actin network in ARSACS patient HDFs. 
Representative confocal images of five ARSACS patient and WT control HDFs. 
Fibroblasts were incubated with both MitoTracker Red and an ActinGreen fluorescent 
marker. Confocal imaging showed the F-actin network in all ARSACS patient HDFs 
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Likewise, ARSACS patient HDFs appear to have a normal microtubule distribution 
when compared to WT control cells (Figure 4.12). Microtubule nucleation from the 
microtubule organising centre (MTOC) did not appear compromised, but interestingly, 
the perinuclear accumulation of vimentin in ARSACS patient HDFs is spatially related 
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Figure 4.12. Organisation of the microtubule network in ARSACS patient HDFs. 
Representative confocal images of five ARSACS patient and WT control HDFs. 
Fibroblasts were incubated with MitoTracker Red and were stained with rabbit anti-
vimentin and mouse anti-β-tubulin antibodies. The microtubule network in all ARSACS 
patient HDFs appeared unaltered from WT controls. White boxes in the merged panels 
are shown zoomed in the far right panels and highlight the MTOC, which is indicated 
by the black arrows. Scale bars = 10 µm.  
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4.2.4.1. Altered acetylated α-tubulin in ARSACS patient HDFs  
Acetylation is a post-translational modification that occurs to many proteins, including 
tubulins. α–tubulin acetylation enhances microtubule stability (Piperno et al., 1987). 
Cellular structures that contain acetylated α–tubulin include primary cilia, centrioles, 
mitotic spindles, midbodies and a subset of cytoplasmic microtubules. Visualisation of 
acetylated α–tubulin by confocal microscopy, keeping confocal settings constant for all 
imaging, revealed an increase in fluorescence intensity in all five ARSACS HDFs 





Figure 4.13. Altered acetylated α-tubulin in ARSACS patient HDFs. Representative 
confocal images of five ARSACS patient and WT control HDFs. All cells were serum 
starved for 72 hours prior to immunocytochemistry. Fibroblasts were stained with an 
acetylated α-tubulin antibody, while nuclei were counterstained with DAPI (blue). Scale 
bars = 20 µm. 
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In summary, the microtubule network, the MTOC, and the actin network have a normal 
distribution in ARSACS patient HDFs when compared with WT controls, indicating a 
specific disruption to IF distribution with loss of sacsin function. An exception to this is 
in the acetylation of α-tubulin, which appears to be increased and shows disorganisation 
in the ARSACS patient HDFs. 
 
4.2.5. Disrupted localisation of other cellular organelles in ARSACS patient HDFs 
IFs help to orchestrate the positioning and function of cellular organelles, including 
mitochondria, Golgi, endosomes, and lysosomes (Toivola et al., 2005). Therefore, it is 
not suprising that pertubations of the IF network can lead to alterations in the 
subcellular distribution of other organelles (Gao and Sztul, 2001; Gao et al., 2002; 
Styers et al., 2004). Due to the collapse of the IF network in ARSACS patient HDFs, 
the distribution of other organelles was investigated.  
 
4.2.5.1. Golgi apparatus 
Disruption of the IF network has previously been shown to affect Golgi localisation. For 
example, expression of CMT-like neurofilament mutant proteins in cultured neurons 
leads to Golgi fragmentation, along with alterations in other organelles (Perez-Olle et 
al., 2005). Also, expression of a keratin 18 (K18) mutation, which disrupts keratin IFs 
in cultured cells, alters Golgi distribution (Kumemura et al., 2004).  
The organisation and location of the Golgi apparatus was analysed in the control and 
ARSACS HDFs by immunocytochemistry, using an antibody to GS28, a marker for a 
28 kDa membrane protein of the cis-Golgi, along with MitoTracker Red to label the 
mitochondria. The Golgi apparatus becomes dispersed and fragmented around the 
perinuclear area of mitochondrial exclusion in all five ARSACS HDF lines compared to 
controls (Figure 4.14).  
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Figure 4.14. Fragmentation of the Golgi apparatus in ARSACS patient HDFs. 
Representative confocal images of five ARSACS patient and WT control HDFs. 
Fibroblasts were incubated with MitoTracker Red and were stained with a mouse anti-
GS28 antibody, a marker for a 28 kDa membrane protein of the cis-Golgi. Confocal 
analysis showed fragmentation of the Golgi apparatus in all five ARSACS HDF lines. 
White boxes are shown as zoomed images in the far right panels. White arrows indicate 
areas of mitochondrial network disruption and Golgi exclusion. Scale bars = 10 µm.  
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4.2.5.2. Primary cilia  
Virtually all cells have a single primary cilium during interphase of the cell cycle. 
Structurally the cilium comprises a centriole-derived basal body from which projects an 
axoneme composed of acetylated microtubules. It has a fundamental role in numerous 
cellular signalling pathways, such as the hedgehog (Corbit et al., 2005; Rohatgi et al., 
2007), Wnt (Corbit et al., 2008), and insulin growth factor (IGF) pathways (Zhu et al., 
2009). Cilia have functional roles in differentiation (Clement et al., 2009; Hoey et al., 
2012), mechanobiology (Malone et al., 2007; Wann et al., 2012), as a cell cyle 
checkpoint (Kim and Tsiokas, 2011), and it is critical to the development and health of 
many tissues.  
The base of the primary cilium lies in close proximity to the Golgi apparatus, therefore 
disruption in Golgi localisation and organisation may indicate disruption of the primary 
cilium. Also, the ARSACS HDFs display a disorganisation of acetylated α-tubulin 
(Figure 4.13), which is a marker for primary cilia, again indicating that primary cilia 
may be disrupted. Hence, primary cilia incidence and length were assessed in ARSACS 
patient HDFs compared to WT controls.  
Cells were serum starved for 72 hours (media without FBS) before being processed for 
immnuocytochemistry using antibodies to ADP-ribosylation factor-like protein 13B 
(ARL13B), and acetylated α-tubulin, which are both markers of the ciliary axoneme. 
Primary cilia were visualised by confocal microscopy. Over 250 cells were scored for 
the presence/absence of a primary cilium per cell line (20 image fields from 2 cover 
slips per cell line). This quantification identified a significant reduction of 26.9 ± 2 % 
(p<0.001) in the mean number of ciliated cells in ARSACS HDF lines compared to WT 
controls (Figure 4.15 A,B). The lengths of at least 100 cilia per cell line (2 cover slips 
per cell line) were measured using ImageJ software (rsb.info.nih.gov/ij). This shows a 
significant reduction in the average cilium length in ARSACS patient HDFs compared 
to WT controls (p<0.001), reducing from a mean length of 4.37 ± 0.04 µm in WT 
controls to 3.90 ± 0.04 µm in the ARSACS HDFs (Figure 4.15 A,C).   
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Figure 4.15. Cilia incidence and length are reduced in ARSACS HDFs. (A) 
Representative confocal images of five ARSACS patient and a WT control HDF line. 
All cells were serum starved for 72 hours prior to processing for immunocytochemistry. 
Primary cilia were labelled with antibodies directed to ARL13B (red) while nuclei were 
counterstained with DAPI (blue). White boxes are shown as zooms to the right of each 
image. Scale bar represents 10 µm. (B) Primary cilia incidence and (C) primary cilia 
length for WT and five ARSACS patient HDFs. Results are expressed as mean ± SD for 
WT control and each patient cell line. WT is pooled data from five different control 
HDF lines (the five WT control HDF lines are shown seperately in appendix 4). Bar 
graphs on the far right represent the combined results from all five WT control and five 
patient HDF lines to give an overall mean ± SEM,***p<0.001. Statistics were carried out 




4.2.5.3. Early endosomes 
There is evidence for IF involvement in the endosomal-lysosomal pathway. For 
example, IFs bind to the adapter protein AP-3, which carries vesicles between 
endosomal-lysosomal compartments (Styers et al., 2005; Styers et al., 2004)	   IF 
disruption may affect the positioning of endosomes and lysosomes.  
The localisation of early endosomes was analysed in the control and ARSACS HDFs by 
immunocytochemistry. Fibroblasts were incubated with MitoTracker Red before being 
processed via immunocytochemistry using an antibody to early endosome antigen 1 
(EEA1). Confocal microscopy reveals a disruption in the normal localisation of early 
endosomes in all five ARSACS HDFs compared to five WT controls (Figure 4.16). 
Early endosomes are relatively dispersed around the perinuclear regions in WT control 
cells; however, they appear to become trapped around the edge of the mitochondrial 
‘hole’ in ARSACS HDFs (indicated by white arrows in figure 4.16).  
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Figure 4.16. Early endosome relocalisation around the area of perinuclear 
mitochondrial disruption in ARSACS patient HDFs. Representative confocal images 
of five ARSACS patient and WT control HDFs. Fibroblasts were incubated with 
MitoTracker Red and were stained with a mouse anti-EEA1 antibody (green), a marker 
for a 180 kDa membrane-associated protein to early endosomes. Confocal analysis 
shows disruption in the localisation of early endosomes in all five ARSACS patient 
HDFs. White boxes in the merged panels are shown as zoomed images in the far right 
panels. White arrows indicate areas of mitochondrial network and early endosome 
disruption. Scale bars = 10 µm. 
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4.2.6. Disorganisation of the vimentin network in sacsin knockdown cells  
The vimentin network was also analysed in WT HDFs that were transiently transfected 
with SACS siRNA or SCRM siRNA.  This cellular knockdown model allows the 
comparison of cells with loss of sacsin to an isogenic control. 
 
4.2.6.1. Collapsed and bundled vimentin IF network 
The effect of SACS siRNA knockdown on the vimentin network was investigated in 
normal HDFs. Cells were transfected with mito-DsRed and either SCRM or SACS 
siRNA, as detailed in the methods. After 48 hours, cells were processed for 
immunocytochemistry using an antibody to vimentin. Confocal microscopy shows that 
the vimentin network appears to be collapsed, with some perinuclear bundling, in cells 
transfected with SACS siRNA compared to SCRM controls (Figure 4.17). 
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Figure 4.17. Sacsin knockdown leads to collapsed and bundled vimentin IFs. 
Representative images of normal HDFs transfected with mito-DsRed and either SCRM 
or SACS siRNA. After 48 hours, cells were fixed and permeabilised, and incubated with 
an anti-vimentin antibody. Maximum intensity projections of z-stacks were taken via 
confocal microscopy. The vimentin network appears collapsed and bundled in SACS 
siRNA transfected cells compared to SCRM control. Scale bars = 10µm. 
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4.2.6.2. Reduced fluorescence recovery of vimentin-GFP in sacsin knockdown cells  
IF assembly requires the polymerisation of individual IF monomers. A dimer forms 
through the coiled-coil interactions of two parallel IF protein chains. Two dimers 
associate in a staggered and antiparallel fashion to form tetramers. On average, eight 
tetramers combine to form structures known as unit length filaments (ULFs). These 
ULFs link up end-to-end and assemble into mature IFs (Colakoglu and Brown, 2009; 
Vikstrom et al., 1992). 
As sacsin deficiency leads to alterations in the arrangement of the vimentin network, 
there may be an impact on the dynamic assembly of the vimentin network. To assess 
this we analysed protein dynamics by fluorescence recovery after photobleaching 
(FRAP). FRAP studies have been widely used as a measure of IF dynamics (Perez-Sala 
et al., 2015; Vikstrom et al., 1992; Winter et al., 2014; Yoon et al., 2001a; Yoon et al., 
1998). SH-SY5Y cells were transfected with a vimentin-targeted GFP, in combination 
with either SCRM or SACS siRNA. After 48 hours FRAP analysis was performed on 
20-25 cells for each treatment. Briefly, this involved photobleaching a small area of 
vimentin-targeted GFP within a cell and then monitoring the diffusion of the fluorescent 
signal within vimentin back into the region of interest from the surrounding region. 
Confocal settings were kept constant for all imaging, and areas of vimentin bundling in 
the SACS siRNA treated cells were avoided. There was a reduced level of fluorescence 
recovery from photobleaching in SACS cells compared to SCRM control. The vimentin-
GFP fluorescence recovers to 56 ± 4.2 % of the initial intensity in SCRM siRNA 
transfected cells, whereas in SACS siRNA transfected cells, the fluorescence recovers to 
only 35 ± 2.5 % of the initial intensity after 85 seconds (Figure 4.18). So the vimentin-
targeted GFP diffuses back into the bleached zone at a slower rate in SACS vs. SCRM 
siRNA transfected cells. This indicates that the mobility of vimentin molecules is 
reduced in cells with loss of SACS expression, suggesting that the vimentin network is 
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Figure 4.18. FRAP analysis showed reduced vimentin-GFP fluorescence recovery 
in sacsin knockdown cells. (A) Representative images of SH-SY5Y cells co-
transfected with vimentin-GFP and either SCRM or SACS siRNA. A 15 x 15 µm area of 
the cell containing vimentin IFs, indicated by the white box, was photobleached and the 
cells imaged every 1.5 seconds for 85 seconds. A 15 x 15 µm area of the cell containing 
vimentin IFs that was not photobleached is indicated by the red box. Fluorescence 
measurements of this area were used as a control for any loss of fluorescence over time 
that was not due to photobleaching. (B) Graphical representation of recovery after 
photobleaching. Fluorescent intensities of the 15 x 15 µm area were normalised to pre-
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4.3. Conclusions 
The subcellular localisation of sacsin has previously been shown to be predominantly 
cytoplasmic with a significant mitochondrial component (Parfitt et al., 2009). In this 
chapter, the localisation of sacsin was further investigated in SH-SY5Y cells using a 
monoclonal antibody that recognises a fragment within human sacsin amino acids 4100-
4200. With the recent advancement of super-resolution microscopy, cells, organelles 
and proteins can be visualised to a much higher resolution. Using the SIM approach to 
super-resolution imaging, a proportion of sacsin was found to be in close proximity to 
vimentin IFs. The previously identified localisation of sacsin with mitochondria was 
also confirmed. Importantly, areas where sacsin localised between the mitochondrial 
and vimentin network were observed. This is a feature of scaffold or cytolinker proteins, 
such as plectin, so intriguingly; this may suggest sacsin has a cytoskeletal linker 
function. This is discussed further in Chapter 6. 
In addition, cellular fractionation studies showed that sacsin was detected in an IF-
enriched fraction, further indicating an association between sacsin and vimentin. The 
mechanism of how sacsin may be associating with vimentin is unknown. However, 
sacsin contains three repeating regions, each with homology to the N-terminal ATPase 
domain of HSP90, the first of which has been shown to have ATPase activity 
(Anderson et al., 2010). The ATPase domain of HSP90 is important for an interaction 
with vimentin, and this interaction protects vimentin from apoptotic cleavage (Zhang et 
al., 2006). Hence, the three regions within sacsin, which have homology to the ATPase 
domain of HSP90, may interact with vimentin.  
Sacsin appears to relocalise from being throughout the cell to concentrating in the 
perinuclear area of vimentin bundling in two ARSACS patient HDFs with some 
remaining sacsin expression (Figures 4.7 and 4.9). This further supports an association 
between sacsin and vimentin because the relocalisation of vimentin is consistent with 
the relocalisation of sacsin. The sacsin mutations present in these two patients 
(p.2801delQ, K1715* and R4331Q, Figure 4.5) do not affect the three HSP90-like 
domains. Therefore, the presence of these HSP90-like domains could explain an 
association between vimentin and sacsin. 
Recently, disrupted neurofilament organisation was identified in somatodendritic 
regions of various neuronal populations from sacsin knockout mice and ARSACS 
brains (Lariviere et al., 2015). In this chapter, a dramatic collapse of vimentin IFs into a 
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perinuclear bundle was observed in almost 80% of dermal fibroblasts from five 
ARSACS patients, all with different SACS mutations. This vimentin phenotype was also 
identified in WT HDFs transfected with SACS siRNA, but was not present in SCRM 
siRNA control cells. This data demonstrates that the neurofilament defect identified in 
neurons of sacsin knockout mice and ARSACS brains extends to other IFs and other 
cell types. Neurons are perhaps more vulnerable to a perturbation of the IF network; 
hence there is more of a detrimental effect in neurons.  
Disruption to the microtubule network, for example with drugs such as colchicine, 
nocodazole or vinblastine, can induce IF disorganisation (Lazarides, 1980). There were 
no apparent changes in morphology of the microtubule and microfilament network in 
the ARSACS patient HDFs, suggesting that the vimentin collapse is not a consequence 
of a disorganised microtubule network. However, there may be an increase in stability 
of the microtubule network, as indicated by increased acetylation of α-tubulin in the 
ARSACS patient HDFs, although this needs to be verified by immunoblotting. It would 
be interesting to investigate whether ARSACS patient HDFs are resistant to 
destabilisation of their microtubule network, for example using nocodazole, as this 
would indicate reduced microtubule dynamics. Also, it is known that inhibiting the 
tubulin deacetylase, HDAC6, enhances microtubule acetylation (Asthana et al., 2013; 
Haggarty et al., 2003; Zhang et al., 2008) thus, HDAC6 levels and activity could be 
analysed in ARSACS patient cells as this may account for the enhanced acetylation of 
α-tubulin.  
Intriguingly, a disruption in the mitochondrial network is seen in the same perinuclear 
location of vimentin bundling. It seems likely that the abnormal vimentin bundle is 
either forcing mitochondria out of this area and/or preventing mitochondria from being 
transported to this region, so mitochondria are seen to accumulate at the periphery of the 
vimentin bundle. 
The organisation of other organelles was also shown to be disrupted in all five 
ARSACS patient HDFs compared to WT controls, and importantly, the disruption is 
also spatially related to the perinuclear vimentin bundling. For example, the Golgi 
becomes dispersed and fragmented around the edge of the vimentin bundle, early 
endosomes become relocalised around the edge of the vimentin bundle, and primary 
cilia, which usually form at the centrosome, are reduced in incidence and length. This 
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suggests that the perinuclear collapse and bundling of vimentin may be disrupting the 
normal localisation of other cellular organelles in ARSACS patient HDFs.  
In fact, the cellular phenotype observed in cells with loss of sacsin function is 
characteristic of what has been shown to occur in cells due to the formation of 
aggresomes (Garcia-Mata et al., 1999; Johnston et al., 1998; Kopito, 2000). 
Aggresomes form due to a disruption in normal cellular protein homeostasis meaning 
that misfolded proteins accumulate and aggregate. Specific characteristic features 
indicative of aggresome formation include a collapse of the IF network into perinuclear 
cage-like structures, and various organelles including mitochondria, Golgi and early 
endosomes are re-localised around the edge of the IF cage (Garcia-Mata et al., 1999; 
Johnston et al., 1998; Kopito, 2000). Aggresomes form at the microtubule organising 
centre (MTOC, (Garcia-Mata et al., 1999; Johnston et al., 1998) and interestingly the 
vimentin bundling in the ARSACS HDFs is spatially related to the MTOC, although 
this needs to be verified using the centrosomal protein, gamma-tubulin, as a marker of 
the MTOC. 
The data also shows that vimentin network dynamics are reduced in cells with loss of 
sacsin function. FRAP analysis was performed in cells transfected with vimentin-GFP 
along with SCRM or SACS siRNA. This shows a reduced level of fluorescence recovery 
in cells with loss of sacsin as the vimentin-targeted GFP moved back into the bleached 
zone at a slower rate, indicating that subunit exchange is slower and less dynamic in 
cells with loss of sacsin. Increased stability and reduced turnover of IFs have previously 
been shown to be consequences of IF bundling (Flitney et al., 2009; Kim et al., 2010b; 
Lee and Coulombe, 2009; Windoffer et al., 2011), hence the reduction in vimentin 
dynamics due to loss of sacsin may be a consequence of alterations in vimentin 
architecture. Vimentin is likely to become more stable in order to form a perinuclear 
cage around protein aggregates. Alternatively, vimentin dynamics may be reduced due 
to misfolding of vimentin itself as a result of loss of sacsin. Interestingly, the molecular 
chaperone HSP27 binds to vimentin and ameliorates vimentin insolubilisation and 
vimentin filament collapse induced by the cytotoxic effects of cadmium, a toxic heavy 
metal (Lee et al., 2005). This suggests that HSP27 may maintain the structure and 
integrity of vimentin filaments under stress conditions. It is possible that sacsin may 
have a similar role as a molecular chaperone for IFs.  
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Collectively, the data here shows that loss of sacsin function leads to a cellular 
phenotype that indicates the formation of an aggresome-like structure. Such structures 
are known to form due to the accumulation of misfolded proteins. This will be 
investigated further in Chapter 5. 
 
4.3.1. Further work 
This chapter has identified that a proportion of sacsin protein localises in close 
proximity to vimentin IFs and is present in an IF-enriched fraction of cells. To 
investigate whether an association between sacsin and vimentin is mediated through 
sacsins HSP90-like domains, these domains could be disrupted by site-directed 
mutagenesis experiments to see if sacsin localisation is altered. This would also provide 
more evidence of an interaction between sacsin and vimentin. 
Also, inhibiting the ATPase activity of HSP90 with geldanamycin has been shown to 
prevent an interaction between HSP90 and vimentin and leads to dramatically reduced 
vimentin levels (Zhang et al., 2006). Perhaps geldanamycin also inhibits the ATPase 
activity of the HSP90-like domains within sacsin. Thus, it would be interesting to 
investigate whether treating cells with geldanamycin affects the association of sacsin 
with vimentin and/or affects the cellular levels of sacsin. This would provide evidence 
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5.1. Introduction and Aims 
Cellular stresses, such as thermal or oxidative stress, and alterations in protein structure 
caused by mutations, RNA modifications, translational errors or post-translational 
modifications, can lead to unfolded or partially folded proteins (Hurle et al., 1994; 
Princiotta et al., 2003; Wetzel, 1994). This may subsequently lead to protein 
aggregation due to undesirable interactions with other molecules. Protein misfolding is 
not rare, with approximately 30% of newly synthesised proteins estimated to be 
misfolded (Schubert et al., 2000). The existence of a cellular ‘quality control’ 
machinery means that misfolded proteins do not normally accumulate in unstressed 
cells. As detailed in the introduction to this thesis, the initial cellular defense against 
misfolded proteins is mediated by molecular chaperone networks, which assist in the 
refolding or degradation of misfolded proteins. If a protein that is normally structured 
cannot be refolded, it is targeted for degradation by the ubiquitin/proteasome system 
(UPS, (Ciechanover, 2006; Muchowski and Wacker, 2005)) or the autophagy-lysosome 
pathway (ALP). However, when these lines of defense fail or are overwhelmed, an 
accumulation of misfolded proteins can ultimately lead to the formation of 
proteinacious aggregates. This is a feature of many neurodegenerative diseases, for 
example, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease 
(HD), spinocerebellar ataxias (SCA), and amyotrophic lateral sclerosis (ALS, (Ross and 
Poirier, 2004; Soto and Estrada, 2008; Tran and Miller, 1999)). 
Misfolded protein aggregates are transported along microtubules, in a retrograde 
direction, by the cytoplasmic dynein-dynactin motor complex. This facilitates their 
delivery to the MTOC where they subsequently accumulate (Garcia-Mata et al., 1999; 
Johnston et al., 1998, Figure 5.1). The perinuclear location into which aggregated 
proteins are sequestered has been termed the aggresome (Johnston et al., 1998). Hence, 
an intact microtubule cytoskeleton is necessary for aggresome formation (Johnston et 
al., 1998). In addition, the correct function of the dynein-dynactin complex is required 
for aggresome formation. Overexpression of the dynamitin (p50) subunit of the 
dynactin complex leads to dissociation of the dynactin complex and inhibits dynein-
mediated transport on microtubules (Burkhardt et al., 1997; Presley et al., 1997), 
resulting in the accumulation of peripherally distributed small protein aggregates rather 
than perinuclear aggresomes (Garcia-Mata et al., 1999; Johnston et al., 1998). 
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Depolymerisation of microtubules does not lead to the rapid dispersal of aggresomes, 
suggesting that they are not dynamic structures (Johnston et al., 1998).  
 
5.1.1. Characteristics of aggresome formation 
One of the most consistent and robust markers of aggresome formation is the 
relocalisation of the IF cytoskeleton from its normal extended cytoplasmic distribution 
to a collapsed perinuclear cage-like structure that surrounds the aggresome (Figure 5.1, 
(Iwata et al., 2005a; Johnston et al., 1998; Kopito, 2000; Wang et al., 2005a)). The type 
of IF that surrounds the aggresome depends on the cell type. For example, in 
mesenchymal cells this will be vimentin and in cardiomyocytes it will be desmin, 
whereas in neurons, aggresomes are surrounded by neurofilaments (Taylor et al., 2003). 
The molecular events that lead to this IF rearrangement are not yet understood. The 
pericentriolar accumulation of protein aggregates also frequently results in expansion of 
the centrosome, as assessed by γ tubulin and pericentrin (Wigley et al., 1999).  
Aggresomes form in the region of the cell usually occupied by the Golgi. The Golgi 
becomes displaced and fragmented around the aggresome, and this becomes more 
apparent as the aggresome grows in size (Garcia-Mata et al., 1999). This has been 
observed in cultured cells overexpressing aggregation-prone proteins (Garcia-Mata et 
al., 1999), in neurons from AD brains, in spinal cords from ALS patients, and in a 
transgenic mouse model of ALS (Gonatas et al., 1998). Surprisingly, in cells that 
contain aggresomes, Golgi function does not seem to be compromised and cargo moves 
from the ER through the Golgi to the plasma membrane as normal (Garcia-Mata et al., 
2002). 
Aggresomes are enriched with the protein that is misfolding, as well as proteins 
involved in maintaining proteostasis, including HSP70, the HSP40 proteins Hdj1 and 
Hdj2, and the chaperonin TriC/TCP (Garcia-Mata et al., 1999; Wigley et al., 1999). In 
addition to chaperones, the presence of both 19S and 26S proteasome subunits in 
aggresomes has been reported (Anton et al., 1999; Fabunmi et al., 2000; Wigley et al., 
1999), whereas the presence of ubiquitin localisation is inconsistent (Johnston et al., 
2002; Garcia-Mata et al., 1999; Wigley et al., 1999; Johnston et al., 1998).  
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Figure 5.1. Schematic model of aggresome formation. Aggresome formation is a 
cellular response to misfolded proteins that aggregate and resist degradation by the 
proteasome. Aggregated proteins are transported along microtubules (MT), in a 
retrograde manner, by the dynein-dynactin motor to the microtubule-organising centre 
(MTOC). At the MTOC they are surrounded by a cage of IFs, and the localisation of 
other cellular organelles is disrupted. Aggresomes accumulate components of the 
ubiquitin-proteasome pathway of protein degradation, including molecular chaperones, 
ubiquitin, and proteasomes (Garcia-Mata et al., 2002; Kopito, 2000). N: nucleus. 
 
 
The overall structure of aggresomes varies depending on the aggregating substrate and 
the ‘host’ cells. For example, mutant ATP7B protein, which is responsible for Wilson 
disease, forms spherical aggresomes, with a diameter of 1-3µm, in HEK293 cells, but 
forms extended ribbon aggresomes in HuH-7 cells (Harada et al., 2001). The molecular 
mechanisms that define the shape of an aggresome are unknown. 
The function of aggresome formation is not fully understood, but it is thought it acts to 
sequester cytotoxic proteins, preventing abnormal interactions with other proteins and 
cell organelles (Chen et al., 2011; Garcia-Mata et al., 2002; Kopito, 2000). Studies have 
found that aggresome formation reduces the amount of mutant huntingtin protein 
present in the rest of the cell and is associated with increased cell survival (Arrasate and 
Finkbeiner, 2005; Arrasate et al., 2004).  
Accumulating evidence suggests that aggresomes are substrates for autophagy, and in 
support of this, autophagic machinery has been found to localise to aggresomes (Fortun 
et al., 2003; Iwata et al., 2005a; Iwata et al., 2005b; Ravikumar et al., 2002; Taylor et 
al., 2003; Yamamoto et al., 2006; Zaarur et al., 2014). 
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5.1.2. Autophagy 
As detailed in the introduction to this thesis (section 1.4.4), macroautophagy involves 
the formation of autophagosomes, which engulf cytoplasmic proteins and organelles 
and deliver them to lysosomes for degradation. Various autophagy (ATG) proteins are 
essential for the formation of autophagosomes (Reggiori and Klionsky, 2002; 
Rubinsztein et al., 2007). A complex of ATG5-ATG12-ATG16 is required for fusion of 
vesicles, and this complex requires the catalytic activities of ATG7 and ATG10. The 
processing of microtubule-associated protein 1 light chain 3 (LC3, also known as 
ATG8) is also important for autophagosome biogenesis. LC3 is cleaved by ATG4B to 
form LC3-I, which is then conjugated to phosphatidylethanolamine by ATG7 and 
ATG3 to form LC3-II (Kabeya et al., 2000).  
As autophagosome formation completes, the ATG5-ATG12-ATG16 complex 
dissociates, whereas LC3-II remains associated with the completed autophagosome. 
Autophagosomes are then trafficked by dynein-dynactin motors along microtubules 
(Ravikumar et al., 2005) to the perinuclear region where they fuse with lysosomes and 
their contents are degraded. Efficient degradation of autophagy substrates can only 
occur if the acidic lysosomal pH is correctly maintained and the lysosomal hydrolases 
are functioning correctly. 
Autophagy is particularly important in neurons because the total content of 
dysfunctional proteins and damaged organelles cannot be reduced through cell division 
(Tooze and Schiavo, 2008; Winslow and Rubinsztein, 2008). Abnormal numbers of 
autophagosomes are indicative of autophagic dysfunction (Nixon et al., 2005; Yang et 
al., 2007), which may be due to an upregulation of autophagy or impaired clearance of 
autophagosomes (Boland et al., 2008; Rubinsztein et al., 2009). Autophagic dysfunction 
has been implicated in the pathogenesis of many neurodegenerative diseases (Boland et 
al., 2008; Kegel et al., 2000; Nixon et al., 2005; Ravikumar et al., 2002). 
As described in Chapter 1, sacsin contains multiple domains linking to molecular 
chaperone and protein degradation pathways. In addition, previous research has shown 
that sacsin is recruited to inclusions of mutant ataxin-1 (Parfitt et al., 2009). When 
sacsin levels were reduced by siRNA, expression of mutant ataxin-1 led to increased 
cell death compared to SCRM siRNA control, which suggests enhanced toxicity of 
mutant ataxin-1 with loss of sacsin (Parfitt et al., 2009). Collectively, this data suggests 
that sacsin has a role in protein quality control pathways. Therefore, loss of sacsin could 
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lead to a disruption in protein quality control and potentially an accumulation of 
misfolded proteins.  
In Chapter 4, data was provided showing that cells with loss of sacsin function have 
several characteristics of aggresome formation. The vimentin network collapses into 
perinuclear cage-like structures, the Golgi complex becomes displaced and fragmented, 
and other organelles, such as mitochondria and early endosomes become relocalised 
around the periphery of the vimentin bundle. Therefore, the aim of this chapter was to 
further investigate whether loss of normal sacsin function leads to an accumulation of 
misfolded proteins and subsequent perinuclear aggregate formation. Molecular 
chaperones, ubiquitin, proteosomal subunits, and markers of autophagy have all 
previously been shown to be recruited to protein aggregates (Garcia-Mata et al., 1999; 
Iwata et al., 2005b; Wigley et al., 1999; Zaarur et al., 2014); hence 
immunocytochemistry for these proteostasis components was performed, followed by 
confocal microscopy. Evidence for an accumulation of misfolded proteins in cells with 
loss of sacsin function would support a role for sacsin in the cellular protein quality 
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5.2. Results  
 
5.2.1. Perinuclear accumulation of HSP70 in ARSACS patient HDFs 
Molecular chaperones, such as HSP70, are known to be abundantly present in, and are 
actively recruited to aggresomes (Garcia-Mata et al., 1999; Johnston et al., 1998; Saliba 
et al., 2002). Therefore, HSP70 localisation was investigated in ARSACS patient HDFs 
compared to WT controls. Cells were incubated with MitoTracker Red, followed by 
immunocytochemistry using antibodies to HSP70 and vimentin. Confocal microscopy 
revealed that HSP70 strongly accumulates in a single perinuclear region in the 
ARSACS patient HDFs, which is where the vimentin network also concentrates. In 
contrast, HSP70 is dispersed throughout the cytoplasm in WT controls (Figure 5.2). 
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Figure 5.2. Perinuclear accumulation of HSP70 in ARSACS patient HDFs. 
Representative confocal images of ARSACS patients and WT control HDFs. Cells were 
incubated with MitoTracker Red, followed by staining with antibodies to HSP70 and 
vimentin. Confocal analysis showed accumulation of HSP70 in perinuclear regions in 
all five ARSACS patient HDFs. White boxes in merged panels are shown zoomed in 
the far right panels. Scale bars = 10 µm.  
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5.2.2. HSP70 protein levels were unchanged in ARSACS patient HDFs  
Cellular stresses leading to an accumulation of misfolded proteins can result in altered 
expression of molecular chaperones, such as HSP70 (Hartl et al., 2011; Mosser et al., 
1988). Due to the re-localisation of HSP70 in ARSACS patient HDFs, an immunoblot 
was performed to analyse total HSP70 protein levels in ARSACS patient HDFs 
compared to WT controls. There was no significant difference in total cellular levels of 





Figure 5.3. Total cellular levels of HSP70 were unchanged in ARSACS patient 
HDFs. (A) Immunoblot analysis of protein lysates from five ARSACS patient and five 
WT control HDFs probed with an anti-HSP70 antibody. GAPDH was used as a loading 
control. (B) Densitometric analyses were performed and mean relative protein levels 
calculated for the five WT and five patient cell lines. Data were normalised to GAPDH. 
Total cellular protein levels of HSP70 did not significantly differ between ARSACS 
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5.2.3. HSP90 colocalisation with vimentin in WT control and ARSACS patient 
HDFs  
HSP90 has been shown to be recruited to protein aggregates (Leu et al., 2011). For 
example, HSP90 is found in Lewy bodies in PD (Auluck et al., 2002; Kalia et al., 2010; 
McLean et al., 2002), and HSP90 levels are increased in the brain of PD patients (Uryu 
et al., 2006). In addition, an interaction between HSP90 and vimentin has previously 
been demonstrated (Zhang et al., 2006). With this in mind, the localisation of HSP90 
was investigated in the ARSACS patient HDFs compared to WT controls. Cells were 
incubated with MitoTracker Red, followed by immunocytochemistry using antibodies 
to HSP90 and vimentin. As previously shown by Zhang et al. (2006), confocal 
microscopy revealed a co-localisation between vimentin and HSP90. This was apparent 
in both WT control and ARSACS patient HDFs (Figure 5.4). HSP90 appeared to be 
associated with perinuclear vimentin bundling in the ARSACS patient cells; however it 
was not exclusively localised in this region and was found in other areas within the 
cytoplasm. Thus, HSP90 does not appear to significantly re-localise in the perinuclear 
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Figure 5.4. HSP90 co-localises with vimentin in WT and ARSACS patient HDFs.  
Representative confocal images of ARSACS patient and WT control HDFs. Cells were 
incubated with MitoTracker Red and were stained with rabbit anti-HSP90 and mouse 
anti-vimentin antibodies. Confocal analysis showed co-localisation of HSP90 with 
vimentin in both WT and ARSACS patient HDFs. White boxes in the merged panels 
are shown zoomed in the far right panels. Scale bars = 10 µm.  
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5.2.4. HSP90 protein levels were unchanged in ARSACS patient HDFs  
Cellular stresses such as heat shock, nutrient deprivation and oxidative stress are 
reported to induce HSP90 expression levels by as much as two-fold (Bagatell et al., 
2000). Total HSP90 protein levels were analysed in the ARSACS patient HDFs 
compared to WT controls by immunoblot analysis using an anti-HSP90 antibody. There 
was no significant difference in total HSP90 protein expression levels relative to β-actin 





Figure 5.5. Total cellular levels of HSP90 were unchanged in ARSACS patient 
HDFs. (A) Immunoblot analysis of protein lysates from five ARSACS patient and five 
WT control HDF lines probed with an anti-HSP90 antibody. β-actin was used as a 
loading control. (B) Densitometric analyses were performed and mean relative protein 
levels calculated for the five WT control and five patient cell lines. Data were 
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5.2.5. Perinuclear accumulation of ubiquitin in ARSACS patient HDFs 
The key signal for targeting proteins, including misfolded proteins, for degradation via 
the UPS or ALP is polyubiquitination. Intracellular inclusion bodies containing 
ubiquitinated proteins are detected in a variety of neurodegenerative diseases (Lowe et 
al., 1988). So far, the ARSACS patient cells appear to show cellular characteristics 
resembling the formation of an aggresome-like structure, therefore the presence of 
ubiquitinated proteins within this structure was investigated.  
ARSACS patient and WT control HDFs were incubated with MitoTracker Red, 
followed by immunocytochemistry using antibodies to ubiquitin and vimentin. Confocal 
microscopy revealed an accumulation of ubiquitin in all of the ARSACS patient HDFs. 
This was in the same perinuclear region as vimentin bundling and HSP70 accumulation. 
In contrast, ubiquitin was dispersed throughout the cytoplasm in WT control cells 
(Figure 5.6). 
 
CHAPTER 5: DISRUPTED PROTEOSTASIS IN ARSACS 
	   174 
 
 
CHAPTER 5: DISRUPTED PROTEOSTASIS IN ARSACS 




CHAPTER 5: DISRUPTED PROTEOSTASIS IN ARSACS 
	   176 
Figure 5.6. Perinuclear accumulation of ubiquitin in ARSACS patient HDFs. 
Representative confocal images of ARSACS patient and WT control HDFs. Cells were 
incubated with MitoTracker Red, followed by staining with antibodies to ubiquitin and 
vimentin. Confocal analysis showed accumulation of ubiquitin in perinuclear regions in 
all five ARSACS patient HDFs. White boxes in the merged panels are shown zoomed 
in the far right panels. White arrows indicate perinuclear accumulation of ubiquitin, 




5.2.6. Perinuclear accumulation of p62/SQSTM1 in ARSACS patient HDFs 
p62/SQSTM1 binds ubiquinated proteins, targeting them for autophagy, and has been 
shown to accumulate with ubiquitin-containing aggregates when autophagy is disrupted 
(Nagaoka et al., 2004; Zatloukal et al., 2002). As the ARSACS patient HDFs show an 
accumulation of ubiquitinated protein, p62 localisation was also explored.  
ARSACS patient and WT control HDFs were incubated with MitoTracker Red, 
followed by immunocytochemistry using an antibody to p62/SQSTM1. Confocal 
microscopy revealed an accumulation of p62 in the same perinuclear region as seen for 
HSP70 and ubiquitin, in all of the ARSACS patient HDF lines (Figure 5.7). There 
seemed to be some variation in the amount of p62 accumulation between the five 
ARSACS patient HDFs. The heterozygous patient with the SACS mutations R2002fs 
and Q4054* appeared to show the highest intensity of p62 accumulation. 
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Figure 5.7. Perinuclear accumulation of p62 in ARSACS patient HDFs. 
Representative confocal images of ARSACS patient and WT control HDFs. Cells were 
incubated with MitoTracker Red, followed by staining with an antibody to 
p62/SQSTM1. Confocal analysis showed accumulation of p62 in perinuclear regions in 
all five ARSACS patient HDFs, indicated by white arrows. White boxes in the merged 
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5.2.7. Re-localisation of lysosomes in ARSACS patient HDFs 
Lysosomes are membrane-bound organelles that contain many hydrolytic enzymes 
capable of degrading proteins, nucleic acids, carbohydrates and lipids. The lysosomal 
enzymes are active only at an acidic pH (4.5-5). To maintain their acidic pH, lysosomes 
actively transport protons into the lysosome via a proton pumping vacuolar-type 
ATPase (V-ATPase) in the membrane, a process that requires energy through ATP 
hydrolysis. Pertubation of the activity of V-ATPases leads to compromised lysosome 
acidification, so hydrolytic enzymes can no longer degrade the contents, which in turn 
leads to accumulation of lysosomes and their undegraded protein contents.  
As lysosomes are involved in the final step of autophagic degradation, their localisation 
and expression levels were investigated in ARSACS patient HDFs compared to WT 
controls. Cells were incubated with MitoTracker Red, followed by 
immunocytochemistry using antibodies to vimentin and lysosome-associated membrane 
protein 2 (LAMP-2), which as the name suggests, is found in the membrane of 
lysosomes. Confocal microscopy revealed that lysosomes become re-localised from 
being dispersed throughout the perinuclear region in WT control HDFs, to having a 
strong perinuclear accumulation of lysosomes in a single region in ARSACS patient 
HDFs (Figure 5.8). This accumulation is in the same cellular region of vimentin 
bundling and mitochondrial disruption, indicated by the white arrows in figure 5.8. The 
same accumulation pattern was observed for HSP70, ubiquitin and p62. Confocal 
settings remained constant throughout imaging. 
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Figure 5.8. Perinuclear accumulation of LAMP-2 in ARSACS patient HDFs. 
Representative confocal images of ARSACS patient and WT control HDFs. Cells were 
incubated with MitoTracker Red, followed by staining with antibodies to LAMP-2 and 
vimentin. Confocal analysis showed perinuclear accumulation of LAMP-2 in all five 
ARSACS patient HDFs. White boxes in the merged panels are shown zoomed in the far 
right panels. White arrows indicate perinuclear accumulation of LAMP-2, vimentin 
bundling and mitochondrial disruption. Scale bars = 10 µm.  
 
CHAPTER 5: DISRUPTED PROTEOSTASIS IN ARSACS 
	   181 
5.2.8. LAMP2 upregulation in sacsin knockdown cells 
Our research group perfomed a microarray experiment using a human Illumina Whole 
Genome Gene Expression BeadChip (HT-12 v.4.0). Transcript levels were compared in 
SH-SY5Y cells transfected with SCRM or SACS siRNA (transfections, RNA extraction 
and purification were performed by Teisha Bradshaw and Suran Nethisinghe). Data 
analyses (carried out by Lisa Romano) identified a 0.5-fold increase in LAMP2 gene 
expression in SACS siRNA treated cells compared to SCRM siRNA (Figure 5.9A). This 
upregulation was verified in an independent experiement by RT-qPCR (Figure 5.9B, 
0.47-fold increase, work performed by Lisa Romano). To further confirm the LAMP2 
gene expression result, LAMP-2 protein levels were measured by immunoblot analysis 
using an anti-LAMP2 antibody. LAMP-2 protein levels were also significantly 
increased by 0.6-fold in cell lysates from SACS siRNA transfected cells compared to 
those transfected with SCRM siRNA control (Figure 5.9C,D **p<0.01). This was 
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Figure 5.9. Upregulation of LAMP2 mRNA and protein expression in sacsin 
knockdown cells. RNA and protein were extracted from SH-SY5Y cells transfected 
with SCRM or SACS siRNA. Endogenous LAMP2  mRNA and protein were assayed by 
microarray, RT-qPCR and immunoblotting. Differential LAMP2 mRNA levels 
determined by microarray (A) and RT-qPCR (B). Results are expressed as mean ± 
SEM. Microarray n=2. RT-qPCR reactions were performed in triplicate. SYBR-green 
was used for RT-qPCR (ThermoFisher Scientific). (C) Representative immunoblot of 
total LAMP-2 protein expression levels in SCRM or SACS siRNA treated cells. Blots 
were probed with an anti-LAMP-2 antibody, along with GAPDH as a loading control. 
(D) Densitometric analyses were performed and mean relative protein levels calculated 
(n=8). Data were normalised to GAPDH and are expressed as mean ± SEM. Statistics 
were carried out using an unpaired, two-tailed Students t-test. **p<0.01, ***p<0.001.  
 
 
Together these data indicate a strong perinuclear accumulation of LAMP-2 in ARSACS 
patient HDFs, along with an upregulation of LAMP-2 mRNA and protein in SACS 
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5.2.9. Investigating mitophagy in ARSACS patient HDFs 
In the immunocytochemistry experiments described in this chapter and Chapter 4, 
mitochondria were stained with MitoTracker Red CMXRos (ThermoFisher Scientific). 
This is a lipophilic cationic fluorescent dye that accumulates inside mitochondria in 
response to highly negative mitochondrial membrane potential (Kholmukhamedov et 
al., 2013; Pendergrass et al., 2004). Therefore, loss of a membrane potential would 
mean MitoTracker is not taken up by mitochondria. This is a potential explanation for 
the perinuclear area of mitochondrial exclusion in ARSACS patient HDFs, as there may 
be mitochondria in this region that are not being detected because they have lost 
membrane potential. This occurs in damaged/unhealthy mitochondria.  
To investigate this in the ARSACS patient and WT control HDFs, dual 
immunocytochemistry was performed using MitoTracker Red along with the 
mitochondrial marker, TOM20 (Translocase of Outer Mitochondrial Membrane 20 
homolog), which is not dependent on membrane potential so will stain healthy and 
unhealthy mitochondria. Cells were incubated with MitoTracker Red, followed by 
immunocytochemistry using an antibody to TOM20. Confocal microscopy revealed that 
MitoTracker and TOM20 staining overlap in both the ARSACS patient and WT control 
HDFs (Figure 5.10). Importantly, like MitoTracker Red fluorescence, staining the 
mitochondria using an antibody to TOM20 also shows a perinuclear area of 
mitochondrial exclusion in the ARSACS patient HDFs (highlighted in zoomed panels 
of figure 5.10), which suggests that unheathly mitochondria without a membrane 
potential are not accumulating in this region.  
 
This data indicates that an increased degradation of dysfunctional mitochondria through 
mitophagy is not the explanation for the perinuclear accumulation of proteostasis 
components and area of mitochondrial network disruption seen in the ARSACS patient 
cells.  
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Figure 5.10. TOM20 and MitoTracker co-localise on mitochondria.  Representative 
confocal images of ARSACS patient and WT control HDFs. Cells were incubated with 
MitoTracker Red and were stained with rabbit anti-TOM20 antibody. Confocal z-stacks 
show co-localisation of TOM20 and MitoTracker Red throughout the cell in both WT 
and ARSACS patient HDFs. White boxes in the merged panels are shown zoomed in 






CHAPTER 5: DISRUPTED PROTEOSTASIS IN ARSACS 
	   186 
5.3. Conclusions 
This chapter has demonstrated a perinuclear accumulation of some markers of 
proteostasis, which resembles an aggresome-like structure. This has been observed in 
the five ARSACS patient HDF lines studied, all of which have different SACS 
mutations. Firstly, the molecular chaperone HSP70 accumulates in a single area 
adjacent to the nucleus in the ARSACS patient HDFs, and this is in the same subcellular 
region where the vimentin network is bundling and the mitochondrial network is 
disrupted (described in Chapter 4). Molecular chaperones are known to accumulate with 
aggregates of misfolded protein as they have a key role in refolding proteins or targeting 
misfolded proteins for degradation (Hartl and Martin, 1995). For example, the 
molecular chaperones HSP70 and HSP40 associate with insoluble, cytoplasmic 
polyglutamine-containing protein aggregates in a cellular model of HD (Waelter et al., 
2001). Furthermore, these molecular chaperones have been shown to be associated with 
Parkin-containing protein aggregates (Junn et al., 2002), and in Lewy bodies of PD 
brains (Auluck et al., 2002).  
Additionally, a perinuclear accumulation of ubiquitinated proteins and p62/SQSTM1 
occurs in the same region as HSP70 in the ARSACS patient HDFs. Ubiquitin tags 
misfolded proteins and targets them for degradation via the UPS or ALP, so this 
suggests the presence of accumulated misfolded proteins that have been targeted for 
degradation. Intracellular protein aggregates containing ubiquitinated proteins are 
detected in many neurodegenerative diseases (Bence et al., 2001; Juenemann et al., 
2015; Ross and Pickart, 2004). This is likely due to UPS impairment and/or its 
functional overload. The ubiquitin-containing protein aggregates identified in multiple 
neurodegenerative disorders also contain p62 (Kuusisto et al., 2001; Nakano et al., 
2004; Zatloukal et al., 2002). p62 binds to ubiquitinated proteins via its ubiquitin-
associated (UBA) domain, targeting them to the autophagy pathway for degradation. 
Inhibition of autophagy has been shown to lead to an increase in the size and number of 
p62-containing protein aggregates and p62 protein levels (Bjorkoy et al., 2005). So the 
observation that ARSACS patient HDFs show perinuclear accumulation of p62, 
suggests autophagy may be impaired. 
Collectively, the demonstration of HSP70, ubiquitin and p62 perinuclear accumulation 
in a single location in the ARSACS patient HDFs is reminiscent to that observed when 
intracellular protein aggregates form in many other neurodegenerative diseases. This 
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data adds support for the presence of perinuclear aggregates of misfolded protein in 
ARSACS.  
Furthermore, LAMP-2, a lysosome membrane marker required for lysosomal fusion 
with autophagosomes, also shows a perinuclear accumulation in the same region of the 
cell as HSP70, ubiquitin and p62, in the ARSACS patient HDFs. This indicates that 
lysosomes have been recruited to the area of the cell where other modulators of 
proteostasis are relocalising. This is potentially to promote removal of misfolded 
proteins that the data suggests has accumulated. Moreover, a microarray experiment 
performed on SH-SY5Y cells transfected with SCRM or SACS siRNA highlighted that 
LAMP2 is upregulated in SACS siRNA transfected cells compared to SCRM controls, a 
result which was verified by both RT-qPCR and immunoblotting.  
LAMP2 is upregulated in lysosomal storage diseases (LSDs), a family of disorders that 
result from inherited gene mutations that perturb lysosomal degradation. This ultimately 
leads to neurodegeneration in infancy/childhood (Wraith, 2002), and less commonly in 
adulthood (Nixon et al., 2008; Shapiro et al., 2008; Spada et al., 2006). An example is 
Gaucher disease, where a mouse model shows increased protein levels of LAMP-2 (Sun 
and Grabowski, 2010). Similar to other more common neurodegenerative diseases, 
LSDs also have cellular accumulations of dysfunctional mitochondria that cannot be 
degraded through mitophagy (Ezaki et al., 1996; Jennings et al., 2006; Takamura et al., 
2008), along with an accumulation of ubiquitinated and aggregate-prone proteins, 
including p62, α-synuclein and Huntingtin protein (Settembre et al., 2008; Suzuki et al., 
2007; Tessitore et al., 2009). Additionally, an increase in LAMP2 gene expression and 
protein levels has recently been identified in the peripheral leukocytes of coronary 
artery disease (CAD) patients due to an accumulation of lysosomes (Wu et al., 2011). 
Thus, like LSDs and CAD, an increase in LAMP-2 expression in cells with loss of 
sacsin function may indicate that autophagy-lysosome degradation is impaired, although 
this requires further investigation. 
Due to the research implicating mitochondrial dysfunction in ARSACS (Blumkin et al., 
2015; Criscuolo et al., 2015; Girard et al., 2012; Pilliod et al., 2015), a perturbation to 
autophagic degradation, and thus mitophagy, may lead to an accumulation of 
dysfunctional mitochondria in ARSACS patient cells. Dysfunctional mitochondria 
usually have a loss of membrane potential; hence MitoTracker Red, which is membrane 
potential dependent, would not accumulate in these mitochondria. So a perinuclear 
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accumulation of dysfunctional mitochondria would appear as negative MitoTracker Red 
staining, which could explain the presence of the perinuclear region of mitochondrial 
exclusion in the ARSACS patient HDFs. However, upon investigation using a TOM20 
antibody, which detects mitochondria regardless of membrane potential, the perinuclear 
area of mitochondrial disruption/exclusion was still present. Perhaps the elongated and 
hyperfused mitochondria in ARSACS patient cells are too large to be engulfed by 
autophagosomes, and are thus not being degraded through mitophagy and are 
accumulating within the cell. 
In conclusion, the data provided in both chapters 4 and 5 points towards the formation 
of an aggresome-like structure in cells due to loss of sacsin function. This may be 
forming due to an accumulation of misfolded protein, which is consistent with sacsin 
having a chaperone-linked role, with ablation of its function leading to problems with 
protein folding and/or degradation. Further work is required to verify this, as a 
disruption to normal proteostasis may contribute to disease pathogenesis in ARSACS.  
 
5.3.1. Further Work 
Further evidence is required to determine if misfolded proteins are accumulating in 
ARSACS. Most importantly, the next step is to determine the identity of any aberrantly 
folded protein species in the ARSACS patient cells. Since aggregated proteins tend to 
have reduced solubility, insoluble protein fractions from ARSACS patient and WT 
control HDF cell lysates could be generated. These protein fractions may then be 
analysed by SDS-PAGE, followed by Coomassie Blue staining, in order to observe 
protein bands that may be present in the ARSACS patients, but are absent in control 
protein. If a protein band(s) was observed to be present only in protein from ARSACS 
patient cells, this would be excised from the gel and submitted for mass spectrometry 
(MS) to determine the identity of the protein(s). Identified proteins would be prioritised 
for further analyses based on whether they have previously been linked to 
neurodegenerative or misfolding diseases. Following this, immunocytochemistry and 
confocal microscopy would be performed to investigate whether these candidate 
proteins are indeed localised to the aggresome-like structure in ARSACS patient HDFs.  
Additionally, in order to further characterise the perinuclear aggresome or aggresome-
like structures, transmission electron microscopy could be carried out on ARSACS 
patient HDFs. Aggresomes appear as large accumulations of closely packed electron-
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dense particles in the region of the centrosome, which are wrapped by bundles of 
filamentous material (Johnston et al., 1998).  
Furthermore, the subcellular localisation of other known markers of aggresomes, such 
as proteosomal subunits and other molecular chaperones, could be analysed in cells with 
loss of sacsin function, to further characterise the formation of aggresome-like 
structures in these cells. Additionally, mutant proteins that are known to form 
aggresomes, such as mutant rhodopsin (Saliba et al., 2002) and the ΔF508 mutation 
within CFTR (Burnett and Pittman, 2005), could be heterologously expressed in sacsin 
null cells to determine if these mutant proteins form aggresomes in the same perinuclear 
region of disruption identified in sacsin null cells. Immunoblotting of p62/SQSTM1 and 
ubiquitin to determine if their levels are increased in sacsin null cells would also 
increase the evidence for proteostasis disruption.  
Our research group is currently generating neurons derived from the ARSACS patient 
HDFs used in this thesis via induced pluripotent stem cell (iPSC) technologies. It will 
be necessary to confirm that the ARSACS cellular phenotypes identified in this thesis 
hold true in neurons, where the disease manifests. It is expected that the evidence 
produced for an accumulation of misfolded protein and formation of perinuclear 
aggresome-like structures in the ARSACS patient HDFs would also be identified in 
neuronal cells.  
Mitophagy could be further investigated in cells lacking normal sacsin, using PINK1 
and Parkin as markers of mitophagy. PINK1 accumulates at the OMM of defective 
mitochondria, which in-turn elicits the translocation of Parkin from the cytosol to 
mitochondria to mediate the clearance of damaged mitochondria (Geisler et al., 2010; 
Narendra et al., 2008; Narendra et al., 2009). Thus, immunoblotting for PINK1 and 
parkin in a mitochondrial fraction could be used to investigate mitophagy, along with 
immunocytochemistry to investigate the localisation of PINK1 and parkin in relation to 
mitochondria. Since a reduction in mitochondrial membrane potential is known to 
accompany mitophagy, the uncoupling agent CCCP, which induces mitochondrial 
membrane depolarisation, has been frequently used when investigating mitophagy 
(Khalil et al., 2015; Tanaka, 2010; Vives-Bauza et al., 2010). Additionally, the co-
localisation of LC3-II, a marker of autophagosomes, with mitochondria has been widely 
used to study mitophagy (Gomez-Sanchez et al., 2014; Kim et al., 2007; Narendra et al., 
2008). Mitophagy is also known to induce ubiquitination of the OMM fusion proteins 
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MFN-1 and MFN-2; hence this could be investigated by immunoblotting of 
mitochondrial fractions (Gegg et al., 2010; Gegg and Schapira, 2011).  
A microarray experiment on SH-SY5Y cells transfected with SCRM or SACS siRNA, 
and also on ARSACS patient and WT control HDF cell lines has been carried out in our 
group. In addition to LAMP2 (section 5.2.8), preliminary analysis of the results from 
this highlight other lysosome related genes that are dysregulated in cells with loss of 
sacsin, for example, the minor lysosome membrane protein sortilin 1 (SORT1), CD68, 
which is a member of the LAMP protein family, and several lysosomal acid hydrolases 
(cathepsins) are upregulated, while the V-ATPase subunits ATP6V0C and ATP6V0B are 
downregulated. These need to be verified by RT-qPCR and immunoblotting as this data 
would provide evidence suggesting lysosome dysfunction in cells due to loss of sacsin, 
which in-turn would lead to impaired autophagic protein degradation. 
In a sacsin knockout mouse model, an accumulation of non-phosphorylated NFH was 
identified (Lariviere et al., 2015). Similarly, alterations in neurofilament organisation 
have been identified in other neurodegenerative diseases (Al-Chalabi and Miller, 2003; 
Forno et al., 1986; Perrot and Eyer, 2009). Vimentin assembly and function is known to 
be regulated by phosphorylation state (Ivaska et al., 2007; Sihag et al., 2007). Site-
specific phosphorylation induces disassembly of vimentin filaments, and an increase in 
phosphorylation accompanies vimentin filament reorganisation in vivo (Inagaki et al., 
1987). Vimentin phosphorylation occurs at several sites by different kinases, for 
example, Rab-7a interacts with and modulates vimentin phosphorylation at positions 
Ser-38 and Ser-55, which affects assembly (Cogli et al., 2013). The site-specific 
phosphorylation state of vimentin could be investigated in the ARSACS patient cells as 
alterations to the phosphorylation state may accompany the vimentin filament 
reorganisation observed. 
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The ultimate aim of this thesis was to decipher the cellular role of sacsin by determining 
how loss of its function leads to the mitochondrial and intermediate filament defects 
identified in ARSACS. Data produced in this thesis provides evidence that the 
mitochondrial and intermediate filament defects may be the result of disrupted 
proteostasis. This is indicated by the formation of aggresome-like structures in sacsin 
deficient cells. Moreover, loss of sacsin leads to reduced DRP1-mediated mitochondrial 
fission, which is necessary for mitochondrial quality control. This likely explains the 
elongated and interconnected mitochondrial network in ARSACS, along with the 
mitochondrial dysfunction. Thus, the data suggests that sacsin has a key role in 
proteostasis, and defects in proteostasis likely have indirect consequences that disrupt 
mitochondrial quality control. 
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6.1. Disrupted Mitochondrial Fission in ARSACS 
The data produced in Chapter 3 provides evidence that the elongated mitochondrial 
network observed in ARSACS is a consequence of impaired DRP1-mediated fission, 
and implicates sacsin as a regulator of DRP1 mitochondrial association. This is 
important as mechanisms that modulate recruitment of DRP1 to the OMM are not fully 
defined. 
DRP1-mediated mitochondrial fission is crucial for survival. A complete loss of DRP1-
mediated mitochondrial fission is embryonic lethal in mice (Ishihara et al., 2009; 
Wakabayashi et al., 2009) and humans (Chang et al., 2010). DRP1 association with 
mitochondria is reduced rather than abolished in sacsin null cells, thus loss of sacsin is 
not embryonic lethal in mice or humans. This less severe ARSACS phenotype signifies 
that sacsin is not essential for DRP1-mediated fission, but may be required for normal 
regulation of mitochondrial division in some cell types.  
An important regulator of DRP1-mediated fission is the dynein-dynactin motor complex 
(Varadi et al., 2004). In Chapter 3, a novel role for the DCTN6 subunit in DRP1-
mediated fission was identified. Specifically, a putative interaction between DCTN6 
and DRP1 was observed by co-IP using heterologously expressed proteins. DRP1 
(Girard et al., 2012) and DCTN6 (Parfitt, 2011) have both previously been shown to 
have putative interactions with sacsin, and interestingly, the mitochondrial phenotype 
observed due to loss of DCTN6 is analogous to that observed due to loss of sacsin. This 
consists of an elongated and overly interconnected mitochondrial network, reduced 
mitochondrial localisation of DRP1, and significantly reduced mitochondrial membrane 
potential, which is indicative of an increase in dysfunctional mitochondria. These 
findings have lead to the hypothesis that sacsin and DCTN6 may function together in 
the recruitment or stabilisation of DRP1 on mitochondria. It is conceivable that sacsin 
may function as a chaperone in the complex assembly of DRP1 with the dynein-
dynactin subunit DCTN6, or perhaps sacsin stabilises DRP1 at the dynein-dynactin 
complex. DRP1 can then be transferred to mitochondria, which are also transported by 
the dynein-dynactin motor complex (Hollenbeck and Saxton, 2005). Once at 
mitochondria, it is known that DRP1 is recruited to the OMM by receptors, such as 
MFF and FIS1, in order to initiate fission (Figure 6.1). 
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DRP1-mediated fission is essential for mitochondrial quality control as it allows 
damaged parts of the mitochondrial network to be isolated from healthy mitochondria. 
Damaged mitochondrial fragments can then be engulfed by autophagosomes for their 
degradation by mitophagy (Arnoult et al., 2005; Gomes and Scorrano, 2008; Kageyama 
et al., 2014; Lu, 2009; Tanaka et al., 2010). Thus, the impairment in DRP1-mediated 
fission observed in sacsin or DCTN6 deficient cells likely leads to perturbations in 
mitophagy. Failure to remove dysfunctional mitochondria may explain the reduction in 
mitochondrial membrane potential observed in sacsin (Girard et al., 2012) and DCTN6 
deficient cells. This is discussed further in section 6.4.2.4.    
Impaired mitochondrial quality control is likely to be particularly detrimental in 
neurons. This is supported by the evidence that defects in mitochondrial dynamics, and 
thus quality control, contribute to numerous neurodegenerative diseases, including 
Alzheimer’s and Parkinson’s (Bereiter-Hahn, 2014; Chen and Chan, 2009; Itoh et al., 
2013). An accumulation of dysfunctional mitochondria in ARSACS patient neurons due 
to impaired mitophagy could mean that the relatively high energetic demands of the 
neurons cannot be met. This likely leads to neurotoxicity and contributes to the Purkinje 
cell death in ARSACS (Winslow and Rubinsztein 2008; Nixon et al., 2008). 
Mitochondrial transport to the cell periphery is also impaired in ARSACS. Specifically, 
an accumulation of mitochondria occurs in the soma and proximal dendrites of cultured 
hippocampal neurons after sacsin knockdown (Girard et al., 2012). Mitochondrial 
motility is also significantly reduced in axons of Sacs-/- mice motor neurons (Lariviere 
et al., 2015). This may be due to a direct effect of loss of sacsin on mitochondrial 
transport, or an indirect effect, through reduced mitochondrial fission. In support of the 
latter, it has previously been suggested that elongated mitochondria are poorer 
substrates for anterograde motors, such as kinesin. Hence, mitochondrial transport to the 
cell periphery becomes impaired, resulting in a perinuclear accumulation of elongated 
mitochondria (Varadi et al., 2004). Disruption of mitochondrial transport into dendrites 
has been shown to lead to abnormal dendritic morphology, and striking alterations are 
observed in the organisation of dendritic fields in the cerebellum of Sacs-/- mice, which 
precedes Purkinje cell death (Lariviere et al., 2015). Thus, the reduction in DRP1-
mediated mitochondrial fission in sacsin deficient cells may ultimately contribute to the 
Purkinje cell death and neurodegeneration in ARSACS. 
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6.2. Cellular Localisation of Sacsin 
In Chapter 4, evidence was provided to suggest a novel association of sacsin with 
vimentin, and the possibility that this association may be mediated through sacsin’s 
HSP90-like domains was discussed (section 4.3). Due to its massive size, heterologous 
expression of full-length sacsin (open reading frame of >12000bp) is difficult. Hence, 
previous studies investigating sacsin interactors have used specific regions of sacsin, for 
example the N-terminal (Girard et al., 2012; Parfitt, 2011) or C-terminal (Lim et al., 
2006) regions. Since two of sacsin’s HSP90-like domains are located outside of these 
regions, this may explain why an interaction between sacsin and vimentin has not yet 
been identified.  
Sacsin is a co-chaperone/putative chaperone and several molecular chaperones are 
known to associate with IFs. Thus, sacsin may have a role related to, or as part of, a 
functional chaperone network with these other molecular chaperones. The small heat 
shock proteins (sHSP), HSP27 and αB-crystallin, associate with several types of IFs, 
such as vimentin, GFAP, keratin and desmin (Perng et al., 1999; Vicart et al., 1998; 
Wisniewski and Goldman, 1998). It has been proposed that one of the major functions 
of this association of sHSPs with IFs is to manage inter-filament interactions (Perng et 
al., 1999). The association of these sHSP is not restricted to a particular IF type, hence it 
would be interesting to investigate whether sacsin associates with other IFs besides 
vimentin.  
HSP27 and αB-crystallin also associate with IF aggregates in certain human pathologies 
(Iwaki et al., 1993; Iwaki et al., 1989), and mutations in αB-crystallin lead to desmin 
aggregation in desmin-related myopathies (Vicart et al., 1998). Both desmin and αB-
crystallin are found in the aggregates. The co-collapse of IFs with mutated sHSPs is 
comparable to what is observed for mutated sacsin and vimentin filaments in some 
ARSACS patient HDF lines (Figure 4.9). HSP27 and αB-crystallin may also associate 
with the vimentin bundles in the ARSACS patient HDFs, although this requires 
investigation.  
So perhaps, similar to these sHSPs, sacsin has a chaperone-like function with IFs, and is 
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6.2.1. Sacsin as a cytoskeletal linker 
In Chapter 4, with the aid of super resolution microscopy, areas where sacsin punctae 
localised between mitochondria and vimentin filaments were identified, indicating that 
sacsin may contact both mitochondria and vimentin simultaneously. This is a feature of 
cytolinker proteins, and suggests that sacsin may bridge together mitochondria and IFs. 
Plectin, a cytoskeletal linker protein of a similarly large size to sacsin (500 kDa), 
mediates interactions between IFs and mitochondria (Winter et al., 2008), as well as 
acting as a mechanical linker between IFs and other cytoskeletal structures and 
organelles, including actin and microtubules (Wiche et al., 2015). Mutations in plectin 
cause epidermolysis bullosa simplex with muscular dystrophy (EBS-MD), which is 
characterised by a severe disorganisation and aggregation of desmin IFs, along with 
mitochondrial dysfunction (Schroder et al., 2002). Interestingly, IF aggregation and 
mitochondrial dysfunction are the two most prominent cellular phenotypes identified in 
sacsin deficient cells; therefore sacsin may have a similar cellular role to plectin. 
Intriguingly, MitoTracker staining of mitochondria in muscle fibres of plectin 1b or 
plectin 1d knockout mice revealed mitochondria-free areas, which the authors denoted 
as ‘black holes’ (Winter et al., 2015). This may be similar to the perinuclear ‘holes’ in 
the mitochondrial network seen in the ARSACS patient HDFs. Aggregation of the 
desmin IF network is also observed in these knockout mice (Winter et al., 2015).  
Since a proportion of sacsin is seen to be localised between mitochondria and IFs, and 
loss of sacsin leads to similar cellular phenotypes to those seen with loss of plectin 
function, this may indicate that sacsin has a similar cytoskeletal linker function as 
plectin. 
Supporting a role for sacsin with the cytoskeleton, putative interactions have been 
observed between the C-terminus of sacsin and several cytoskeletal-linked proteins, 
namely the microtubule-associated protein 1A (MAP1A, (Anderson, 2011)) and α-
actinin-4 (ACTN4, (Lim et al., 2006)).  
MAP1A is expressed almost exclusively in the brain (Huber and Matus, 1984) and 
binds to microtubules, forming cross-bridges between microtubules and/or microtubules 
with other cellular structures, including actin and IFs (Pedrotti et al., 1994; Shiomura 
and Hirokawa, 1987). Thus, if this putative interaction was real, MAP1A may represent 
an important link between sacsin and IFs.  
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ACTN4 belongs to a family of actin-binding proteins that cross-link and bundle actin 
filaments (Otey and Carpen, 2004). They are also involved in the organisation of the 
submembranous cortical cytoskeleton (Pelletier et al., 2003; Wachsstock et al., 1993). 
Microtubules, actin and IFs networks are interlinked through multiple cytoskeletal 
associated proteins (CAPs (Fuchs and Cleveland, 1998; Leung et al., 1999)); hence 
sacsin may be an important organiser of the cytoskeletal network, perhaps indirectly 
through its interactions with other CAPs, like MAP1A and ACTN4.  
Moreover, preliminary analysis of sacsins protein sequence using the bioinformatics 
tool, Homology detection & structure prediction (HHpred), predicts that sacsin may 
contain a CAP-Gly (glycine-rich cytoskeleton-associated protein)-like domain within 
the C-terminal 4175-4304 amino acids (Figure 6.2). CAP-Gly domains are conserved 
motifs (GKNDG) identified in numerous CAPs, including restin, dynactins and CLIP-
170 (Figure 6.2 (Riehemann and Sorg, 1993)).  
 
 
Figure 6.2. Structure-aided alignment of the C-termius of sacsin with cytoskeletal 
associated proteins containing a CAP-Gly domain. Accession numbers of the 
proteins that sacsin aligns with are as follows: Dynactin-1: NP_004073.2, Restin: 
NP_002947.1, CLIP-170: NP_056341.1. The position of each sequence is indicated at 
the start of each sequence. Identical amino acids between the sequences are indicated in 
bold red. The conserved CAP-Gly motif (GKNDG) is indicated by the blue box. 
 
The predicted CAP-Gly domain is in the same C-terminal region of sacsin that was used 
to identify a putative interaction with ACTN4 (Lim et al., 2006), and part of the same 
region used to identify a putative interaction with MAP1A (Anderson, 2011). Thus, 
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perhaps a CAP-Gly domain within sacsin is mediating interactions with these proteins, 
and possibly other cytoskeletal proteins. This adds further support indicating that sacsin 
may have a role in mediating cytoskeletal interactions or functions. 
Sacsins predicted CAP-Gly domain could be investigated in future work. Cellular 
localisation and fractionation studies could be performed using C-terminal constructs of 
sacsin to investigate an interaction with the cytoskeleton. Also, site-directed 
mutagenesis within this C-terminal region could be performed to investigate whether 
mutations in this region affect an association with the cytoskeleton.  
 
6.3. Intermediate Filament Disruption in ARSACS 
It is intriguing that not only an association between sacsin and vimentin was identified 
in this thesis, but that a collapse and perinuclear bundling of the vimentin network was 
identified in ARSACS patient HDFs and SH-SY5Y cells transfected with siRNA 
targeting sacsin. This data suggests that sacsin may have a role in maintaining the 
vimentin IF network.  
In addition to the vimentin network disruption in ARSACS patient HDFs, neurons from 
Sacs-/- knockout mice and ARSACS brains display specific accumulations of non-
phoshorylated NFH (npNFH, Lariviere et al., 2015). Aberrantly phosphorylated IF 
accumulations may be the result of disrupted turnover or abnormal post-translational 
modifications. Many properties of IFs are tightly associated with phosphorylation state, 
thus disrupting this may affect IF assembly and organisation. For example, mutating a 
phosphorylation site in NF-L leads to the formation of NF-L inclusions in the cell 
bodies of neurons from transgenic mice, along with the development of swollen 
Purkinje cell axons (Gibb et al., 1998). The phosphorylation state of the vimentin 
accumulations in ARSACS patient HDFs is yet to be determined.  
So like the previously identified mitochondrial phenotype, multiple cell types display IF 
disruptions in ARSACS, which suggests that a neurofilament-specific function for 
sacsin is unlikely, and rather, sacsin has a more general role with IFs. 
Giant axonal neuropathy (GAN) is also characterised by abnormal accumulations of IF 
proteins in multiple cell types (Bomont and Koenig, 2003; Cleveland et al., 2009; 
Gordon, 2004). The defective protein, gigaxonin, is proposed to function as a substrate 
adaptor for an E3 ubiquitin ligase, which affects proteasome-dependent degradation of 
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microtubule-related proteins, including MAP1B, MAP8 and the tubulin folding 
chaperone TBCB (Allen et al., 2005; Cleveland et al., 2009; Ding et al., 2006; Wang et 
al., 2005b). Ablation of gigaxonin causes a substantial accumulation of MAP1B in 
neurons (Allen et al., 2005).  
IFs are known to redistribute into perinuclear cage-like structures that surround 
inclusion bodies and aggresomes that have formed due to proteostasis disruption in 
many neurodegenerative diseases (Mayer et al., 1989). Hence, the IF rearrangements 
observed in GAN may reflect the formation of IF-cage like structures around protein 
aggregates that have accumulated due to disrupted proteasome-dependent degradation. 
In support of this, the abnormal IF accumulations are in close proximity to the MTOC 
(Bomont and Koenig, 2003), which is where inclusion bodies/aggresomes are known to 
form.  
Lewy bodies in PD and hyaline inclusions in ALS are surrounded by NFs, and the 
inclusion bodies in Pick’s disease are surrounded by the IF protein GFAP (Mayer et al., 
1989). The purpose of this cage-like IF structure is unclear, although it may promote the 
stability of the inclusion/aggresome or prevent non-specific interactions with other 
proteins within the cytoplasm (Mayer et al., 1989).  
This IF rearrangement into a perinuclear cage-like structure coincides with what was 
observed in the ARSACS patient HDFs in Chapter 4. So rather than a direct effect of 
loss of sacsin function on the IF network, perhaps loss of sacsin leads to disrupted 
proteostasis, which in-turn leads to the collapse of the IF network around aggresomes. 
Further supporting this, other organelles, such as mitochondria, the Golgi, and early 
endosomes, become relocalised around the periphery of the IF cage-like structure. 
These are key characteristics seen in other cells when aggresomes form (Garcia-Mata et 
al., 1999; Lee et al., 2011; Saliba et al., 2002; Waelter et al., 2001). 
This could also explain the accumulations of NFs in neurons from Sacs-/- mice and 
ARSACS brains. Interestingly, axonal torpedoes (rounded swellings of Purkinje cell 
axons) were identified in the Sacs-/- mice (Lariviere et al., 2015). Similar axonal 
torpedoes identified in essential tremor (ET), a common neurological disease, have 
accumulations of disorganised NFs within the torpedoes (Louis et al., 2009). 
Mitochondria and smooth ER were also abundant, particularly at the periphery of the 
torpedoes (Louis et al., 2009). Thus, the axonal torpedoes in the Sacs-/- mice may 
represent the formation of inclusions containing NF accumulations, possibly with 
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mitochondria and other organelles at the periphery of the torpedoes. These cellular 
characteristics are akin to those identified in the ARSACS patient HDFs. 
The potential formation of aggresomes in ARSACS patient cells suggests that 
proteostasis may be disrupted due to loss of sacsin function.  
 
6.4. Disrupted Proteostasis in ARSACS 
Many neurodegenerative diseases are now recognised as ‘conformational diseases’, 
because they are characterised by an accumulation of misfolded protein and the 
formation of intracellular or extracellular protein aggregates. Together with the 
misfolded protein, aggregates tend to include the presence of proteostasis components, 
such as ubiquitin and HSP70 (Table 6.1). Similar to these conformational diseases, 
ARSACS patient HDFs display the characteristic features of aggresomes, which 
includes the accumulation of proteostasis components, such as HSP70, ubiquitin and 
p62 (Table 6.1). This suggests the possibility of protein aggregate formation due to 
disrupted proteostasis. Thus, further research may lead to ARSACS also being 
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Table 6.1. Characteristics of protein aggregates in conformational diseases  
Disease Proteins 
involved 
Protein deposit Additional protein 
components 




















Huntington’s disease Huntingtin 
Nuclear, 
cytoplasmic  

























GFAP: glial fibrillary protein, CFTR: cystic fibrosis transmembrane regulator, UCH-
L1: ubiquitin carboxy-terminal hydrolase L1, SCAs: Spinocerebellar ataxia. Adapted 
from (Garcia-Mata et al., 2002). 
 
 
Some conformational diseases are caused by mutations in proteins that are key 
regulators of proteostasis (Cataldo et al., 1996; Kegel et al., 2000; Keller et al., 2000; 
McNaught et al., 2001; Mittal and Ganesh, 2010). These proteins typically contain 
domains that mediate interactions with polyubiquitinated proteins or the proteasome, 
such as an UbL or UbA domain, or UIMs (Grabbe and Dikic, 2009; Su and Lau, 2009). 
An example is the E3 ubiquitin ligase Parkin, which localises to Lewy bodies in 
sporadic PD patients (Murakami et al., 2004; Schlossmacher et al., 2002; Shimura et al., 
2001), and to aggresomes formed in cultured cells induced by proteasomal impairment 
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(Junn et al., 2002; Muqit et al., 2004; Zhao et al., 2003). Similarly, ataxin-3 interacts 
with subunits of the proteasome and has a putative role in protein degradation (Berke et 
al., 2005; Doss-Pepe et al., 2003; Tsai et al., 2003). WT ataxin-3 is found in intranuclear 
inclusions in spinocerebellar ataxia (Uchihara et al., 2001) and in aggresomes formed 
by expression of the ΔF508 mutation within the cystic fibrosis transmembrane 
conductance regulator (CFTR, (Burnett and Pittman, 2005)). Ablation of ataxin-3 
function leads to cytoskeletal disorganisation, ubiquitin-positive aggregate formation 
and specific neuronal death. 
As described in the introduction to this thesis (section 1.4.3.2), mutations have also 
been identified in DNAJ co-chaperones, which cause disrupted proteostasis, aggregate 
formation and neurodegeneration (Blumen et al., 2012; Chapple and Cheetham, 2003; 
Gess et al., 2014; Koutras and Braun, 2014; Mitsuhashi and Kang, 2012).  
Sacsin is a member of the DNAJ family of proteins (DNAJC29) due to the presence of a 
J-domain. Additionally, sacsin also contains an UbL domain and UIMs, and several 
HSP90-like domains, which all suggest that sacsin may be a key regulator of 
proteostasis. Furthermore, this thesis has demonstrated that loss of sacsin function leads 
to cellular characteristics that resemble what is observed when proteostasis is disrupted. 
Specifically, the intracellular organisation of ARSACS patient HDFs dramatically alters 
and is indicative of the formation of aggresomes. This is comparable to cells from 
patients with autosomal dominant, demyelinating CMT type 1C (CMT1C), where 
aggresomes are encaged by vimentin and enriched with ubiquitin and HSP70 (Lee et al., 
2011). Moreover, the intracellular organisation of ARSACS patient HDFs is analogous 
to cells that have formed aggresomes due to mutant rhodopsin (Kaushal and Khorana, 
1994; Olsson et al., 1992; Roof et al., 1994; Saliba et al., 2002). This includes the 
relocalisation of vimentin into cage-like structures close to the MTOC, disruption to 
Golgi localisation, recruitment of HSC70 and ubiquitin to the aggresome, and the 
structures were surrounded by mitochondria (Saliba et al., 2002).  
These are all cellular phenotypes that were identified in the ARSACS patient HDFs, 
thus indicating that aggresomes may be forming as a result of disrupted proteostasis. In 
line with this hypothesis, the microtubule network appears to be intact in ARSACS 
patient HDFs, so protein aggregates can be transported along microtubules to the 
MTOC where aggresomes form. Additionally, like WT ataxin-3, WT sacsin is recruited 
to expanded ataxin-1 nuclear inclusions (82Q), implying that sacsin may have a 
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protective role against expanded ataxin-1 induced toxicity (Parfitt et al., 2009). It would 
be interesting to investigate if sacsin is recruited to inclusions formed in other 
neurodegenerative diseases, such as intranuclear inclusions of aggregated huntingtin 
containing polyQ expansions in HD. Considering the data, the pathogenesis of 
ARSACS may be caused by similar pathological mechanisms to that of other 
conformational diseases. 
Originally, it was assumed that the formation of aggresomes or inclusion bodies 
containing aggregated proteins were the cause of cellular toxicity in neurodegenerative 
diseases. However, it is now thought that they may serve a neuroprotective role 
(Caughey and Lansbury, 2003; Tanaka et al., 2004; Taylor et al., 2003), and provide a 
way for cells to remove aggregated proteins from the cytosol, where they may interfere 
with cellular functions. Blocking aggresome formation has been shown to enhance the 
cytotoxicity of mutant proteins in various neurodegenerative diseases (Taylor et al., 
2003; Tanaka et al., 2004), suggesting a protective role for aggresome formation.  
Increasing evidence suggests that aggresome formation serves as a mechanism for 
concentrating misfolded and aggregated proteins for subsequent clearance by autophagy 
(Chin et al., 2010; Fortun et al., 2003; Iwata et al., 2005a; Taylor et al., 2003). 
Supporting this, autophagic machinery has been found to localise to inclusions, 
including those formed in mouse models of polyglutamine disease (Iwata et al., 2005a), 
and Lewy bodies in PD (Iwata et al., 2005a). Importantly, in Chapter 5, autophagic 
markers were shown to accumulate with the aggresome-like structures in the ARSACS 
patient HDFs (discussed further in section 6.4.1).  
Studies have also shown that the clearance of aggresomes can be facilitated by the 
induction of autophagy and blocked by autophagic dysfunction (Fortun et al., 2003; 
Ravikumar et al., 2002; Yamamoto et al., 2006; Ravikumar et al., 2004). Interestingly, 
there is evidence for autophagic dysfunction in ARSACS. 
 
6.4.1. Autophagy dysfunction in ARSACS 
In neurons, protein quality control mechanisms are crucial to identify abnormal proteins 
and/or damaged organelles and assure their autophagic degradation before their 
accumulation leads to neurotoxicity (Winslow and Rubinsztein 2008; Nixon et al., 
2008). Autophagic dysfunction has been directly linked to a growing number of 
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neurodegenerative diseases, including AD, PD, HD and ALS (Lee, 2012; Ravikumar et 
al., 2002; Stefanis et al., 2001; Webb et al., 2003).  
Defective autophagy is indicated by an abnormal accumulation of autophagosomes, 
particularly in the affected neurons in neurodegenerative diseases (Nixon et al., 2005; 
Yang et al., 2007). This may be due to increased autophagic activity, meaning that more 






Figure 6.3. Schematic representation of autophagy when turnover is blocked vs. 
normal autophagic flux. (A) Following the induction of autophagy, autophagic 
substrates and/or damaged organelles are engulfed by an isolation membrane known as 
a phagophore. This expands into an autophagosome, which fuses with lysosomes 
(autolysosome) to degrade their contents by the action of lysosomal hydrolases, 
allowing complete flux through the pathway. (B) Autophagy is initiated, but a defect in 
autophagosome turnover due, for example, to a block in fusion with lysosomes or 
disruption of lysosomal functions, results in an increased number of autophagosomes. 
So, autophagy has been induced, but there is no or limited autophagic flux. 
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In AD, autophagy is induced and the clearance of autophagosomes is impaired, leading 
to autophagosome accumulation in dystrophic neurites (Boland et al., 2008). In PD, 
mutations in α-synuclein result in upregulated autophagy (Lynch-Day et al., 2012), and 
likewise, in HD, increased autophagy results in excess autophagosomes in brains from 
HD patients (Lynch-Day et al., 2012; Lee, 2012). Increased numbers of 
autophagosomes promotes neuronal cell death due to an accumulation of toxic proteins 
(Lee, 2012). 
Several autophagosome and lysosome markers are typically used when investigating 
autophagy dysfunction. Inhibition of autophagy results in an increase in size and 
number of p62/SQSTM1-containing inclusion bodies, along with an increase in 
p62/SQSTM1 protein levels (Bjorkoy et al., 2005; Nagaoka et al., 2004; Rusten and 
Stenmark, 2010; Zatloukal et al., 2002). This is coupled with an accumulation of 
ubiquitin-containing aggregates (Nagaoka et al., 2004; Zatloukal et al., 2002). 
Intriguingly, perinuclear p62/SQSTM1 and ubiquitin accumulations were identified in 
the ARSACS patient HDFs, which is comparable to that observed in many other 
neurodegenerative diseases. For example, p62/SQSTM1 is present in neuronal and glial 
inclusions in AD and frontotemporal lobar degeneration (Pikkarainen et al., 2008), 
inclusions in Pick’s disease and PD (Kuusisto et al., 2002), and polyQ-containing 
inclusions in SCAs (Pikkarainen et al., 2011).  
Furthermore, during autophagy, a cytosolic form of microtubule-associated 1A/1B-light 
chain 3 (LC3-I) is conjugated to phosphatidylethanolamine to form LC3-
phosphatidylethanolamine conjugate (LC3-II), which is recruited to autophagosomal 
membranes. So the number of autophagosomes is correlated with the amount of LC3-II 
protein. LC3-II is found in Lewy bodies in patients with sporadic PD (Alvarez-Erviti et 
al., 2010; Dehay et al., 2010). LC3-II protein levels and localisation are yet to be 
determined in sacsin deficient cells. 
Additionally, an accumulation of lysosomes can be identified by observing the 
expression levels of the late endosome and lysosome membrane proteins LAMP-1 and 
LAMP-2 (Sun and Grabowski, 2010; Wu et al., 2011; Zaglia et al., 2014). LAMP-1 is 
found in Lewy bodies in patients with sporadic PD (Chu et al., 2009). Interestingly, 
LAMP-2 accumulations were observed within the aggresome-like structures in the 
ARSACS patient HDFs. Along with this, a significant increase in LAMP-2 was 
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identified at the transcript and protein level in sacsin deficient cells, which may suggest 
lysosome accumulation (Wu et al., 2011).  
Together, increased levels of LC3-II, p62/SQSTM1, LAMP-1 and LAMP-2 indicate 
autophagy disruption (Fetalvero et al., 2013; Kinouchi et al., 2010). Thus, the data 
presented in the ARSACS patient HDFs points towards autophagic disruption. 
Interestingly, acetylation of microtubules has been suggested to be required for the 
fusion of autophagosomes with lysosomes (Xie et al., 2010). This is because 
microtubule acetylation allows the recruitment of the molecular motors dynein and 
kinesin-1 to microtubules, enabling increased transport of vesicles along microtubules 
(Bulinski, 2007; Dompierre et al., 2007). This may explain the observed increase in 
acetylation of α-tubulin in the ARSACS patient HDFs (section 4.2.4.1). A disruption to 
autophagy may lead to an accumulation of autophagosomes, which in-turn may lead to 
a compensatory increase in the transport of autophagosomes to lysosomes in order for 
them to be degraded.  
This thesis has presented evidence of disruption to autophagy-mediated protein 
degradation in ARSACS patient HDF. This is analogous to other neurodegenerative 
diseases and may be due to an upregulation of the pathway and/or impaired lysosomal 
degradation and reduced clearance of autophagosomes. If aggregates of misfolded 
proteins cannot be removed by autophagy, this could explain the aggresome-like 
structures observed in the ARSACS patient HDFs. 
 
6.4.2. Potential mechanisms of autophagy dysfunction in ARSACS 
Interestingly, Y2H screening previously carried out in our group identified putative 
interactions between the N-terminal region of sacsin encompassing the UbL domain 
(amino acids 1-650) and ATP6AP2 (ATPase 6 accessory protein 2), snapin, DCTN6, 
and CSN5, a component of the COP9 signalsome (Parfitt, 2011). This is also the same 
region of sacsin that has been shown to interact with DRP1 by co-IP (Girard et al., 
2012). These proteins all link to roles in protein degradation via the UPS or autophagy 
pathways (Figure 6.4), so it is plausible that loss of sacsin function may affect the 
localisation or function of these interacting proteins, which may lead to impaired UPS 
and autophagy-mediated degradation, most likely of a specific client. 
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Figure 6.4. Putative interactions between the N-terminal region of sacsin 





ATP6AP2 is an essential accessory component of V-ATPase, a large multisubunit 
complex that has an important function in maintaining the acidic pH in lysosomes and 
endosomes, and in ensuring the fusion of autophagosomes with endosomes and 
lysosomes (Toei et al., 2010). Thus, the V-ATPase is required for lysosomal 
degradation. 
V-ATPase is composed of an 8-subunit V1 sector that is responsible for ATP hydrolysis 
and a 6-subunit V0 sector that serves as a transmembrane proton channel (Peters et al., 
2001; Yokoyama and Imamura, 2005). ATP6AP2 is specifically associated with the V0 
sector, and loss of ATP6AP2 protein destabilses V0, preventing its assembly, which 
results in deacidification of lysosomes (Kinouchi et al., 2010). So, loss of sacsin may be 
detrimental to ATP6AP2 function, which in-turn may compromise V0 assembly and 
disrupt lysosome function. This could explain the phenotypic characteristics indicating 
autophagy dysfunction in the ARSACS patient HDFs.  
Intriguingly, preliminary observations from a microarray experiment performed by our 
group on four ARSACS patient and two WT control HDF lines indicate a 
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downregulation of the V0 subunits ATP6V0B and ATP6V0C (0.77 and 0.75 fold change, 
respectively) in the ARSACS patient HDF lines. If this data is confirmed by RT-qPCR 
and immunoblotting, it provides evidence for destabilisation of the V0 sector in 
ARSACS patient HDFs, which may be mediated by ATP6AP2 dysfunction. In-line with 
this, others have shown that loss of ATP6AP2 function leads to significantly decreased 
protein levels of V0 subunits, including ATP6V0C (Kinouchi et al., 2010; Kinouchi et 
al., 2013). 
Furthermore, ATP6AP2 loss of function studies describe cellular and molecular 
phenotypes that resemble what has been observed in the ARSACS patient HDFs 
(Hedera et al., 2002; Korvatska et al., 2013; Ramser et al., 2005).  For example, cardiac-
specific ATP6AP2 conditional-knockout mice show perinuclear accumulation of 
autophagosomes, along with an accumulation of LAMP-2, LC3-II and p62 (Kinouchi et 
al., 2010).  
Perhaps sacsin has a role in targeting ATP6AP2 to the V0 sector of the V-ATPase, or in 
targeting V-ATPase to lysosomes, which would be a similar role to the AD-related 
protein PS1 (Lee et al., 2010). 
 
6.4.2.2. Snapin 
Snapin has a critical role in the autophagy-lysosome pathway in neurons (Cai et al., 
2010; Cai and Sheng, 2011). Snapin assists the dynein-driven retrograde transport of 
late endosomes to lysosomes for degradation of their contents. This is via a direct 
interaction between snapin and the dynein intermediate chain (DIC, (Cai et al., 2010)). 
Snapin-/- neurons show an increase in expression of LAMP-1 and LAMP-2, along with 
increased LC3-II positive autophagosomes, polyubiquitinated proteins and 
p62/SQSTM1 (Cai et al., 2010; Lu et al., 2009). This suggests aberrant accumulation of 
autophagosomes and reduced lysosomal degradation, which results in reduced neuron 
viability and neurodegeneration (Cai et al., 2010; Lu et al., 2009; Zhou et al., 2011).  
If an interaction between snapin and sacsin is verified by co-IP, then loss of sacsin may 
be detrimental to snapin function, which in-turn may compromise late endosome 
transport and lysosomal degradation in sacsin deficient cells.   
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6.4.2.3. COP9 signalsome 
The COP9 signalosome (CSN) comprises of eight essential subunits (CSN1-CSN8) and 
is responsible for the regulation of the UPS (Su et al., 2011; Wei et al., 2008). A 
putative interaction was shown between sacsin and the CSN5 subunit, also known as 
COPS5. Interestingly, ablation of one of the subunits, CSN8, compromises UPS 
function and results in excessive accumulation of autophagosomes (Su et al., 2011). 
Loss of CSN5 function may have a similar effect, so if loss of sacsin function is 
detrimental to CSN5 function, a disruption to the UPS may occur and an accumulation 
of autophagosomes may be observed.   
 
6.4.2.4. DRP1 
A putative interaction has been identified between sacsin and DRP1 by co-IP (Girard et 
al., 2012), and importantly, a significant reduction in mitochondrial localised DRP1 in 
sacsin knockdown cells was demonstrated in Chapter 3 of this thesis. This is also 
observed in ARSACS patient HDFs (Bradshaw et al., 2016). Since DRP1-mediated 
mitochondrial fission is required for the removal of damaged/dysfunctional 
mitochondria by mitophagy, sacsin deficient cells potentially accumulate dysfunctional 
mitochondria. This is evident in various models of ARSACS, including sacsin 
knockdown cells (Girard et al., 2012), Purkinje neurons from Sacs-/- mice (Girard et al., 
2012) and ARSACS patient HDFs (Criscuolo et al., 2015; Bradshaw et al., 2016). Thus, 
reduced Drp1-mediated fission represents a mechanism contributing to the decline of 
mitochondrial health in ARSACS. 
Data from Chapter 5 (Figure 5.10) suggests that dysfunctional mitochondria are not 
accumulating within the perinuclear region where ubiquitin, HSP70, p62 and LAMP-2 
accumulate in the ARSACS patient HDFs. This is consistent with the theory of 
impaired mitophagy in ARSACS. The hypothesis is that reduced DRP1-mediated 
mitochondrial fission in ARSACS means that dysfunctional mitochondrial fragments 
cannot be sequestered for autophagic degradation, thus are not transported to the 
MTOC. Additionally, as suggested by Gomes and Scorrano (2013), the resulting 
elongated and hyperfused mitochondria may be too large to be engulfed by 
autophagosomes (Gomes and Scorrano, 2013). This results in an accumulation of 
dysfunctional mitochondria, thus contributing to the molecular pathology of ARSACS. 
This hypothesis is in-line with previous data showing that reduced mitochondrial fission 
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impairs mitophagy (Arnoult et al., 2005; Gomes and Scorrano, 2013; Parone et al., 
2008; Twig et al., 2008). 
 
6.4.2.5. DCTN6 
DCTN6 may be linked to the autophagy pathway of protein degradation via several 
avenues. Firstly, in Chapter 3, an interaction was identified between heterologously 
expressed DCTN6 and DRP1. DCTN6 siRNA-mediated knockdown also resulted in a 
significant reduction in mitochondrial localised DRP1, along with an elongated 
mitochondrial network. Thus, DCTN6 function may also be important for mitochondrial 
quality control through maintaining DRP1-mediated mitochondrial fission. DCTN6 
knockdown also lead to a reduction in mitochondrial membrane potential, suggesting an 
accumulation of dysfunctional mitochondria may be occurring, which may be attributed 
to impaired mitophagy. Varadi et al (2004) have previously shown that the dynein-
dynactin complex is required for DRP1 recruitment to mitochondria (Varadi et al., 
2004), which supports that this motor complex may be, indirectly, necessary for 
mitophagy.  
The dynein-dynactin motor is also required for the retrograde transport of 
autophagosomes along microtubules to lysosomes (Ravikumar et al., 2005; Rubinsztein 
et al., 2005). Reduced dynein-dynactin function impairs autophagic clearance of 
aggregate-prone proteins, leading to the accumulation of protein aggregates and 
inclusion formation. This is observed when the dynactin subunit, p150Glued, is mutated, 
which causes a motor neuron disease (Levy et al., 2006; Puls et al., 2003).  
So if loss of sacsin function interferes with DCTN6 function, this may impair 
autophagic degradation, which may contribute to the accumulation of dysfunctional 
mitochondria observed in ARSACS, and possibly protein aggregation and aggresome 
formation.  
 
In summary, it is compelling that putative interactions have been identified between the 
N-terminus of sacsin and five proteins involved in protein degradation pathways. This, 
together with the evidence produced in this thesis for disrupted proteostasis in 
ARSACS, strongly suggests a role for sacsin in proteostasis. This could be a direct role, 
or an indirect role, through interactions with other key regulators of proteostasis, such as 
ATP6AP2, snapin, DCTN6, COPS5 and DRP1. Given the large size of sacsin and the 
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multiple functional domains, it is feasible that sacsin may act as a scaffold protein, 
interacting with multiple members of the proteostasis pathway.  
 
6.4.3. Further work to investigate autophagy dysfunction in ARSACS 
Further research is required to investigate a role for sacsin in proteostasis. The number 
of autophagosomes is correlated with the amount of LC3-II protein. Increased LC3-II 
along with reduced LC3-I levels would indicate an accumulation of autophagosomes in 
sacsin deficient cells, hence would help to determine if autophagy is impaired. This 
could be investigated using immunoblotting and immunocytochemistry in sacsin 
deficient cells compared to controls. 
Also, dual immunocytochemistry for LC3-II and LAMP-2 followed by high-resolution 
confocal microscopy could be performed in sacsin deficient and control cells. If these 
two proteins do not co-localise, then it suggests that autophagosome-lysosome fusion 
may be perturbed, which blocks autophagic flux and autophagosome clearance (Zaglia 
et al., 2014). 
Our research group carried out a microarray experiment on SH-SY5Y cells transfected 
with SCRM or SACS siRNA, and on ARSACS patient and WT control HDF cell lines. 
Preliminary analyses of the results from this highlight various autophagy-related genes 
that are dysregulated in cells with loss of sacsin. For example, ATG5 is upregulated by 
1.25-fold, and CTSH and CTSB, which encode lysosomal cathepsins, are upregulated by 
1.22-fold and 1.24-fold, respectively. These need to be verified by RT-qPCR and 
immunoblotting as this data would provide evidence suggesting autophagic dysfunction 
in cells due to loss of sacsin. 
The putative interactions between sacsin and ATP6AP2, snapin, COPS5, and DCTN6 
also need to be verified. A number of methods could be used, for example, Co-IP 
studies, subcellular immunofluorescent co-localisation studies or tissue 
immunohistochemical studies. The protein and mRNA expression levels and the 
subcellular localisation of these proteins could also be investigated for any change in 
cells with loss of sacsin compared to controls. If these interactions are verified, then it 
may highlight a potential mechanism for disrupted proteostasis in sacsin deficient cells. 
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Moreover, lysosomal pH could be investigated in cells with loss of sacsin, for example 
by using LysoSensor (ThermoFisher Scientific). A deacidification of lysosomes would 
be indicated by an increase in pH. 
 
6.5. Potential Therapeutic Strategies for ARSACS 
There is currently no available therapy for ARSACS. Defining the molecular 
pathogenesis of ARSACS represents the first step in identifying a therapeutic strategy. 
The data produced in this thesis suggests that loss of sacsin function disrupts cellular 
proteostasis. Further investigation of the mechanisms leading to this disrupted 
proteostasis may provide a target for therapeutics. Also, the cellular phenotypes 
identified, such as the collapse of the vimentin network into perinuclear bundles, could 
be used in high-throughput screening to identify therapeutic targets for ARSACS.   
If autophagic degradation is impaired, then manipulating this pathway may be a viable 
strategy for treating ARSACS. Mammalian target of rapamycin (mTOR) is an 
intracellular serine/threonine protein kinase that has a central role in several cellular 
processes, including autophagy (Hay and Sonenberg, 2004; Wullschleger et al., 2006; 
Zoncu et al., 2011). Inhibiting mTOR using rapamycin leads to the induction of 
autophagy. Data from studies of cell, animal, and fly models show that this may reduce 
toxicity in many neurodegenerative diseases where mutant proteins lead to 
aggresome/inclusion formation (Berger et al., 2006). For example, rapamycin treatment 
reduces protein aggregation and toxicity in HD (Ravikumar et al., 2002; Ravikumar et 
al., 2004), SCA3 (Menzies et al., 2010), and PD (Bove et al., 2011; Dehay et al., 2010; 
Malagelada et al., 2010; Xiong et al., 2011). 
Another possible therapeutic strategy, that has been shown to reduce inclusion 
formation and prevent cell toxicity in several models of neurodegeneration, is to 
enhance chaperone levels. This may restore proteostasis by increasing protein folding, 
reducing aggregation, and promoting proteasomal degradation. For example, HSP70 
overexpression reduced α-synuclein accumulation and toxicity in mouse and 
Drosophila models of PD (Auluck et al., 2002; Klucken et al., 2004). Furthermore, 
overexpression of the HSP40 protein HDJ-2 (DNAJA1) caused a significant reduction 
in the incidence of ataxin-1 inclusions (Cummings et al., 1998).  
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6.6. Final Conclusions 
Sacsin is a large multi-domain protein, which contains regions of similarity to 
molecular chaperones and domains linking to protein degradation pathways, which 
suggests a potential role in maintaining proteostasis.  
The main findings of this thesis include the observation that cells with loss of sacsin 
function display the characteristics of aggresome formation. Aggresomes form due to 
the accumulation and aggregation of misfolded proteins, which occurs when 
proteostasis is impaired. Thus, the potential presence of aggresome-like structures 
suggests proteostasis may be disrupted due to loss of sacsin function. 
Furthermore, a reduction in DRP1-mediated mitochondrial fission has been identified in 
sacsin deficient cells. This may be due to loss of an interaction between sacsin, DRP1 
and DCNT6, which may result in reduced transport of DRP1 to mitochondria via the 
dynein-dynactin complex. Since, DRP1-mediated mitochondrial fission is necessary for 
mitochondrial quality control, a disruption to mitochondrial quality control is likely to 
occur in sacsin deficient cells. This may explain the mitochondrial dysfunction, 
observed by our group and others, in ARSACS. Moreover, a disruption to dynein-
dynactin-based microtubule transport may also have implications for IF network 
assembly and organisation (Helfand et al., 2002). 
Mitochondrial dysfunction, cytoskeletal disruption, and protein misfolding and 
aggregation are particular detrimental in neurons and are characteristic features of many 
neurodegenerative diseases. Sacsin is highly expressed in neurons, particularly in motor 
neurons and Purkinje neurons in the cerebellum (Parfitt, 2011), indicating a vital role in 
these neurons. This may reflect the importance of proteostasis in these neurons. 
In summary, the findings of this thesis, together with the knowledge of sacsins domain 
structure, indicate a role for sacsin in maintaining proteostasis. Impaired proteostasis 
likely leads to mitochondrial dysfunction and neurotoxicity, and may contribute to the 
cerebellar ataxia and neurodegeneration in ARSACS. Further work will be required to 
fully elucidate the role of sacsin in protein and mitochondrial quality control.  
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1 55 F 
2 NA NA 
3 NA NA 
4 54 M 
5 NA NA 
 
These were purchased from PromoCell or were kindly provided by Dr. Tristan McKay 
(St George’s, University of London), or Dr. Sascha Vermeer (Radboud University, 
Nijmegen). WT controls were not age and gender matched with ARSACS HDF lines. 
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Appendix 4. Cilia incidence and length are reduced in ARSACS HDFs. 
 
 
 
